Thermo Fisher Scientific (TMO) 10-K 24 Feb 22 2021 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Feb. 05, 2022	Jul. 02, 2021
Entity Listings [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Document Transition Report	false
Entity File Number	1-8002
Entity Registrant Name	THERMO FISHER SCIENTIFIC INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-2209186
Entity Address, Address Line One	168 Third Avenue
Entity Address, City or Town	Waltham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02451
City Area Code	781
Local Phone Number	622-1000
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
ICFR Auditor Attestation Flag	true
Entity Public Float			$ 201,672,052
Entity Common Stock, Shares Outstanding		391,191,770
Documents Incorporated by Reference [Text Block]	Sections of Thermo Fisher’s definitive Proxy Statement for the 2022 Annual Meeting of Shareholders are incorporated by reference into Parts II and III of this report.
Entity Central Index Key	0000097745
Amendment Flag	false
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Auditor Firm ID	238
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	Boston, Massachusetts
Common Stock, $1.00 par value
Entity Listings [Line Items]
Title of 12(b) Security	Common Stock, $1.00 par value
Entity Stock Trading Symbol	TMO
Security Exchange Name	NYSE
0.750% Notes due 2024
Entity Listings [Line Items]
Title of 12(b) Security	0.750% Notes due 2024
Entity Stock Trading Symbol	TMO 24A
Security Exchange Name	NYSE
0.125% Notes due 2025
Entity Listings [Line Items]
Title of 12(b) Security	0.125% Notes due 2025
Entity Stock Trading Symbol	TMO 25B
Security Exchange Name	NYSE
2.000% Notes due 2025
Entity Listings [Line Items]
Title of 12(b) Security	2.000% Notes due 2025
Entity Stock Trading Symbol	TMO 25
Security Exchange Name	NYSE
1.400% Notes due 2026
Entity Listings [Line Items]
Title of 12(b) Security	1.400% Notes due 2026
Entity Stock Trading Symbol	TMO 26A
Security Exchange Name	NYSE
1.450% Notes due 2027
Entity Listings [Line Items]
Title of 12(b) Security	1.450% Notes due 2027
Entity Stock Trading Symbol	TMO 27
Security Exchange Name	NYSE
1.750% Notes due 2027
Entity Listings [Line Items]
Title of 12(b) Security	1.750% Notes due 2027
Entity Stock Trading Symbol	TMO 27B
Security Exchange Name	NYSE
0.500% Notes due 2028
Entity Listings [Line Items]
Title of 12(b) Security	0.500% Notes due 2028
Entity Stock Trading Symbol	TMO 28A
Security Exchange Name	NYSE
1.375% Notes due 2028
Entity Listings [Line Items]
Title of 12(b) Security	1.375% Notes due 2028
Entity Stock Trading Symbol	TMO 28
Security Exchange Name	NYSE
1.950% Notes due 2029
Entity Listings [Line Items]
Title of 12(b) Security	1.950% Notes due 2029
Entity Stock Trading Symbol	TMO 29
Security Exchange Name	NYSE
0.875% Notes due 2031
Entity Listings [Line Items]
Title of 12(b) Security	0.875% Notes due 2031
Entity Stock Trading Symbol	TMO 31
Security Exchange Name	NYSE
2.375% Notes due 2032
Entity Listings [Line Items]
Title of 12(b) Security	2.375% Notes due 2032
Entity Stock Trading Symbol	TMO 32
Security Exchange Name	NYSE
2.875% Notes due 2037
Entity Listings [Line Items]
Title of 12(b) Security	2.875% Notes due 2037
Entity Stock Trading Symbol	TMO 37
Security Exchange Name	NYSE
1.500% Notes due 2039
Entity Listings [Line Items]
Title of 12(b) Security	1.500% Notes due 2039
Entity Stock Trading Symbol	TMO 39
Security Exchange Name	NYSE
1.875% Notes due 2049
Entity Listings [Line Items]
Title of 12(b) Security	1.875% Notes due 2049
Entity Stock Trading Symbol	TMO 49
Security Exchange Name	NYSE

Consolidated Balance Sheet

Consolidated Balance Sheet - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 4,477	$ 10,325
Accounts receivable, less allowances of $150 and $135	7,977	5,741
Inventories	5,051	4,029
Contract assets, net	968	731
Other current assets	1,640	1,131
Total current assets	20,113	21,957
Property, plant and equipment, net	8,333	5,912
Acquisition-related intangible assets, net	20,113	12,685
Other assets	4,640	2,457
Goodwill	41,924	26,041
Total assets	95,123	69,052
Current liabilities:
Short-term obligations and current maturities of long-term obligations	2,537	2,628
Accounts payable	2,867	2,175
Accrued payroll and employee benefits	2,427	1,916
Contract liabilities	2,655	1,271
Other accrued expenses	2,950	2,314
Total current liabilities	13,436	10,304
Deferred income taxes	3,837	1,794
Other long-term liabilities	4,540	3,330
Long-term obligations	32,333	19,107
Commitments and Contingencies
Redeemable noncontrolling interest	122	0
Thermo Fisher Scientific Inc. shareholders’ equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued
Common stock, $1 par value, 1,200,000,000 shares authorized; 439,154,741 and 437,088,297 shares issued	439	437
Capital in excess of par value	16,174	15,579
Retained earnings	35,431	28,116
Treasury stock at cost, 44,720,112 and 40,417,789 shares	(8,922)	(6,818)
Accumulated other comprehensive items	(2,329)	(2,807)
Total Thermo Fisher Scientific Inc. shareholders’ equity	40,793	34,507
Noncontrolling interests	62	10
Total equity	40,855	34,517
Total liabilities, redeemable noncontrolling interest and equity	$ 95,123	$ 69,052

Consolidated Balance Sheet (Par

Consolidated Balance Sheet (Parenthetical) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Accounts Receivable Allowances	$ 150	$ 135
Preferred Stock, $100 Par Value - Par Value (in dollars per share)	$ 100	$ 100
Preferred Stock, $100 Par Value - Shares Authorized (in shares)	50,000	50,000
Preferred Stock, $100 Par Value - Shares Issued (in shares)	0	0
Common Stock, $1 Par Value - Par Value (in dollars per share)	$ 1	$ 1
Common Stock, $1 Par Value - Shares Authorized (in shares)	1,200,000,000	1,200,000,000
Common Stock, $1 Par Value - Shares Issued (in shares)	439,154,741	437,088,297
Treasury Stock at Cost (in shares)	44,720,112	40,417,789

Consolidated Statement of Incom

Consolidated Statement of Income - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenues
Revenues	$ 39,211	$ 32,218	$ 25,542
Costs and operating expenses:
Selling, general and administrative expenses	8,007	6,930	6,144
Research and development expenses	1,406	1,181	1,003
Restructuring and other costs (income)	197	99	(413)
Total costs and operating expenses	29,183	24,424	20,948
Operating income	10,028	7,794	4,594
Interest income	43	65	224
Interest expense	(536)	(553)	(676)
Other income/(expense)	(694)	(76)	(70)
Income before income taxes	8,841	7,230	4,072
Provision for income taxes	(1,109)	(850)	(374)
Equity in (losses) earnings of unconsolidated entities	(4)	(3)	0
Net income	7,728	6,377	3,698
Less: net income attributable to noncontrolling interests and redeemable noncontrolling interest	3	2	2
Net income attributable to Thermo Fisher Scientific Inc.	$ 7,725	$ 6,375	$ 3,696
Earnings per share attributable to Thermo Fisher Scientific Inc.
Basic (in dollars per share)	$ 19.62	$ 16.09	$ 9.24
Diluted (in dollars per share)	$ 19.46	$ 15.96	$ 9.17
Weighted average shares
Basic (in shares)	394	396	400
Diluted (in shares)	397	399	403
Product [Member]
Revenues
Revenues	$ 30,361	$ 25,306	$ 19,496
Costs and operating expenses:
Cost of revenues	13,594	11,407	10,037
Service [Member]
Revenues
Revenues	8,850	6,912	6,046
Costs and operating expenses:
Cost of revenues	$ 5,979	$ 4,807	$ 4,177

Consolidated Statement of Compr

Consolidated Statement of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Comprehensive income
Net income	$ 7,728	$ 6,377	$ 3,698
Currency translation adjustment:
Currency translation adjustment (net of tax provision (benefit) of $231, $(221) and $25)	373	(118)	(106)
Reclassification adjustment for losses included in net income	0	0	30
Unrealized gains and losses on hedging instruments:
Unrealized losses on hedging instruments (net of tax benefit of $0, $20 and $12)	0	(65)	(38)
Reclassification adjustment for losses included in net income (net of tax benefit of $17, $14 and $6)	56	45	19
Pension and other postretirement benefit liability adjustments:
Pension and other postretirement benefit liability adjustments arising during the period (net of tax provision (benefit) of $11, $(1) and $(31))	36	(8)	(93)
Amortization of net loss and prior service benefit included in net periodic pension cost (net of tax benefit of $6, $4 and $2)	13	18	8
Total other comprehensive items	478	(128)	(180)
Comprehensive income	8,206	6,249	3,518
Less: comprehensive income attributable to noncontrolling interests and redeemable noncontrolling interest	2	2	3
Comprehensive income attributable to Thermo Fisher Scientific Inc.	$ 8,204	$ 6,247	$ 3,515

Consolidated Statement of Com_2

Consolidated Statement of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement of Comprehensive Income [Abstract]
Tax provision (benefit) on currency translation adjustment	$ 231	$ (221)	$ 25
Tax benefit on unrealized holding losses on hedging instruments arising during the period	0	20	12
Tax benefit on reclassification adjustment for losses on hedging instruments recognized in net income	17	14	6
Tax provision (benefit) on pension and other postretirement benefit liability adjustments arising during the period	11	(1)	(31)
Tax benefit on amortization of net loss and prior service benefit included in net periodic pension cost	$ 6	$ 4	$ 2

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating activities
Net income	$ 7,728	$ 6,377	$ 3,698
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation of property, plant and equipment	831	658	564
Amortization of acquisition-related intangible assets	1,761	1,667	1,713
Change in deferred income taxes	(647)	(552)	(302)
Gain on sales of businesses	0	0	(482)
Stock-based compensation	230	196	181
Loss on early extinguishment of debt	767	0	184
Other non-cash expenses	190	338	82
Changes in assets and liabilities, excluding the effects of acquisitions and disposition:
Accounts receivable	(204)	(1,302)	(225)
Inventories	(1,065)	(508)	(458)
Accounts payable	479	59	266
Contributions to retirement plans	(34)	(96)	(50)
Other	(724)	1,452	(198)
Net cash provided by operating activities	9,312	8,289	4,973
Investing activities
Acquisitions, net of cash acquired	(19,395)	(38)	(1,843)
Proceeds from sale of business, net of cash divested	0	0	1,128
Purchase of property, plant and equipment	(2,523)	(1,474)	(926)
Proceeds from sale of property, plant and equipment	20	8	36
Other investing activities, net	(34)	(6)	118
Net cash used in investing activities	(21,932)	(1,510)	(1,487)
Financing activities
Net proceeds from issuance of debt	18,137	3,464	5,638
Repayment of debt	(11,738)	(710)	(6,355)
Proceeds from issuance of commercial paper	2,512	383	2,781
Repayments of commercial paper	0	(387)	(3,464)
Purchases of company common stock	(2,000)	(1,500)	(1,500)
Dividends paid	(395)	(337)	(297)
Net proceeds from issuance of company common stock under employee stock plans	156	196	153
Other financing activities, net	(91)	(150)	(74)
Net cash provided by (used in) financing activities	6,581	959	(3,118)
Exchange rate effect on cash	194	176	(63)
(Decrease) increase in cash, cash equivalents and restricted cash	(5,845)	7,914	305
Cash, cash equivalents and restricted cash at beginning of year	10,336	2,422	2,117
Cash, cash equivalents and restricted cash at end of year	$ 4,491	$ 10,336	$ 2,422

Consolidated Statement of Redee

Consolidated Statement of Redeemable Noncontrolling Interest and Equity - USD ($) shares in Millions, $ in Millions	Total	Cumulative Effect, Period of Adoption, Adjustment [Member]	Common Stock, $1.00 par value	Capital in Excess of Par Value [Member]	Retained Earnings [Member]	Retained Earnings [Member]Cumulative Effect, Period of Adoption, Adjustment [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Items [Member]	Total Thermo Fisher Scientific Inc. Shareholders' Equity	Total Thermo Fisher Scientific Inc. Shareholders' EquityCumulative Effect, Period of Adoption, Adjustment [Member]	Noncontrolling Interests
Balance (in shares) at Dec. 31, 2018			432				29
Balance at Dec. 31, 2018	$ 27,594	$ 4	$ 432	$ 14,621	$ 18,696	$ 4	$ (3,665)	$ (2,498)	$ 27,586	$ 4	$ 8
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under employees' and directors' stock plans (in shares)			2				1
Issuance of shares under employees' and directors' stock plans	193		$ 2	262			$ (71)		193
Stock-based compensation	181			181					181
Purchases of company common stock (in shares)							6
Purchases of company common stock	(1,500)						$ (1,500)		(1,500)
Dividends declared	(304)				(304)				(304)
Net income	3,698				3,696				3,696		2
Other comprehensive items	(180)							(181)	(181)		1
Contributions from (distributions to) noncontrolling interests	(2)										(2)
Balance (in shares) at Dec. 31, 2019			434				36
Balance at Dec. 31, 2019	29,684	$ (1)	$ 434	15,064	22,092	$ (1)	$ (5,236)	(2,679)	29,675	$ (1)	9
Redeemable Noncontrolling Interest, Balance at Dec. 31, 2020	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under employees' and directors' stock plans (in shares)			3				0
Issuance of shares under employees' and directors' stock plans	240		$ 3	319			$ (82)		240
Stock-based compensation	196			196					196
Purchases of company common stock (in shares)							4
Purchases of company common stock	(1,500)						$ (1,500)		(1,500)
Dividends declared	(350)				(350)				(350)
Net income	6,377				6,375				6,375		2
Other comprehensive items	(128)							(128)	(128)
Contributions from (distributions to) noncontrolling interests	(1)										(1)
Balance (in shares) at Dec. 31, 2020			437				40
Balance at Dec. 31, 2020	34,517		$ 437	15,579	28,116		$ (6,818)	(2,807)	34,507		10
Redeemable Noncontrolling Interest [Roll Forward]
Noncontrolling Interest, Increase from Business Combination	122
Net income (loss) attributable to redeemable noncontrolling interest	1
Other comprehensive items attributable to redeemable noncontrolling interest	(1)
Redeemable Noncontrolling Interest, Balance at Dec. 31, 2021	122
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under employees' and directors' stock plans (in shares)			2				1
Issuance of shares under employees' and directors' stock plans	222		$ 2	324			$ (104)		222
Stock-based compensation	230			230					230
Purchases of company common stock (in shares)							4
Purchases of company common stock	(2,000)						$ (2,000)		(2,000)
Dividends declared	(410)				(410)				(410)
Net income	7,727				7,725				7,725		2
Other comprehensive items	478							478	478
Contributions from (distributions to) noncontrolling interests	50										50
Other	41			41					41
Balance (in shares) at Dec. 31, 2021			439				45
Balance at Dec. 31, 2021	$ 40,855		$ 439	$ 16,174	$ 35,431		$ (8,922)	$ (2,329)	$ 40,793		$ 62

Consolidated Statement of Red_2

Consolidated Statement of Redeemable Noncontrolling Interest and Equity (Parenthetical) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement of Stockholders' Equity [Abstract]
Cash Dividends Declared per Common Share (in dollars per share)	$ 1.04	$ 0.88	$ 0.76

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Summary of Significant Accounting Policies [Text Block]	Note 1. Nature of Operations and Summary of Significant Accounting Policies Nature of Operations Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and therapies, and increase laboratory productivity. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics. Principles of Consolidation The accompanying financial statements include the accounts of the company and its wholly and majority-owned subsidiaries. All material intercompany accounts and transactions have been eliminated. The company accounts for investments in businesses using the equity method when it has the ability to exercise significant influence but not control (generally between 20% and 50% ownership), is not the primary beneficiary and has not elected the fair value option. At December 31, 2021 and 2020, the company had such investments with carrying amounts of $576 million and $32 million, respectively. The company has elected the fair value option of accounting for certain of its investments with readily determinable fair values that would otherwise be accounted for under the equity method. At December 31, 2021, the fair value of such investments was $217 million. Redeemable Noncontrolling Interest The company owns 60% of its consolidated subsidiary PPD-SNBL K.K. The 40% ownership interest held by a third party is classified as a redeemable noncontrolling interest on the consolidated balance sheet due to certain put options under which the third party may require the company to purchase the remaining ownership interest at its pre-acquisition fair value. Presentation Certain reclassifications of prior year amounts have been made to conform to the current year presentation. Revenue Recognition Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues (primarily clinical research, pharmaceutical, and instrument and enterprise services) are recognized over time as customers receive and consume the benefits of such services. For revenues recognized over time, the company generally uses costs accumulated relative to total estimated costs to measure progress as this method approximates satisfaction of the performance obligation. For contracts that contain multiple performance obligations, the company allocates the consideration to which it expects to be entitled (i.e., the transaction price) to each performance obligation based on relative standalone selling prices and recognizes the related revenues when or as control of each individual performance obligation is transferred to customers. The company exercises judgment in determining the timing of revenue by analyzing the point in time or the period over which the customer has the ability to direct the use of and obtain substantially all of the remaining benefits of the asset. The company immediately expenses contract costs that would otherwise be capitalized and amortized over a period of less than one year. Changes to the scope of services contracts generally also include changes in the transaction price. Typically, these contract modifications are not distinct from existing services provided under the contract, and result in cumulative adjustments to revenue on the modification date. Payments from customers for most instruments and consumables are typically due in a fixed number of days after shipment or delivery of the product. Service arrangements commonly call for payments in advance of performing the work (e.g., extended service contracts), upon completion of the service (e.g., pharmaceutical services) or a mix of both. Some arrangements include variable amounts of consideration that arise from discounts, rebates, and other programs and practices. In such arrangements, the company estimates the amount by which to reduce the stated contract amount to reflect the transaction price. The company records reimbursement for third-party pass-through and out-of-pocket costs as revenues and the related expenses as costs of revenues. Contract-related Balances Accounts receivable include unconditional rights to consideration from customers, which generally represent billings that do not bear interest. The company maintains allowances for doubtful accounts for estimates of expected losses resulting from the inability of its customers to pay amounts due. The allowance for doubtful accounts is the company’s best estimate of the amount of probable credit losses in existing accounts receivable. The company determines the allowance based on history of similarly aged receivables, the creditworthiness of the customer, reasons for delinquency, current economic conditions, expectations associated with future events and circumstances where reasonable and supportable forecasts are available and any other information that is relevant to the judgment. Receivables from academic and government customers as well as large, well-capitalized commercial customers have historically experienced less collectability risk. Account balances are charged off against the allowance when the company believes it is probable the receivable will not be recovered. The company does not have any off-balance-sheet credit exposure related to customers. Contract assets include revenues recognized in advance of billings where the company’s right to bill includes something other than the passage of time. Such amounts are recorded net of estimated losses resulting from the inability to invoice customers, which is primarily due to risk associated with the company’s performance. Contract assets are classified as current or noncurrent based on the amount of time expected to lapse until the company's right to consideration becomes unconditional. Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenues on service contracts. Contract liabilities are classified as current or noncurrent based on the periods over which remaining performance obligations are expected to be transferred to customers. Contract assets and liabilities are presented on a net basis in the consolidated balance sheet if they arise from different performance obligations in the same contract. Warranty Obligations The company provides for the estimated cost of standard product warranties, primarily from historical information, in cost of product revenues at the time product revenues are recognized. The liability for warranties is included in other accrued expenses in the accompanying balance sheet. Extended warranty agreements are considered service contracts, which are discussed above. Costs of service contracts are recognized as incurred. Leases Operating leases that have commenced are included in other assets, other accrued expenses and other long-term liabilities in the consolidated balance sheet. Finance leases that have commenced are included in property, plant and equipment, net, current maturities of long-term obligations and long-term obligations in the consolidated balance sheet. Classification of lease liabilities as either current or noncurrent is based on the expected timing of payments due under the company’s obligations. Right-of-use (ROU) assets represent the company’s right to use an underlying asset for the lease term and lease liabilities represent the company’s obligation to make lease payments arising from the lease. Lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. The company recognizes operating lease expense on a straight-line basis over the lease term. Finance lease expense includes depreciation, which is recognized on a straight-line basis over the expected life of the leased asset, and an immaterial amount of interest expense. Because most of the company’s leases do not provide an implicit interest rate, the company estimates incremental borrowing rates based on the information available at the commencement date in determining the present value of lease payments. The company uses the implicit rate when readily determinable. Lease terms include the effect of options to extend or terminate the lease when it is reasonably certain that the company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. As a lessee, the company accounts for the lease and non-lease components as a single lease component. Research and Development The company conducts research and development activities to increase its depth of capabilities in technologies, software and services. Research and development costs include employee compensation and benefits, consultants, facilities related costs, material costs, depreciation and travel. Research and development costs are expensed as incurred. Restructuring Costs Accounting for the timing and amount of termination benefits provided by the company to employees is determined based on whether: (a) the company has a substantive plan to provide such benefits, (b) the company has a written employment contract with the affected employees that includes a provision for such benefits, (c) the termination benefits are due to the occurrence of an event specified in an existing plan or agreement, or (d) the termination benefits are a one-time benefit. In certain circumstances, employee termination benefits may meet more than one of the characteristics listed above and therefore, may have individual elements that are subject to different accounting models. From time to time when executing a restructuring or exit plan, the company also incurs costs other than termination benefits, such as lease termination costs, that are not associated with or will not be incurred to generate revenues. These include costs that represent amounts under contractual obligations that exist prior to the restructuring plan communication date and will either continue after the restructuring plan is completed with no economic benefit or result in a penalty to cancel a contractual obligation. Such costs are recognized when incurred, which generally occurs at the contract termination or over the period from when a plan to abandon a leased facility is approved through the cease-use date but charges may continue over the remainder of the original contractual period. Income Taxes The company recognizes deferred income taxes based on the expected future tax consequences of differences between the financial statement basis and the tax basis of assets and liabilities, calculated using enacted tax rates in effect for the year in which the differences are expected to be reflected in the tax return. A valuation allowance is provided for tax assets that will more likely than not go unused. The financial statements reflect expected future tax consequences of uncertain tax positions that the company has taken or expects to take on a tax return presuming the taxing authorities’ full knowledge of the positions and all relevant facts, but without discounting for the time value of money. Earnings per Share Basic earnings per share has been computed by dividing net income attributable to Thermo Fisher Scientific Inc. by the weighted average number of shares outstanding during the year. Except where the result would be antidilutive to net income attributable to Thermo Fisher Scientific Inc., diluted earnings per share has been computed using the treasury stock method for outstanding stock options and restricted units. Cash and Cash Equivalents Cash equivalents consists principally of money market funds, commercial paper and other marketable securities purchased with an original maturity of three months or less. These investments are carried at cost, which approximates market value. Inventories Inventories are valued at the lower of cost or net realizable value, cost being determined by the first-in, first-out (FIFO) method. As discussed below, prior to the third quarter of 2021 certain of the company's businesses utilized the last-in, first-out (LIFO) method. The company periodically reviews quantities of inventories on hand and compares these amounts to the expected use of each product or product line. In addition, the company has certain inventory that is subject to fluctuating market pricing. The company records a charge to cost of sales for the amount required to reduce the carrying value of inventory to net realizable value. Costs associated with the procurement of inventories, such as inbound freight charges, purchasing and receiving costs, and internal transfer costs, are included in cost of revenues in the accompanying statement of income. The components of inventories are as follows: December 31, December 31, (In millions) 2021 2020 Raw materials $ 1,922 $ 1,305 Work in process 676 540 Finished goods 2,453 2,184 Inventories $ 5,051 $ 4,029 Prior to the third quarter of 2021, certain of the company’s businesses utilized the LIFO method of accounting for inventories. During the third quarter of 2021, these businesses, which comprised approximately 5% of consolidated inventories, changed from the LIFO method to the FIFO method. The company believes this change is preferable as it will provide a consistent, uniform costing method for all inventories across the company, better reflect the current value of inventories, and improve comparability with peers. Prior financial statements have not been retrospectively adjusted due to immateriality. The cumulative pre-tax effect of this change in accounting principle of $33 million was recorded as an increase to inventories and a decrease to cost of product revenues in the third quarter of 2021. This change was recorded in the Laboratory Products and Biopharma Services ($20 million) and Specialty Diagnostics ($13 million) segments. The value of inventories maintained using the LIFO method was $274 million at December 31, 2020, which was below estimated replacement cost by $49 million. Reductions to cost of revenues as a result of the liquidation of LIFO inventories were nominal during 2019, 2020 and the first half of 2021. Property, Plant and Equipment Property, plant and equipment are recorded at cost. The costs of additions and improvements are capitalized, while maintenance and repairs are charged to expense as incurred. The company generally provides for depreciation and amortization using the straight-line method over the estimated useful lives of the property as follows: buildings and improvements, 25 to 40 years; machinery and equipment (including software), 3 to 10 years; and leasehold improvements, the shorter of the term of the lease or the life of the asset. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and the resulting gain or loss is reflected in the accompanying statement of income. Property, plant and equipment consists of the following: December 31, December 31, (In millions) 2021 2020 Land $ 431 $ 410 Buildings and improvements 2,575 2,192 Machinery, equipment and leasehold improvements 9,587 6,975 Property, plant and equipment, at cost 12,593 9,577 Less: Accumulated depreciation and amortization 4,260 3,665 Property, plant and equipment, net $ 8,333 $ 5,912 Acquisition-related Intangible Assets Acquisition-related intangible assets include the costs of acquired customer relationships, product technology, tradenames, backlog and other specifically identifiable intangible assets, and are being amortized using the straight-line method over their estimated useful lives, which range up to 20 years. The company reviews these intangible assets for impairment when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets. When impairment indicators exist, the company determines whether the carrying value of its intangible assets exceeds the related undiscounted cash flows. In these situations, the carrying value is written down to fair value. In addition, the company has tradenames and in-process research and development that have indefinite lives and which are not amortized. Intangible assets with indefinite lives are reviewed for impairment annually or whenever events or changes in circumstances indicate they may be impaired. The company may perform an optional qualitative assessment. If the company determines that the fair value of the indefinite-lived intangible asset is more likely than not greater than its carrying amount, no additional testing is necessary. If not, or if the company bypasses the optional qualitative assessment, it writes the carrying value down to the fair value, if applicable. Acquisition-related intangible assets are as follows: Balance at December 31, 2021 Balance at December 31, 2020 (In millions) Gross Accumulated Amortization Net Gross Accumulated Amortization Net Definite lived: Customer relationships $ 22,802 $ (7,792) $ 15,010 $ 16,593 $ (7,450) $ 9,143 Product technology 6,041 (3,977) 2,064 5,523 (3,532) 1,991 Tradenames 1,722 (919) 803 1,213 (897) 316 Backlog 1,060 (59) 1,001 — — — 31,625 (12,747) 18,878 23,329 (11,879) 11,450 Indefinite lived: Tradenames 1,235 N/A 1,235 1,235 N/A 1,235 Acquisition-related intangible assets $ 32,860 $ (12,747) $ 20,113 $ 24,564 $ (11,879) $ 12,685 The estimated future amortization expense of acquisition-related intangible assets with definite lives is as follows: (In millions) 2022 $ 2,489 2023 2,358 2024 1,992 2025 1,669 2026 1,392 2027 and thereafter 8,978 Estimated future amortization expense of definite-lived intangible assets $ 18,878 Other Assets Other assets in the accompanying balance sheet include operating lease right-of-use assets, investments, deferred tax assets, pension assets, cash surrender value of life insurance, insurance recovery receivables related to product liability matters, certain intangible assets and other assets. At December 31, 2021 and 2020, the company had $33 million and $43 million, respectively, of intangible assets not derived from acquisitions, net of accumulated amortization, which are being amortized using the straight-line method over their estimated useful lives, which range up to 20 years. Equity investments that do not have readily determinable fair values and are not eligible for the net asset value (NAV) practical expedient are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investments of the same issuer. The company performs qualitative assessments to identify impairments of these investments. At December 31, 2021 and 2020, the company had such investments with carrying amounts of $22 million and $28 million, respectively, and investments measured at NAV of $16 million and $0 million, respectively, which are included in other assets. Goodwill The company assesses goodwill for impairment at the reporting unit level annually and whenever events occur or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Such events or circumstances generally include the occurrence of operating losses or a significant decline in earnings associated with one or more of the company’s reporting units. The company is permitted to first assess qualitative factors to determine whether the quantitative goodwill impairment test is necessary. If the qualitative assessment results in a determination that the fair value of a reporting unit is more likely than not less than its carrying amount, the company performs a quantitative goodwill impairment test. The company may bypass the qualitative assessment for the reporting unit in any period and proceed directly to the goodwill impairment test. The company estimates the fair value of its reporting units by using forecasts of discounted future cash flows and peer market multiples. The company would record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value (limited to the amount of goodwill). The company determined that no impairments existed in 2021, 2020 or 2019. The changes in the carrying amount of goodwill by segment are as follows: (In millions) Life Sciences Analytical Specialty Laboratory Total Balance at December 31, 2019 $ 8,544 $ 4,928 $ 3,184 $ 9,058 $ 25,714 Acquisition 35 — — — 35 Currency translation 11 151 186 (56) 292 Balance at December 31, 2020 8,590 5,079 3,370 9,002 26,041 Acquisitions 1,560 56 8 14,400 16,024 Currency translation (7) (92) (101) 59 (141) Balance at December 31, 2021 $ 10,143 $ 5,043 $ 3,277 $ 23,461 $ 41,924 Loss Contingencies Accruals are recorded for various contingencies, including legal proceedings, environmental, workers’ compensation, product, general and auto liabilities, self-insurance and other claims that arise in the normal course of business. The accruals are based on management’s judgment, historical claims experience, the probability of losses and, where applicable, the consideration of opinions of internal and/or external legal counsel and actuarial estimates. Additionally, the company records receivables from third-party insurers up to the amount of the loss when recovery has been determined to be probable. Certain liabilities acquired in acquisitions have been recorded at readily determinable fair values and, as such, were discounted to present value at the dates of acquisition. Currency Translation All assets and liabilities of the company’s subsidiaries operating in non-U.S. dollar currencies are translated at period-end exchange rates. Resulting translation adjustments are reflected in the “accumulated other comprehensive items” component of shareholders’ equity. Revenues and expenses are translated at average exchange rates for the period. Currency transaction gains are included in the accompanying statement of income and in aggregate were $25 million, $24 million and $52 million in 2021, 2020 and 2019, respectively. Derivative Contracts The company is exposed to certain risks relating to its ongoing business operations including changes to interest rates and currency exchange rates. The company uses derivative instruments primarily to manage currency exchange and interest rate risks. The company recognizes derivative instruments as either assets or liabilities and measures those instruments at fair value. If a derivative is a hedge, depending on the nature of the hedge, changes in the fair value of the derivative are either offset against the change in fair value of the hedged item through earnings or recognized in other comprehensive items until the hedged item is recognized in earnings. Derivatives that are not designated as hedges are recorded at fair value through earnings. The company uses short-term forward and option currency exchange contracts primarily to hedge certain balance sheet and operational exposures resulting from changes in currency exchange rates, predominantly intercompany loans and cash balances that are denominated in currencies other than the functional currencies of the respective operations. The currency-exchange contracts principally hedge transactions denominated in euro, Swiss franc, British pounds sterling, Canadian dollars, Czech koruna, Japanese yen and Hong Kong dollars. The company does not hold or engage in transactions involving derivative instruments for purposes other than risk management. Cash flow hedges . For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative is reported as a component of other comprehensive items and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings and is presented in the same income statement line item as the earnings effect of the hedged item. Fair value hedges. For derivative instruments that are designated and qualify as a fair value hedge, the gain or loss on the derivative, as well as the offsetting loss or gain on the hedged item attributable to the hedged risk, are recognized in earnings. Net investment hedges. The company uses foreign currency-denominated debt and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A portion of the company’s euro-denominated senior notes and its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and businesses that are used in assessing the risk of impairment. Risks and uncertainties associated with the ongoing COVID-19 global pandemic materially adversely affected certain of the company’s businesses in 2020, particularly in the Analytical Instruments segment and, to a lesser extent, some businesses within the other three segments. The negative impacts significantly lessened in 2021. The extent and duration of negative impacts in the future, which may include inflationary pressures and supply chain disruptions, are uncertain and may require changes to estimates. Actual results could differ from those estimates. Recent Accounting Pronouncements In November 2021, the FASB issued new guidance to require entities to disclose information about certain types of government assistance they receive, including cash grants and tax credits. Among other things, the new guidance requires expanded disclosure regarding the qualitative and quantitative characteristics of the nature, amount, timing, and significant terms and conditions of transactions with a government arising from a grant or other forms of assistance accounted for under a contribution model. The company will adopt this guidance in 2022 using a prospective method. The adoption of this guidance is not expected to have a material impact on the company’s disclosures; however, the impact will be dependent on the extent of transactions of this nature entered into by the company in periods subsequent to the date of adoption. In October 2021, the FASB amended guidance to recognize and measure contract assets and contract liabilities acquired in a business combination. Generally, this new guidance will result in the company recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. The company adopted this guidance in the fourth quarter of 2021 retrospectively to all business combinations completed in the first three quarters of 2021 and prospectively to all future business combinations. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements for acquisitions that closed in 2021; however, the impact in future periods will be dependent on the contract assets and contract liabilities acquired in future business combinations. In July 2021, the FASB amended guidance to require lessors to classify leases as operating leases if they have certain variable lease payment structures and would have selling losses if they were classified as sales-type or direct financing leases. The company adopted the guidance in the third quarter of 2021 using a prospective method. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements. In January 2020, the FASB issued new guidance to clarify the interaction of the accounting for certain equity securities, equity method investments, and certain forward contracts and purchased options. Among other things, the new guidance clarifies that an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying measurement principles for certain equity securities immediately before applying or discontinuing the equity method. The company adopted this guidance in 2020 using a prospective method. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements. In December 2019, the FASB issued new guidance to simplify the accounting for income taxes. Among other things, the new guidance requires the effects of enacted changes in tax laws or rates to be reflected in the annual effective tax rate computation in the interim period that includes the enactment date. The company adopted this guidance in 2021 using a prospective method. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements; however, the impact in future periods will be dependent on the extent of future events or conditions that would be affected such as enacted changes in tax laws or rates. In August 2018, the FASB issued new guidance to modify the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The company adopted the guidance in 2020 using a retrospective method. The adoption of this guidance did not have a material impact on the company’s disclosures. In August 2018, the FASB issued new guidance to modify the disclosure requirements on fair value measurements. The company adopted the guidance in 2020 with some items requiring a prospective method and others requiring a retrospective method. The adoption of this guidance did not have a material impact on the company’s disclosures. In June 2016, the FASB issued new guidance to require a financial asset measured at amortized cost basis, such as accounts receivable, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. During 2018 and 2019, the FASB issued additional guidance and clarification. The company adopted the guidance in 2020 using a modified retrospective method. The adoption of this guidance reduced accounts receivable and retained earnings by $1 million on January 1, 2020. In February 2016, the FASB issued new guidance which requires lessees to record most leases on their balance sheets as lease liabilities, initially measured at the present value of the future lease payments, with corresponding right-of-use assets. The new guidance also sets forth new disclosure requirements related to leases. During 2017 - 2019, the FASB issued additional guidance and clarification. The company adopted this guidance in January 2019. The company elected to adopt the guidance using a modified retrospective method, by applying the transition approach as of the beginning of the period of adoption. Comparative periods have not been restated. As permitted upon transition, the company did not reassess whether any expired or

Acquisitions and Dispositions

Acquisitions and Dispositions	12 Months Ended
	Dec. 31, 2021
Business Combinations [Abstract]
Acquisitions and Dispositions [Text Block]	Note 2. Acquisitions and Disposition The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforce. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products. Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred. 2021 On January 15, 2021, the company acquired, within the Laboratory Products and Biopharma Services segment, the Belgium-based European viral vector manufacturing business of Groupe Novasep SAS for $830 million in net cash consideration. The European viral vector manufacturing business provides manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers. The acquisition expands the segment’s capabilities for cell and gene vaccines and therapies. The goodwill recorded as a result of this business combination is not tax deductible. On February 25, 2021, the company acquired, within the Life Sciences Solutions segment, Mesa Biotech, Inc., a U.S.-based molecular diagnostic company, for $407 million in net cash consideration and contingent consideration with an initial fair value of $65 million due upon the completion of certain milestones. Mesa Biotech has developed and commercialized a polymerase chain reaction (PCR) based rapid point-of-care testing platform available for detecting infectious diseases including COVID-19. The acquisition enables the company to accelerate the availability of reliable and accurate advanced molecular diagnostics at the point of care. The goodwill recorded as a result of this business combination is not tax deductible. On September 30, 2021, the company assumed operating responsibility, within the Laboratory Products and Biopharma Services segment, of a new state-of-the-art biologics manufacturing facility in Lengnau, Switzerland from CSL Limited to perform pharma services for CSL with capacity to serve other customers as well. The company expects to make fixed lease payments aggregating to $555 million (excluding renewals) from 2021 to 2041, with additional amounts dependent on the extent of revenues from customers of the facility other than CSL. The goodwill recorded as a result of this business combination is not tax deductible. On December 8, 2021, the company acquired, within the Laboratory Products and Biopharma Services segment, PPD, Inc., a U.S.-based global provider of clinical research services to the pharma and biotech industry, for $15.99 billion in net cash consideration and $43 million of equity awards exchanged. The addition of PPD’s clinical research services enhances our offering to biotech and pharma customers by enabling them to accelerate innovation and increase their productivity within the drug development process. The goodwill recorded as a result of this business combination is not tax deductible. On December 30, 2021, the company acquired, within the Life Sciences Solutions segment, PeproTech, Inc., a U.S. based developer and manufacturer of recombinant proteins, for $1.86 billion in net cash consideration. PeproTech provides bioscience reagents known as recombinant proteins, including cytokines and growth factors. The acquisition expands the segment’s bioscience offerings. The goodwill recorded as a result of this business combination is not tax deductible. In addition, in 2021, the company acquired, within the Life Sciences Solutions segment, cell sorting technology assets, an Ireland-based life sciences distributor and a developer of a digital PCR platform; within the Analytical Instruments segment, a Belgium-based developer of micro-chip based technology for liquid chromatography columns; and within the Specialty Diagnostics segment, a transplant diagnostics information system provider. The components of the purchase price and net assets acquired for 2021 acquisitions are as follows: (In millions) PPD PeproTech European Viral Vector Business Mesa Biotech Lengnau biologics manufacturing facility Other Purchase price Cash paid $ 17,237 $ 1,947 $ 848 $ 421 $ 17 $ 298 Fair value of equity awards exchanged 43 — — — — — Fair value of contingent consideration — — — 65 1 117 Cash acquired (1,244) (83) (18) (14) — (13) $ 16,036 $ 1,864 $ 830 $ 472 $ 18 $ 402 Net assets acquired Current assets $ 2,510 $ 63 $ 39 $ 54 $ — $ 12 Property, plant and equipment 562 18 59 2 92 2 Definite-lived intangible assets: Customer relationships 6,264 514 302 — — 2 Product technology — 282 25 279 — 224 Tradenames 603 — — 2 — 2 Backlog 1,060 — — — — — Goodwill 13,781 1,190 600 237 18 198 Other assets 1,108 11 3 3 376 2 Contract liabilities (1,570) — (59) — — (1) Deferred tax assets (liabilities) (1,803) (193) (80) (72) — (28) Finance lease liabilities (86) — (24) — (82) — Debt assumed (4,299) — — — — — Other liabilities assumed (1,972) (21) (35) (33) (386) (11) Redeemable noncontrolling interest (122) — — — — — $ 16,036 $ 1,864 $ 830 $ 472 $ 18 $ 402 The weighted-average amortization periods for definite-lived intangible assets acquired in 2021 are 17 years for customer relationships, 11 years for product technology, 7 years for tradenames and 3 years for backlog. The weighted average amortization period for all definite-lived intangible assets acquired in 2021 is 14 years. The preliminary allocations of the purchase price for the acquisitions of the Lengnau biologics manufacturing facility, PPD and PeproTech were based on estimates of the fair value of the net assets acquired and are subject to adjustment upon finalization, largely with respect to acquired intangible assets, lease assets and liabilities, and the related deferred taxes. Measurements of these items inherently require significant estimates and assumptions. Unaudited Pro Forma Information The following unaudited pro forma information provides the effect of the company's 2021 acquisition of PPD as if the acquisition had occurred on January 1, 2020: Year Ended December 31, December 31, (In millions) 2021 2020 Revenues $ 44,886 $ 36,887 Net income attributable to Thermo Fisher Scientific Inc. $ 7,369 $ 5,361 The historical consolidated financial information of the company and PPD has been adjusted in the pro forma information to give effect to pro forma events that are directly attributable to the acquisitions and related financing arrangements and are factually supportable. To reflect the acquisition of PPD as if it had occurred on January 1, 2020, the unaudited pro forma results include adjustments to reflect, among other things, the incremental intangible asset amortization to be incurred based on the preliminary values of each identifiable intangible asset and the interest expense from debt financings obtained to partially fund the cash consideration transferred. Pro forma adjustments were tax effected at the company's historical statutory rates in effect for the respective periods. The unaudited pro forma amounts are not necessarily indicative of the combined results of operations that would have been realized had the acquisitions and related financings occurred on the aforementioned dates, nor are they meant to be indicative of any anticipated combined results of operations that the company will experience after the transaction. In addition, the amounts do not include any adjustments for actions that may be taken following the completion of the transaction, such as expected cost savings, operating synergies, or revenue enhancements that may be realized subsequent to the transaction. Pro forma net income attributable to Thermo Fisher Scientific Inc. for the year ended December 31, 2021, excludes $312 million of transaction costs, initial restructuring costs, and debt extinguishment costs directly attributable to the PPD acquisition that were included in the determination of net income attributable to Thermo Fisher Scientific Inc. for that period. These items have reduced pro forma net income attributable to Thermo Fisher Scientific Inc. for the year ended December 31, 2020, by $197 million. The company’s results would not have been materially different from its pro forma results had the company’s other 2021 acquisitions occurred at the beginning of 2020. PPD’s revenues and losses attributable to Thermo Fisher Scientific Inc. in 2021, subsequent to the acquisition date, were $378 million and $(60) million, respectively. The loss includes non-recurring transaction and compensation costs. 2020 In 2020, the company acquired, within the Life Sciences Solutions segment, a U.S.-based provider of a spectral dye platform for high-resolution biology applications which will extend the company’s existing tools for protein and cell analysis applications, for a total purchase price of $63 million including the fair value of contingent consideration. 2019 On April 30, 2019, the company acquired, within the Laboratory Products and Biopharma Services segment, Brammer Bio for approximately $1.67 billion in cash. Brammer Bio is a leading viral vector contract development and manufacturing organization for gene and cell therapies. The acquisition expanded the segment’s contract manufacturing capabilities. The purchase price exceeded the fair value of the identifiable net assets and, accordingly, $938 million was allocated to goodwill, $405 million of which is tax deductible. In addition, in 2019 the company acquired, within the Analytical Instruments segment, a Slovakia-based provider of mass spectrometry software used for identification of compounds, and, within the Laboratory Products and Biopharma Services segment, an active pharmaceutical ingredient manufacturing facility in Cork, Ireland, for an aggregate purchase price of $169 million. The components of the purchase price and net assets acquired for 2019 acquisitions are as follows: (In millions) Brammer Bio Other Purchase price Cash paid $ 1,710 $ 169 Cash acquired (36) — $ 1,674 $ 169 Net assets acquired Current assets $ 52 $ 58 Property, plant and equipment 147 102 Definite-lived intangible assets: Customer relationships 744 — Product technology 65 7 Tradenames 7 — Goodwill 938 9 Other assets 49 — Contract liabilities (110) — Deferred tax liabilities (110) (6) Other liabilities assumed (108) (1) $ 1,674 $ 169 The weighted-average amortization periods for definite-lived intangible assets acquired in 2019 are 14 years for customer relationships, 13 years for product technology and 2 years for tradenames. The weighted average amortization period for all definite-lived intangible assets acquired in 2019 is 14 years. Disposition

Revenue and Contract-related Ba

Revenue and Contract-related Balances	12 Months Ended
	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer [Text Block]	Note 3. Revenues and Contract-related Balances Disaggregated Revenues Revenues by type are as follows: (In millions) 2021 2020 2019 Revenues Consumables $ 22,608 $ 18,527 $ 13,109 Instruments 7,753 6,779 6,387 Services 8,850 6,912 6,046 Consolidated revenues $ 39,211 $ 32,218 $ 25,542 Revenues by geographic region based on customer location are as follows: (In millions) 2021 2020 2019 Revenues North America $ 19,659 $ 17,081 $ 12,896 Europe 11,134 8,284 6,358 Asia-Pacific 7,218 5,822 5,524 Other regions 1,200 1,031 764 Consolidated revenues $ 39,211 $ 32,218 $ 25,542 Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions. See Note 4 for revenues by reportable segment and other geographic data. Remaining Performance Obligations The aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of December 31, 2021 was $28.30 billion. The company will recognize revenues for these performance obligations as they are satisfied, approximately 59% of which is expected to occur within the next twelve months. Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service agreements, which typically have durations of three to five years. Contract-related Balances Noncurrent contract assets are included within other assets in the accompanying balance sheet. Noncurrent contract liabilities are included within other long-term liabilities in the accompanying balance sheet. Contract asset and liability balances are as follows: December 31, December 31, (In millions) 2021 2020 Current contract assets, net $ 968 $ 731 Noncurrent contract assets, net 9 11 Current contract liabilities 2,655 1,271 Noncurrent contract liabilities 1,238 763 Substantially all of the current contract liabilities balance at December 31, 2020 and 2019 was recognized in revenues during 2021 and 2020, respectively.

Business Segment and Geographic

Business Segment and Geographical Information	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Business Segment and Geographical Information [Text Block]	Note 4. Business Segment and Geographical Information The company’s financial performance is reported in four segments. A description of each segment follows. Life Sciences Solutions: provides an extensive portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of disease (including COVID-19 through its polymerase chain reaction (PCR) testing and sample preparation capabilities). These products and services are used by customers in pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets. Analytical Instruments: provides a broad offering of instruments, consumables, software and services that are used for a range of applications in the laboratory, on the production line and in the field. These products and services are used by customers in pharmaceutical, biotechnology, academic, government, environmental and other research and industrial markets, as well as the clinical laboratory. Specialty Diagnostics: provides a wide range of diagnostic test kits, reagents, culture media, instruments and associated products used to increase the speed and accuracy of diagnoses. These products are used by customers in healthcare, clinical, pharmaceutical, industrial and food safety laboratories. Laboratory Products and Biopharma Services (formerly known as Laboratory Products and Services): provides virtually everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial and healthcare settings. The segment also includes a comprehensive offering of outsourced services used by the pharmaceutical and biotech industries for drug development, clinical trials logistics, clinical research services and commercial drug manufacturing. The company’s management evaluates segment operating performance based on operating income before certain charges/credits to cost of revenues and selling, general and administrative expenses, principally associated with acquisition accounting; restructuring and other costs/income including costs arising from facility consolidations such as severance and abandoned lease expense and gains and losses from the sale of real estate and product lines as well as from significant litigation-related matters; and amortization of acquisition-related intangible assets. The company uses this measure because it helps management understand and evaluate the segments’ core operating results and facilitates comparison of performance for determining compensation. Business Segment Information (In millions) 2021 2020 2019 Revenues Life Sciences Solutions $ 15,631 $ 12,168 $ 6,856 Analytical Instruments 6,069 5,124 5,522 Specialty Diagnostics 5,659 5,343 3,718 Laboratory Products and Biopharma Services 14,862 12,245 10,599 Eliminations (3,010) (2,662) (1,153) Consolidated revenues 39,211 32,218 25,542 Segment Income Life Sciences Solutions 7,817 6,109 2,446 Analytical Instruments 1,197 808 1,273 Specialty Diagnostics 1,280 1,368 930 Laboratory Products and Biopharma Services 1,844 1,271 1,324 Subtotal reportable segments 12,138 9,556 5,973 Cost of revenues charges (8) (6) (17) Selling, general and administrative (charges) credits (144) 10 (62) Restructuring and other (costs) income (197) (99) 413 Amortization of acquisition-related intangible assets (1,761) (1,667) (1,713) Consolidated operating income 10,028 7,794 4,594 Interest income 43 65 224 Interest expense (536) (553) (676) Other income/(expense) (694) (76) (70) Income before income taxes $ 8,841 $ 7,230 $ 4,072 Depreciation Life Sciences Solutions $ 197 $ 140 $ 130 Analytical Instruments 83 76 75 Specialty Diagnostics 128 100 67 Laboratory Products and Biopharma Services 423 342 292 Consolidated depreciation $ 831 $ 658 $ 564 Cost of revenues charges included in the above table consist of charges for the sale of inventories revalued at the date of acquisition and accelerated depreciation on fixed assets to estimated disposal value in connection with the consolidation of operations. Selling, general and administrative charges/credits included in the above table consist of third-party transaction/integration costs (including reimbursement thereof) related to recent/terminated acquisitions, charges/credits for changes in estimates of contingent acquisition consideration, and charges/credits related to product liability litigation. (In millions) 2021 2020 2019 Total assets Life Sciences Solutions $ 22,751 $ 20,209 $ 18,306 Analytical Instruments 9,692 9,773 9,896 Specialty Diagnostics 6,010 6,534 5,867 Laboratory Products and Biopharma Services 52,639 22,711 21,761 Corporate/other (a) 4,031 9,825 2,551 Consolidated total assets $ 95,123 $ 69,052 $ 58,381 Capital expenditures Life Sciences Solutions $ 810 $ 392 $ 151 Analytical Instruments 79 74 64 Specialty Diagnostics 167 175 83 Laboratory Products and Biopharma Services 1,327 772 554 Corporate/other 140 61 74 Consolidated capital expenditures $ 2,523 $ 1,474 $ 926 (a) Corporate assets consist primarily of cash and cash equivalents and property and equipment at the company's corporate offices. Geographical Information (In millions) 2021 2020 2019 Revenues (b) United States $ 18,907 $ 16,435 $ 12,366 China 3,444 2,797 2,752 Other 16,860 12,986 10,424 Consolidated revenues $ 39,211 $ 32,218 $ 25,542 Long-lived Assets (c) United States $ 5,578 $ 3,686 $ 3,099 Other 4,286 3,001 2,349 Consolidated long-lived assets $ 9,864 $ 6,687 $ 5,448 (b) Revenues are attributed to countries based on customer location. (c) Includes property, plant and equipment, net, and operating lease ROU assets.

Other Expense, Net

Other Expense, Net	12 Months Ended
	Dec. 31, 2021
Other Income and Expenses [Abstract]
Other Expense, Net [Text Block]	Note 5. Other Income/(Expense) In all periods, other income/(expense) includes currency transaction gains and losses on non-operating monetary assets and liabilities and net periodic pension benefit cost/income, excluding the service cost component which is included in operating expenses on the accompanying statement of income. In 2021, other income/(expense) includes $767 million of losses on the early extinguishment of debt (Note 10), $36 million of financing costs associated with obtaining bridge financing commitments in connection with the agreement to acquire PPD (Note 2), offset in part by $66 million of net gains on investments. The company had a cash outlay of $36 million in 2021 associated with obtaining the bridge financing commitments, included in other financing activities, net, in the accompanying statement of cash flows. In 2020, other income/(expense) includes $81 million of financing costs for a terminated acquisition, primarily for loan commitment fees and entering into hedging contracts and $42 million reclassified from accumulated other comprehensive items related to a hedge arrangement (Note 14), offset in part by $10 million of net gains on investments. The company had a cash outlay of $51 million in 2020 associated with obtaining the loan commitments included in other financing activities, net, in the accompanying statement of cash flows.

Stock-based Compensation Expens

Stock-based Compensation Expense	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Stock-based Compensation Expense [Text Block]	Note 6. Stock-based Compensation Expense The company has stock-based compensation plans for its key employees, directors and others. These plans permit the grant of a variety of stock and stock-based awards, including restricted stock units, stock options or performance-based shares, as determined by the compensation committee of the company’s Board of Directors or, for certain non-officer grants, by the company’s employee equity committee, which consists of its chief executive officer. The company generally issues new shares of its common stock to satisfy option exercises and restricted unit vesting. Grants of stock options and restricted units generally provide that in the event of both a change in control of the company and a qualifying termination of an option or unit holder’s employment, all options and service-based restricted unit awards held by the recipient become immediately vested (unless an employment or other agreement with the employee provides for different treatment). Compensation cost is based on the grant-date fair value and is recognized ratably over the requisite vesting period or to the date based on qualifying retirement eligibility, if earlier, and is primarily included in selling, general and administrative expenses. Stock Options The company’s practice is to grant stock options at fair market value. Options vest over 3-5 years with terms of 7-10 years, assuming continued employment with certain exceptions. Vesting of the option awards is contingent upon meeting certain service conditions. The fair value of most option grants is estimated using the Black-Scholes option pricing model. For option grants that require the achievement of both service and market conditions, a lattice model is used to estimate fair value. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility was calculated based on the historical volatility of the company’s stock. Historical data on exercise patterns is the basis for estimating the expected life of an option. The risk-free interest rate is based on U.S. Treasury zero-coupon issues with a remaining term which approximates the expected life assumed at the date of grant. The expected annual dividend rate was calculated by dividing the company’s annual dividend, based on the most recent quarterly dividend rate, by the closing stock price on the grant date. The compensation expense recognized for all stock-based awards is net of estimated forfeitures. Forfeitures are estimated based on an analysis of actual option forfeitures. The weighted average assumptions used in the Black-Scholes option pricing model are as follows: 2021 2020 2019 Expected stock price volatility 26 % 22 % 21 % Risk free interest rate 0.8 % 1.1 % 2.4 % Expected life of options (years) 4.3 4.3 4.3 Expected annual dividend 0.2 % 0.3 % 0.3 % The weighted average per share grant-date fair values of options granted during 2021, 2020 and 2019 were $123.97, $61.19 and $53.37, respectively. The total intrinsic value of options exercised during the same periods was $501 million, $457 million and $320 million, respectively. The intrinsic value is the difference between the market value of the shares on the exercise date and the exercise price of the option. A summary of the company’s option activity for the year ended December 31, 2021 is presented below: Shares Weighted average exercise price Weighted average remaining contractual term Aggregate intrinsic Outstanding at December 31, 2020 5.9 $ 221.22 Granted 1.5 552.26 Issued in connection with an acquisition 0.2 492.35 Exercised (1.4) 183.63 Canceled/expired (0.2) 341.83 Outstanding at December 31, 2021 6.0 $ 319.95 4.5 $ 2,094 Vested and unvested expected to vest at December 31, 2021 5.7 $ 306.64 4.3 $ 2,035 Exercisable at December 31, 2021 2.8 $ 193.39 2.9 $ 1,307 As of December 31, 2021, there was $243 million of total unrecognized compensation cost related to unvested stock options granted. The cost is expected to be recognized through 2025 with a weighted average amortization period of 2.9 years. Restricted Share/Unit Awards Awards of restricted units convert into an equivalent number of shares of common stock. The awards generally vest over 3-4 years, assuming continued employment, with some exceptions. Vesting of the awards is contingent upon meeting certain service conditions and may also be contingent upon meeting certain performance and/or market conditions. The fair market value of the award at the time of the grant is amortized to expense over the requisite service period of the award, which is generally the vesting period. Recipients of restricted units have no voting rights but are entitled to accrue dividend equivalents. The fair value of service- and performance-based restricted unit awards is determined based on the number of units granted and the market value of the company’s shares on the grant date. For awards with market-based vesting conditions, the company uses a lattice model to estimate the grant-date fair value of the award. A summary of the company’s restricted unit activity for the year ended December 31, 2021 is presented below: Units Weighted Unvested at December 31, 2020 0.8 $ 276.74 Granted 0.4 444.61 Issued in connection with an acquisition 0.2 628.71 Vested (0.5) 295.70 Forfeited (0.1) 326.90 Unvested at December 31, 2021 0.8 $ 425.39 The total fair value of shares vested during 2021, 2020 and 2019 was $151 million, $126 million and $118 million, respectively. As of December 31, 2021, there was $250 million of total unrecognized compensation cost related to unvested restricted stock unit awards. The cost is expected to be recognized through 2025 with a weighted average amortization period of 2.1 years. Employee Stock Purchase Plans Qualifying employees are eligible to participate in an employee stock purchase plan sponsored by the company. Shares may be purchased under the program at 95% of the fair market value at the end of the purchase period and the shares purchased are not subject to a holding period. Shares are purchased through payroll deductions of up to 10% of each participating employee’s qualifying gross wages. The company issued 0.1 million, 0.1 million and 0.2 million shares, respectively, of its common stock in 2021, 2020 and 2019 under the employee stock purchase plan.

Pension and Other Postretiremen

Pension and Other Postretirement Benefit Plans	12 Months Ended
	Dec. 31, 2021
Retirement Benefits [Abstract]
Pension and Other Postretirement Benefit Plans [Text Block]	Note 7. Pension and Other Postretirement Benefit Plans 401(k) Savings Plan and Other Defined Contribution Plans The company’s 401(k) savings and other defined contribution plans cover the majority of the company’s eligible U.S. and certain non-U.S. employees. Contributions to the plans are made by both the employee and the company. Company contributions are based on the level of employee contributions. Company contributions to these plans are based on formulas determined by the company. In 2021, 2020 and 2019, the company charged to expense $299 million, $254 million and $232 million, respectively, related to its defined contribution plans. Defined Benefit Pension Plans Employees of a number of the company’s non-U.S. and certain U.S. subsidiaries participate in defined benefit pension plans covering substantially all full-time employees at those subsidiaries. Some of the plans are unfunded, as permitted under the plans and applicable laws. The company also maintains postretirement healthcare programs at several acquired businesses where certain employees are eligible to participate. The liabilities and costs associated with the company’s postretirement healthcare programs are generally funded on a self-insured and insured-premium basis and are not material for any period presented. The company recognizes the funded status of defined benefit pension and other postretirement benefit plans as an asset or liability. This amount is defined as the difference between the fair value of plan assets and the benefit obligation. The company is required to recognize as a component of other comprehensive items, net of tax, the actuarial gains/losses and prior service costs/credits that arise but were not previously required to be recognized as components of net periodic benefit cost. Other comprehensive items is adjusted as these amounts are later recognized in income as components of net periodic benefit cost. When a company with a pension plan is acquired, any excess of projected benefit obligation over the plan assets is recognized as a liability and any excess of plan assets over the projected benefit obligation is recognized as an asset. The recognition of a new liability or a new asset results in the elimination of (a) previously existing unrecognized net gain or loss and (b) unrecognized prior service cost or credits. The company funds annually, at a minimum, the statutorily required minimum amount as actuarially determined. During 2021, 2020 and 2019, the company made cash contributions of approximately $34 million, $96 million and $50 million, respectively. Contributions to the plans included in the following table are estimated at between $40 and $60 million for 2022. The following table provides a reconciliation of benefit obligations and plan assets of the company’s domestic and non-U.S. pension plans: Domestic pension Non-U.S. pension (In millions) 2021 2020 2021 2020 Change in projected benefit obligations Benefit obligation at beginning of year $ 1,302 $ 1,302 $ 1,486 $ 1,303 Acquisitions — — 170 — Service costs — — 27 24 Interest costs 23 35 11 18 Settlements — — (7) (38) Plan participants' contributions — — 6 5 Actuarial (gains) losses 20 44 (57) 119 Benefits paid (85) (79) (30) (26) Currency translation and other — — (54) 81 Benefit obligation at end of year $ 1,260 $ 1,302 $ 1,552 $ 1,486 Change in fair value of plan assets Fair value of plan assets at beginning of year $ 1,267 $ 1,201 $ 1,160 $ 986 Acquisitions — — 158 — Actual return on plan assets 37 138 14 92 Employer contribution 7 7 27 87 Settlements — — (7) (38) Plan participants' contributions — — 6 5 Benefits paid (85) (79) (30) (26) Currency translation and other — — (26) 54 Fair value of plan assets at end of year $ 1,226 $ 1,267 $ 1,302 $ 1,160 Funded status $ (34) $ (35) $ (250) $ (326) Accumulated benefit obligation $ 1,260 $ 1,302 $ 1,475 $ 1,417 Amounts recognized in balance sheet Noncurrent assets $ 32 $ 38 $ 205 $ 157 Current liability (7) (8) (10) (9) Noncurrent liabilities (59) (65) (445) (474) Net amount recognized $ (34) $ (35) $ (250) $ (326) Amounts recognized in accumulated other comprehensive items Net actuarial loss $ 157 $ 142 $ 167 $ 242 Prior service credits — — (3) (2) Net amount recognized $ 157 $ 142 $ 164 $ 240 For domestic pension plans, actuarial losses experienced in 2021 were driven by differences between actual and expected returns on plan assets for certain portions of plan benefits indexed to asset returns, which were partially offset by actuarial gains due to increases in the weighted average discount rates used to determine the projected benefit obligation differences. For non-U.S. pension plans, actuarial gains experienced in 2021 were principally driven by increases in the weighted average discount rates used to determine the projected benefit obligation. For both domestic and non-U.S. pension plans, actuarial losses experienced in 2020 were principally driven by decreases in the weighted average discount rates used to determine the projected benefit obligation. For domestic pension plans, the 2020 actuarial losses were partially offset by gains recognized due to the adoption of an updated mortality assumption. The actuarial assumptions used to compute the funded status for the plans are based upon information available as of December 31, 2021 and 2020 and are as follows: Domestic pension Non-U.S. pension 2021 2020 2021 2020 Weighted average assumptions used to determine projected benefit obligations Discount rate for determining benefit obligation 2.70 % 2.33 % 1.45 % 0.95 % Interest crediting rate for cash balance plans 2.58 % 2.16 % 1.25 % 1.25 % Average rate of increase in employee compensation N/A N/A 2.73 % 2.30 % The actuarial assumptions used to compute the net periodic pension benefit cost (income) are based upon information available as of the beginning of the year, as presented in the following table: Domestic pension benefits Non-U.S. pension benefits 2021 2020 2019 2021 2020 2019 Weighted average assumptions used to determine net benefit cost (income) Discount rate - service cost N/A N/A N/A 0.65 % 1.21 % 1.97 % Discount rate - interest cost 2.33 % 3.13 % 4.22 % 0.80 % 1.44 % 2.06 % Average rate of increase in employee compensation N/A N/A N/A 2.30 % 2.27 % 2.47 % Expected long-term rate of return on assets 4.25 % 5.00 % 5.76 % 2.02 % 2.33 % 3.25 % The discount rate reflects the rate the company would have to pay to purchase high-quality investments that would provide cash sufficient to settle its current pension obligations. The discount rate is determined based on a range of factors, including the rates of return on high-quality, fixed-income corporate bonds and the related expected duration of the obligations or, in certain instances, the company has used a hypothetical portfolio of high quality instruments with maturities that mirror the benefit obligation in order to accurately estimate the discount rate relevant to a particular plan. The company utilizes a full yield curve approach in the estimation of these components by applying the specific spot-rates along the yield curve used in the determination of the benefit obligation to the relevant projected cash flows. The expected long-term rate of return on plan assets reflects the average rate of earnings expected on the funds invested, or to be invested, to provide for the benefits included in the projected benefit obligations. In determining the expected long-term rate of return on plan assets, the company considers the relative weighting of plan assets, the historical performance of total plan assets and individual asset classes and economic and other indicators of future performance. In addition, the company may consult with and consider the opinions of financial and other professionals in developing appropriate return benchmarks. Asset management objectives include maintaining an adequate level of diversification to reduce interest rate and market risk and providing adequate liquidity to meet immediate and future benefit payment requirements. The expected rate of compensation increase reflects the long-term average rate of salary increases and is based on historic salary increase experience and management’s expectations of future salary increases. The projected benefit obligation and fair value of plan assets for the company’s qualified and non-qualified pension plans with projected benefit obligations in excess of plan assets are as follows: Pension plans (In millions) 2021 2020 Pension plans with projected benefit obligations in excess of plan assets Projected benefit obligation $ 2,010 $ 2,047 Fair value of plan assets 1,521 1,529 The accumulated benefit obligation and fair value of plan assets for the company's qualified and non-qualified pension plans with accumulated benefit obligations in excess of plan assets are as follows: Pension plans (In millions) 2021 2020 Pension plans with accumulated benefit obligations in excess of plan assets Accumulated benefit obligation $ 1,937 $ 1,976 Fair value of plan assets 1,521 1,526 The measurement date used to determine benefit information is December 31 for all plan assets and benefit obligations. The net periodic pension benefit cost (income) includes the following components: Domestic pension benefits Non-U.S. pension benefits (In millions) 2021 2020 2019 2021 2020 2019 Components of net benefit cost (income) Service cost $ — $ — $ — $ 27 $ 24 $ 23 Interest cost on benefit obligation 23 35 45 11 18 24 Expected return on plan assets (40) (47) (55) (19) (19) (30) Amortization of actuarial net loss 7 6 2 12 10 6 Amortization of prior service benefit — — — — (1) (1) Settlement/curtailment loss — — — — 8 4 Net periodic benefit cost (income) $ (10) $ (6) $ (8) $ 31 $ 40 $ 26 Expected benefit payments are estimated using the same assumptions used in determining the company’s benefit obligation at December 31, 2021. Benefit payments will depend on future employment and compensation levels, average years employed and average life spans, among other factors, and changes in any of these factors could significantly affect these estimated future benefit payments. Estimated future benefit payments during the next five years and in the aggregate for the five fiscal years thereafter, are as follows: (In millions) Domestic Non-U.S. Expected benefit payments 2022 $ 93 $ 45 2023 89 45 2024 88 49 2025 86 52 2026 84 56 2027-2031 368 307 Domestic Pension Plan Assets The company’s overall objective is to manage the assets in a liability framework where investments are selected that are expected to have similar changes in fair value as the related liabilities will have upon changes in interest rates. The company invests in a portfolio of both return-seeking and liability-hedging assets, primarily through the use of institutional collective funds, to achieve long-term growth and to insulate the funded position from interest rate volatility. The strategic asset allocation uses a combination of risk controlled and index strategies in fixed income and global equities. The target allocations for the investments are approximately 10% to funds investing in U.S. equities, approximately 10% to funds investing in international equities and approximately 80% to funds investing in fixed income securities. The portfolio maintains enough liquidity at all times to meet the near-term benefit payments. Non-U.S. Pension Plan Assets The company maintains specific plan assets for many of the individual pension plans outside the U.S. The investment strategy of each plan has been uniquely established based on the country specific standards and characteristics of the plans. Several of the plans have contracts with insurance companies whereby the market risks of the benefit obligations are borne by the insurance companies. When assets are held directly in investments, generally the objective is to invest in a portfolio of diversified assets with a variety of fund managers. The investments may include equity funds, fixed income funds, hedge funds, multi-asset funds, alternative investments and derivative funds with the target asset allocations ranging from approximately 0% - 25% for equity funds, 40% - 90% for fixed income funds, 0% - 35% for multi-asset funds, and 0% - 30% for funds holding derivatives. The derivatives held by the funds are primarily interest rate swaps intended to match the movements in the plan liabilities. Each plan maintains enough liquidity at all times to meet the near-term benefit payments. The fair values of the company’s plan assets at December 31, 2021 and 2020, by asset category are as follows: December 31, Quoted Significant Significant Not subject to leveling (a) (In millions) 2021 (Level 1) (Level 2) (Level 3) Domestic pension plan assets U.S. equity funds $ 124 $ — $ — $ — $ 124 International equity funds 117 — — — 117 Fixed income funds 966 — — — 966 Money market funds 19 — — — 19 Total domestic pension plans $ 1,226 $ — $ — $ — $ 1,226 Non-U.S. pension plan assets Equity funds $ 17 $ — $ — $ — $ 17 Fixed income funds 651 — — — 651 Hedge funds 3 — — — 3 Multi-asset funds 73 — — — 73 Derivative funds 253 — — — 253 Alternative investments 1 — — — 1 Insurance contracts 295 — 295 — — Cash / money market funds 9 5 — — 4 Total non-U.S. pension plans $ 1,302 $ 5 $ 295 $ — $ 1,002 (a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. December 31, Quoted Significant Significant Not subject to leveling (a) (In millions) 2020 (Level 1) (Level 2) (Level 3) Domestic pension plan assets U.S. equity funds $ 125 $ — $ — $ — $ 125 International equity funds 126 — — — 126 Fixed income funds 1,001 — — — 1,001 Money market funds 15 — — — 15 Total domestic pension plans $ 1,267 $ — $ — $ — $ 1,267 Non-U.S. pension plan assets Equity funds $ 74 $ — $ — $ — $ 74 Fixed income funds 510 — — — 510 Hedge funds 59 — — — 59 Multi-asset funds 45 — — — 45 Derivative funds 149 — — — 149 Alternative investments 6 — — — 6 Insurance contracts 262 — 262 — — Cash / money market funds 55 7 — — 48 Total non-U.S. pension plans $ 1,160 $ 7 $ 262 $ — $ 891 (a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. The tables above present the fair value of the company’s plan assets in accordance with the fair value hierarchy (Note 14). Certain investments that are measured at fair value using the net asset value per share practical expedient have not been classified in the fair value hierarchy. The fair value amounts of these investments presented in the above tables are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension plan assets. These investments were also redeemable at the balance sheet date or within limited time restrictions.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes [Text Block]	Note 8. Income Taxes The components of income before provision for income taxes are as follows: (In millions) 2021 2020 2019 U.S. $ 3,340 $ 4,762 $ 2,280 Non-U.S. 5,501 2,468 1,792 Income before income taxes $ 8,841 $ 7,230 $ 4,072 The components of the provision for income taxes are as follows: (In millions) 2021 2020 2019 Current income tax provision Federal $ 446 $ 521 $ 267 Non-U.S. 1,148 423 544 State 160 175 62 1,754 1,119 873 Deferred income tax provision (benefit) Federal $ (227) $ (237) $ (222) Non-U.S. (399) (18) (252) State (19) (14) (25) (645) (269) (499) Provision for income taxes $ 1,109 $ 850 $ 374 The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before income taxes due to the following: (In millions) 2021 2020 2019 Statutory federal income tax rate 21 % 21 % 21 % Provision for income taxes at statutory rate $ 1,857 $ 1,518 $ 855 Increases (decreases) resulting from: Foreign rate differential (255) (223) (204) Income tax credits (315) (335) (213) Global intangible low-taxed income 76 86 92 Foreign-derived intangible income (119) (156) (111) Excess tax benefits from stock options and restricted stock units (124) (114) (80) Provision for (reversal of) tax reserves, net (17) (26) 62 Intra-entity transfers (284) — (79) Foreign exchange loss on inter-company debt refinancing — (47) (62) Domestication transaction — (263) — Valuation allowance 36 379 (4) Withholding taxes 164 115 38 Basis difference on disposal of business — — 73 Tax return reassessments and settlements 1 (196) (6) State income taxes, net of federal tax 82 147 22 Other, net 7 (35) (9) Provision for income taxes $ 1,109 $ 850 $ 374 The company has operations and a taxable presence in approximately 50 countries outside the U.S. The company's effective income tax rate differs from the U.S. federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes, and foreign taxes that are different than the U.S. federal statutory rate. During 2021, the company recorded a $188 million income tax benefit related to the deferred tax implications of an intra-entity transfer of assets. Also in 2021, the company recorded a $96 million income tax benefit related to a capital loss resulting from certain intra-entity transactions. During 2020, the company settled an IRS audit relating to the 2014, 2015, and 2016 tax years. The company recorded a $25 million net tax benefit primarily from this settlement and related impacts, which resulted in a decrease in the company’s unrecognized tax benefits of $378 million, of which $144 million was reclassified to income taxes payable. The company recorded $53 million of charges for expired tax credits and other related components of the settlement. The company recorded a charge of $156 million to establish a valuation allowance against certain U.S. foreign tax credits which the company believes will more likely than not expire unutilized. In 2020, the company recorded a $263 million income tax benefit related to a domestication transaction involving the transfer of certain non-U.S. subsidiaries to the U.S., including interest expense of those subsidiaries. The company also recorded a valuation allowance of $212 million against the amount of interest expense that the company believes will more likely than not go unused. Also in 2020, the company recorded a $47 million income tax benefit, including both U.S. federal and state taxes, related to a foreign exchange loss for tax purposes on certain intercompany financing arrangements. In 2019, the company recorded a $62 million income tax benefit, including both U.S. federal and state taxes, related to a foreign exchange loss for tax purposes on certain intercompany financing arrangements as well as a tax provision of $191 million related to the gain on the sale of the Anatomical Pathology business. Also in 2019, the company recorded a $79 million benefit related to the deferred tax implications of intra-entity transactions which included a tax benefit to release a valuation allowance against net operating losses previously determined to be unrealizable. The foreign tax credits discussed below are the result of foreign earnings and profits remitted or deemed remitted to the U.S. during the reporting year and the U.S. treatment of taxes paid in the foreign jurisdictions in the years those profits were originally earned. In 2020, the company implemented foreign tax credit planning in Sweden which resulted in $96 million of foreign tax credits, with no related incremental U.S. income tax expense. In 2019, the company implemented foreign tax credit planning in Sweden which resulted in $75 million of foreign tax credits, with no related incremental U.S. income tax expense. The company generally receives a tax deduction upon the exercise of non-qualified stock options by employees, or the vesting of restricted stock units held by employees, for the difference between the exercise price and the market price of the underlying common stock on the date of exercise. The company uses the incremental tax benefit approach for utilization of tax attributes. These excess tax benefits reduce the tax provision. In 2021, 2020 and 2019, the company's tax provision was reduced by $124 million, $114 million and $80 million, respectively, of such benefits. Net deferred tax asset (liability) in the accompanying balance sheet consists of the following: (In millions) 2021 2020 Deferred tax asset (liability) Depreciation and amortization $ (4,687) $ (2,962) Net operating loss and credit carryforwards 1,652 1,668 Reserves and accruals 162 164 Accrued compensation 318 253 Inventory basis difference 181 112 Deferred interest 295 227 Unrealized (gains) losses on hedging instruments (33) 242 Other, net 251 124 Deferred tax liabilities, net before valuation allowance (1,861) (172) Less: Valuation allowance 968 933 Deferred tax liabilities, net $ (2,829) $ (1,105) The company estimates the degree to which tax assets and loss and credit carryforwards will result in a benefit based on expected profitability by tax jurisdiction and provides a valuation allowance for tax assets and loss and credit carryforwards that it believes will more likely than not expire unutilized. At December 31, 2021, all of the company’s valuation allowance relates to deferred tax assets, primarily net operating losses and disallowed interest expense carryforward, for which any subsequently recognized tax benefits will reduce income tax expense. The changes in the valuation allowance are as follows: Year Ended December 31, (In millions) 2021 2020 2019 Beginning balance $ 933 $ 408 $ 471 Additions (reductions) charged to income tax provision, net 24 514 (27) Additions due to acquisitions 30 — — Reduction due to a divestiture — — (33) Currency translation and other (19) 11 (3) Ending balance $ 968 $ 933 $ 408 At December 31, 2021, the company had net federal, state and non-U.S. net operating loss carryforwards of $72 million, $88 million and $1.18 billion, respectively. Use of the carryforwards is limited based on the future income of certain subsidiaries. The federal and state net operating loss carryforwards expire in the years 2022 through 2041. Of the net non-U.S. net operating loss carryforwards, $419 million expire in the years 2025 through 2041, and the remainder do not expire. At December 31, 2021, the company had foreign tax credit carryforwards of $610 million and deferred interest carryforwards of $295 million. The foreign tax credit carryforwards will expire in the years 2022 through 2030 while deferred interest carryforwards do not expire. U.S. federal taxes have been recorded on $24 billion of undistributed foreign earnings as of December 31, 2021. A provision has not been made for certain U.S. state income taxes or additional non-U.S. taxes that would be due when cash is repatriated to the U.S. as the company’s undistributed foreign earnings are intended to be reinvested outside of the U.S. indefinitely. The determination of the amount of the unrecognized deferred tax liability related to the undistributed foreign earnings is not practicable due to the uncertainty in the manner in which these earnings will be distributed. The company’s intent is to only make distributions from non-U.S. subsidiaries in the future when they can be made at no net tax cost. Unrecognized Tax Benefits As of December 31, 2021, the company had $1.12 billion of unrecognized tax benefits substantially all of which, if recognized, would reduce the effective tax rate. A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows: (In millions) 2021 2020 2019 Beginning balance $ 1,091 $ 1,552 $ 1,442 Additions due to acquisitions 26 — — Additions for tax positions of current year 32 8 53 Additions for tax positions of prior years 60 — 69 Reductions for tax positions of prior years (5) (296) (7) Closure of tax years (27) — — Settlements (53) (173) (5) Ending balance $ 1,124 $ 1,091 $ 1,552 Substantially all of the unrecognized tax benefits are classified as long-term liabilities. The company does not expect its unrecognized tax benefits to change significantly over the next twelve months. During 2021, the company’s unrecognized tax benefits increased by $80 million as a result of uncertain tax positions relating to foreign tax positions and decreased $75 million relating to U.S. federal and state tax positions. The company also assumed $26 million of uncertain tax benefits as part of the acquisition of PPD. During 2020, the company’s unrecognized tax benefits decreased $51 million as a result of uncertain tax positions relating to foreign tax positions and $410 million relating to U.S. federal and state tax positions which included $378 million from the settlement of the IRS audit of the 2014, 2015 and 2016 tax years. During 2019, the company’s unrecognized tax benefits increased $70 million as a result of uncertain tax positions relating to foreign tax positions and $45 million relating to U.S. federal and state tax positions. The company classified interest and penalties related to unrecognized tax benefits as income tax expense. The total amount of interest and penalties related to uncertain tax positions and recognized in the balance sheet as of December 31, 2021 and 2020 was $59 million and $78 million, respectively. The company conducts business globally and, as a result, Thermo Fisher or one or more of its subsidiaries files income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. In the normal course of business, the company is subject to examination by taxing authorities throughout the world, including such major jurisdictions as Australia, Canada, China, Denmark, Finland, France, Germany, Japan, Singapore, Sweden, the United Kingdom and the United States. With few exceptions, the company is no longer subject to U.S. state and local or non-U.S. income tax examinations for years before 2012 and no longer subject to U.S. federal income tax examinations for years before 2017.

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Note 9. Earnings per Share (In millions except per share amounts) 2021 2020 2019 Net income attributable to Thermo Fisher Scientific Inc. $ 7,725 $ 6,375 $ 3,696 Basic weighted average shares 394 396 400 Plus effect of: stock options and restricted stock units 3 3 3 Diluted weighted average shares 397 399 403 Basic earnings per share $ 19.62 $ 16.09 $ 9.24 Diluted earnings per share $ 19.46 $ 15.96 $ 9.17 Antidilutive stock options excluded from diluted weighted average shares 1 1 1

Debt and Other Financing Arrang

Debt and Other Financing Arrangements	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Debt and Other Financing Arrangements [Text Block]	Note 10. Debt and Other Financing Arrangements Effective interest rate at December 31, December 31, December 31, (Dollars in millions) 2021 2021 2020 Commercial Paper 0.01 % $ 2,522 $ — 2.15% 7-Year Senior Notes, Due 7/21/2022 (euro-denominated) — 611 3.00% 7-Year Senior Notes, Due 4/15/2023 — 1,000 Floating Rate (SOFR + 0.35%) 1.5-Year Senior Notes, Due 4/18/2023 1,000 — Floating Rate (SOFR + 0.39%) 2-Year Senior Notes, Due 10/18/2023 500 — 0.797% 2-Year Senior Notes, Due 10/18/2023 1.03 % 1,350 — Floating Rate (EURIBOR + 0.20%) 2-Year Senior Notes Due 11/18/2023 (euro-denominated) 0.00 % 1,933 — 0.000% 2-Year Senior Notes Due 11/18/2023 (euro-denominated) 0.06 % 625 — 4.15% 10-Year Senior Notes, Due 2/1/2024 — 1,000 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) 0.94 % 1,137 1,222 1.215% 3-Year Senior Notes, Due 10/18/2024 1.42 % 2,500 — Floating Rate (SOFR + 0.53%) 3-Year Senior Notes, Due 10/18/2024 500 — 0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated) 0.41 % 910 977 4.133% 5-Year Senior Notes, Due 3/25/2025 — 1,100 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) 2.10 % 728 782 0.000% 4-Year Senior Notes Due 11/18/2025 (euro-denominated) 0.16 % 625 — 3.65% 10-Year Senior Notes, Due 12/15/2025 3.77 % 350 350 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) 1.53 % 796 855 2.95% 10-Year Senior Notes, Due 9/19/2026 — 1,200 Effective interest rate at December 31, December 31, December 31, (Dollars in millions) 2021 2021 2020 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) 1.66 % 568 611 1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated) 1.97 % 682 733 3.20% 10-Year Senior Notes, Due 8/15/2027 — 750 0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated) 0.77 % 910 977 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) 1.46 % 682 733 1.750% 7-Year Senior Notes, Due 10/15/2028 1.89 % 700 — 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) 2.08 % 796 855 2.60% 10-Year Senior Notes, Due 10/1/2029 2.74 % 900 900 4.497% 10-Year Senior Notes, Due 3/25/2030 — 1,100 0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated) 0.89 % 1,990 — 0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated) 1.13 % 1,023 1,099 2.00% 10-Year Senior Notes, Due 10/15/2031 2.23 % 1,200 — 2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated) 2.55 % 682 733 1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated) 1.21 % 1,706 — 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) 2.94 % 796 855 1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated) 1.73 % 1,023 1,099 2.80% 20-Year Senior Notes, Due 10/15/2041 2.90 % 1,200 — 1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated) 1.78 % 1,421 — 5.30% 30-Year Senior Notes, Due 2/1/2044 5.37 % 400 400 4.10% 30-Year Senior Notes, Due 8/15/2047 4.23 % 750 750 1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated) 1.98 % 1,137 1,222 2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated) 2.07 % 853 — Other 76 5 Total borrowings at par value 34,971 21,919 Fair value hedge accounting adjustments — 25 Unamortized discount (117) (102) Unamortized debt issuance costs (184) (114) Total borrowings at carrying value 34,670 21,728 Finance lease liabilities 200 7 Less: Short-term obligations and current maturities 2,537 2,628 Long-term obligations $ 32,333 $ 19,107 SOFR - Secured Overnight Financing Rate EURIBOR - Euro Interbank Offered Rate The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discount and the amortization of any debt issuance costs. See Note 14 for fair value information pertaining to the company’s long-term borrowings. As of December 31, 2021, the annual repayment requirements for debt obligations are as follows: (In millions) Borrowings Finance Lease Liabilities 2022 $ 2,522 $ 15 2023 5,396 12 2024 4,138 12 2025 2,610 12 2026 797 12 2027 and thereafter 19,508 137 $ 34,971 $ 200 In addition to available borrowings under the company’s revolving credit agreements, discussed below, the company had unused lines of credit of $78 million as of December 31, 2021. These unused lines of credit generally provide for short-term unsecured borrowings at various interest rates. Credit Facilities On January 7, 2022, the company entered into a new revolving credit facility (the Facility) with a bank group that provides for up to $5.00 billion of unsecured multi-currency revolving credit The Facility replaces the company’s $3.00 billion credit facility which was in place at December 31, 2021 (the prior credit facility). The Facility expires on January 7, 2027. The revolving credit agreement calls for interest at either a Term SOFR, a EURIBOR-based rate (for funds drawn in euro) or a rate based on the prime lending rate of the agent bank, at the company’s option. The agreement contains affirmative, negative and financial covenants, and events of default customary for facilities of this type. The covenants in the Facility include a Consolidated Net Interest Coverage Ratio (Consolidated EBITDA to Consolidated Net Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum Consolidated Interest Coverage Ratio of 3.5:1.0 as of the last day of any fiscal quarter. As of December 31, 2021, no borrowings were outstanding under the prior credit facility, although available capacity was reduced by approximately $4 million as a result of outstanding letters of credit. Commercial Paper Programs The company has commercial paper programs pursuant to which it may issue and sell unsecured, short-term promissory notes (CP Notes). Under the U.S. program, a) maturities may not exceed 397 days from the date of issue and b) the CP Notes are issued on a private placement basis under customary terms in the commercial paper market and are not redeemable prior to maturity nor subject to voluntary prepayment. Under the euro program, maturities may not exceed 183 days and may be denominated in euro, U.S. dollars, Japanese yen, British pounds sterling, Swiss franc, Canadian dollars or other currencies. Under both programs, the CP Notes are issued at a discount from par (or premium to par, in the case of negative interest rates), or, alternatively, are sold at par and bear varying interest rates on a fixed or floating basis. As of December 31, 2021, there were $2.52 billion outstanding borrowings under these programs. Senior Notes Interest is payable quarterly on the floating rate senior notes, annually on the euro-denominated fixed rate senior notes and semi-annually on all other senior notes. Each of the fixed rate senior notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium and accrued interest. Except for the euro-denominated floating rate senior notes, which may not be redeemed early, the floating rate senior notes may be redeemed in whole or in part on or after their applicable call dates at a redemption price of 100% of the principal amount plus accrued interest. The company is subject to certain affirmative and negative covenants under the indentures governing the senior notes, the most restrictive of which limits the ability of the company to pledge principal properties as security under borrowing arrangements. The company was in compliance with all covenants at December 31, 2021. The company intends to allocate an amount equal to the net proceeds from the 0.000% senior notes due 2025 to finance or refinance, in whole or in part, certain green or social eligible projects. Pending allocation to green or social eligible projects, such net proceeds may be temporarily invested in cash, cash equivalents, short-term investments, or used to repay other borrowings. In 2021, the company redeemed some of its existing senior notes. In connection with these redemptions, the company incurred $767 million of losses on the early extinguishment of debt included in other income/(expense) on the accompanying statement of income. Upon redemption of the senior notes, the company terminated the related fixed to floating rate interest rate swap arrangements and received $22 million, included in other financing activities, net, in the accompanying statement of cash flows. In 2019, the company refinanced certain of its debt by issuing new senior notes and using the proceeds to redeem some of its existing senior notes. In connection with these redemptions, the company incurred $184 million of losses on the early extinguishment of debt included in other income/(expense) on the accompanying statement of income. Upon redemption of the senior notes, the company terminated the related fixed to floating rate interest rate swap arrangements and paid $17 million, included in other financing activities, net, in the accompanying statement of cash flows. The company also terminated related cross-currency interest rate swap arrangements and received $44 million, included in other investing activities, net, in the accompanying statement of cash flows. In February 2022, the company redeemed all of its 3.650% Senior Notes due 2025. In connection with the redemption the company incurred approximately $26 million of losses on the early extinguishment of debt in the first quarter of 2022.

Leases

Leases	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Lessee, Operating Leases [Text Block]	Note 11. Leases As a lessee, the company leases certain logistics, office, and manufacturing facilities, as well as vehicles, copiers, and other equipment. These operating leases generally have remaining lease terms between 1 month and 30 years, and some include options to extend (generally for 1 to 10 years) or have options to terminate the arrangement within 1 year. The company has guaranteed the residual value of three leased operating facilities with lease terms ending in 2023, 2024 and 2025. The company has agreed with the lessor to comply with certain financial covenants consistent with its other debt arrangements (Note 10). The aggregate maximum guarantee under these three lease arrangements is $147 million. Operating lease ROU assets and lease liabilities for these lease arrangements are recorded on the consolidated balance sheet as of December 31, 2021, but exclude any amounts for residual value guarantees. As a lessee, the consolidated financial statements include the following relating to operating leases: (In millions) 2021 2020 2019 Balance sheet ROU assets $ 1,531 $ 775 Operating lease liabilities - current 266 184 Operating lease liabilities - noncurrent 1,203 626 Statement of income Operating lease costs $ 254 $ 224 $ 208 Variable lease costs 66 49 41 Statement of cash flows Cash used in operating activities for payments of amounts included in the measurement of operating lease liabilities $ 288 $ 222 $ 208 Operating lease ROU assets obtained in exchange for new operating lease liabilities 293 202 205 Weighted average at end of year Remaining operating lease term 9.9 years 6.3 years 6.2 years Discount rate 2.6 % 3.4 % 4.0 % ROU assets are classified in other assets other accrued expenses other long-term liabilities Lease costs arising from finance leases, short-term leases, and sublease income are not material. See Note 10 for additional information relating to finance leases. As of December 31, 2021, future payments of operating lease liabilities are as follows: (In millions) 2022 $ 303 2023 248 2024 193 2025 144 2026 120 2027 and thereafter 650 Total lease payments 1,658 Less: imputed interest 189 Total operating lease liability $ 1,469 As a lessor, operating leases, sales-type leases and direct financing leases are not material.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies [Text Block]	Note 12. Commitments and Contingencies Purchase Obligations The company has entered into unconditional purchase obligations, in the ordinary course of business, that include agreements to purchase goods, services or fixed assets and to pay royalties that are enforceable and legally binding and that specify all significant terms including: fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. Purchase obligations exclude agreements that are cancelable at any time without penalty. The aggregate amount of the company’s unconditional purchase obligations totaled $2.51 billion at December 31, 2021 and the majority of these obligations are expected to be settled during 2022. The Analytical Instruments segment recorded a charge to cost of product revenues for $108 million in 2020 related to an existing supply contract for components of electron microscopy instruments. The agreement requires the company to make future minimum purchases through 2025. The company developed and launched an alternative product beginning in 2020 and based on the expected demand for the internally developed product vs. the third-party product, the company does not expect to use all of the product it will be required to buy, resulting in a loss on the purchase commitment. Letters of Credit, Guarantees and Other Commitments Outstanding letters of credit and bank guarantees totaled $266 million at December 31, 2021. Substantially all of these letters of credit and guarantees expire before 2039. Outstanding surety bonds and other guarantees totaled $95 million at December 31, 2021. The expiration of these bonds and guarantees ranges through 2023. The letters of credit, bank guarantees and surety bonds principally secure performance obligations, and allow the holder to draw funds up to the face amount of the letter of credit, bank guarantee or surety bond if the applicable business unit does not perform as contractually required. The company is a guarantor of pension plan obligations of a divested business. The purchaser of the divested business has agreed to pay for the pension benefits, however the company was required to guarantee payment of these pension benefits should the purchaser fail to do so. The amount of the guarantee at December 31, 2021 was $36 million. In connection with the sale of businesses of the company, the buyers have assumed certain contractual obligations of such businesses and have agreed to indemnify the company with respect to those assumed liabilities. In the event a third-party to a transferred contract does not recognize the transfer of obligations or a buyer defaults on its obligations under the transferred contract, the company could be liable to the third-party for such obligations. However, in such event, the company would be entitled to seek indemnification from the buyer. Indemnifications In conjunction with certain transactions, primarily divestitures, the company has agreed to indemnify the other parties with respect to certain liabilities related to the businesses that were sold or leased properties that were abandoned (e.g., retention of certain environmental, tax, employee and product liabilities). The scope and duration of such indemnity obligations vary from transaction to transaction. Where probable, an obligation for such indemnifications is recorded as a liability. Generally, a maximum obligation cannot be reasonably estimated. Other than obligations recorded as liabilities at the time of divestiture, historically the company has not made significant payments for these indemnifications. In connection with the company’s efforts to reduce the number of facilities that it occupies, the company has vacated some of its leased facilities or sublet them to third parties. When the company sublets a facility to a third-party, it remains the primary obligor under the master lease agreement with the owner of the facility. As a result, if a third-party vacates the sublet facility, the company would be obligated to make lease or other payments under the master lease agreement. The company believes that the financial risk of default by sublessors is individually and in the aggregate not material to the company’s financial position or results of operations. In connection with the sale of products in the ordinary course of business, the company often makes representations affirming, among other things, that its products do not infringe on the intellectual property rights of others and agrees to indemnify customers against third-party claims for such infringement. The company has not been required to make material payments under such provisions. Environmental Matters The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot predict all potential costs related to environmental remediation matters and the possible impact on future operations given the uncertainties regarding the extent of the required cleanup, the complexity and interpretation of applicable laws and regulations, the varying costs of alternative cleanup methods and the extent of the company’s responsibility. Expenses for environmental remediation matters related to the costs of installing, operating and maintaining groundwater-treatment systems and other remedial activities related to historical environmental contamination at the company’s domestic and international facilities were not material in any period presented. The company records accruals for environmental remediation liabilities, based on current interpretations of environmental laws and regulations, when it is probable that a liability has been incurred and the amount of such liability can be reasonably estimated. The company calculates estimates based upon several factors, including input from environmental specialists and management’s knowledge of and experience with these environmental matters. The company includes in these estimates potential costs for investigation, remediation and operation and maintenance of cleanup sites. At December 31, 2021, the company’s total environmental liability was approximately $65 million. While management believes the accruals for environmental remediation are adequate based on current estimates of remediation costs, the company may be subject to additional remedial or compliance costs due to future events such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies or changes in the conduct of the company’s operations, which could have a material adverse effect on the company’s financial position, results of operations or cash flows. Litigation and Related Contingencies The company is involved in various disputes, governmental and/or regulatory inspections, inquiries, investigations and proceedings, and litigation matters that arise from time to time in the ordinary course of business. The disputes and litigation matters include product liability, intellectual property, employment and commercial issues. The company determines the probability and range of possible loss based on the current status of each of these matters. A liability is recorded in the financial statements if it is believed to be probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The company establishes a liability that is an estimate of amounts expected to be paid in the future for events that have already occurred. The company accrues the most likely amount or at least the minimum of the range of probable loss when a range of probable loss can be estimated. The accrued liabilities are based on management’s judgment as to the probability of losses for asserted and unasserted claims and, where applicable, actuarially determined estimates. Accrual estimates are adjusted as additional information becomes known or payments are made. The amount of ultimate loss may differ from these estimates. Due to the inherent uncertainties associated with pending litigation or claims, the company cannot predict the outcome, nor, with respect to certain pending litigation or claims where no liability has been accrued, make a meaningful estimate of the reasonably possible loss or range of loss that could result from an unfavorable outcome. The company has no material accruals for pending litigation or claims for which accrual amounts are not disclosed below, nor are material losses deemed probable for such matters. It is reasonably possible, however, that an unfavorable outcome that exceeds the company’s current accrual estimate, if any, for one or more of the matters described below could have a material adverse effect on the company’s results of operations, financial position and cash flows. Product Liability, Workers Compensation and Other Personal Injury Matters The company is involved in various proceedings and litigation that arise from time to time in connection with product liability, workers compensation and other personal injury matters. The range of probable loss for product liability, workers compensation and other personal injury matters of the company’s continuing operations at December 31, 2021, was approximately $216 million to $375 million on an undiscounted basis. The portion of these liabilities assumed in the 2006 merger with Fisher was recorded at its fair (present) value at the date of merger. The company’s accrual for all such matters in total, including the discounted liabilities, was $216 million at December 31, 2021 (or $223 million undiscounted). The accrual includes estimated defense costs and is gross of estimated amounts due from insurers of $100 million at December 31, 2021 (or $106 million undiscounted) that are included in other assets in the accompanying balance sheet. The portion of these insurance assets assumed in the merger with Fisher was also recorded at its fair value at the date of merger. In addition to the above accrual, as of December 31, 2021, the company had a product liability accrual of $11 million (undiscounted) relating to divested businesses.

Comprehensive Income and Shareh

Comprehensive Income and Shareholders Equity	12 Months Ended
	Dec. 31, 2021
Stockholders' Equity Note [Abstract]
Comprehensive Income and Shareholders' Equity [Text Block]	Note 13. Comprehensive Income and Shareholders' Equity Comprehensive Income (Loss) Comprehensive income combines net income and other comprehensive items. Other comprehensive items represent certain amounts that are reported as components of shareholders’ equity in the accompanying balance sheet. Changes in each component of accumulated other comprehensive items, net of tax are as follows: (In millions) Currency Unrealized Pension and Total Balance at December 31, 2020 $ (2,438) $ (91) $ (278) $ (2,807) Other comprehensive items before reclassifications 373 — 36 409 Amounts reclassified from accumulated other comprehensive items — 56 13 69 Net other comprehensive items 373 56 49 478 Balance at December 31, 2021 $ (2,065) $ (35) $ (229) $ (2,329) Shareholders’ Equity At December 31, 2021, the company had reserved 23 million unissued shares of its common stock for possible issuance under stock-based compensation plans.

Fair Value Measurements and Fai

Fair Value Measurements and Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements and Fair Value of Financial Instruments [Text Block]	Note 14. Fair Value Measurements and Fair Value of Financial Instruments Fair Value Measurements The company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2021. The company’s financial assets and liabilities carried at fair value are primarily comprised of investments in publicly traded securities, insurance contracts, investments in derivative contracts, mutual funds holding publicly traded securities and other investments in unit trusts held as assets to satisfy outstanding deferred compensation and retirement liabilities; and acquisition-related contingent consideration. Assets and liabilities carried at fair value are classified and disclosed in one of the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities that the company has the ability to access. Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data such as quoted prices, interest rates and yield curves. Level 3: Inputs are unobservable data points that are not corroborated by market data. The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2021 and December 31, 2020: December 31, Quoted Significant Significant (In millions) 2021 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 2,210 $ 2,210 $ — $ — Investments 298 298 — — Warrants 15 — 15 — Insurance contracts 181 — 181 — Derivative contracts 36 — 36 — Total assets $ 2,740 $ 2,508 $ 232 $ — Liabilities Derivative contracts $ 1 $ — $ 1 $ — Contingent consideration 317 — — 317 Total liabilities $ 318 $ — $ 1 $ 317 December 31, Quoted Significant Significant (In millions) 2020 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 8,971 $ 8,971 $ — $ — Investments 21 21 — — Warrants 7 — 7 — Insurance contracts 157 — 157 — Derivative contracts 28 — 28 — Total assets $ 9,184 $ 8,992 $ 192 $ — Liabilities Derivative contracts $ 132 $ — $ 132 $ — Contingent consideration 70 — — 70 Total liabilities $ 202 $ — $ 132 $ 70 The company uses the Black-Scholes model to value its warrants. The company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer. The fair value of derivative contracts is the estimated amount that the company would receive/pay upon liquidation of the contracts, taking into account the change in interest rates and currency exchange rates. The company initially measures the fair value of acquisition-related contingent consideration based on amounts expected to be transferred (probability-weighted) discounted to present value. Changes to the fair value of contingent consideration are recorded in selling, general and administrative expense. The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones, as well as changes in the fair values of the investments underlying a recapitalization investment portfolio), of the contingent consideration. (In millions) 2021 2020 Contingent consideration Beginning balance $ 70 $ 55 Acquisitions (including assumed balances) 403 28 Payments (109) (4) Changes in fair value included in earnings (47) (9) Ending balance $ 317 $ 70 Derivative Contracts The following table provides the aggregate notional value of outstanding derivative contracts. December 31, December 31, (In millions) 2021 2020 Notional amount Interest rate swaps - fair value hedges $ — $ 1,000 Cross-currency interest rate swaps - designated as net investment hedges 900 900 Currency exchange contracts 2,149 5,206 While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the balance sheet. The following tables present the fair value of derivative instruments in the accompanying balance sheet and statement of income. Fair value – assets Fair value – liabilities December 31, December 31, December 31, December 31, (In millions) 2021 2020 2021 2020 Derivatives designated as hedging instruments Interest rate swaps (a) $ — $ 25 $ — $ — Cross-currency interest rate swaps (a) 25 — — 46 Derivatives not designated as hedging instruments Currency exchange contracts (b) 11 3 1 86 Total derivatives $ 36 $ 28 $ 1 $ 132 (a) The fair values of the interest rate swaps and cross-currency interest rate swaps are included in the accompanying balance sheet under the caption other assets or other long-term liabilities. (b) The fair value of the currency exchange contracts is included in the accompanying balance sheet under the captions other current assets or other accrued expenses. The following amounts related to cumulative basis adjustments for fair value hedges were included in the accompanying balance sheet under the caption long-term obligations: Carrying amount of the hedged liability Cumulative amount of fair value hedging adjustment - increase (decrease) included in carrying amount of liability December 31, December 31, December 31, December 31, (In millions) 2021 2020 2021 2020 Long-term obligations $ — $ 1,020 $ — $ 25 Gain (loss) recognized (In millions) 2021 2020 Fair value hedging relationships Interest rate swaps Hedged long-term obligations - included in other income/(expense) $ 25 $ (38) Derivatives designated as hedging instruments - included in other income/(expense) (3) 38 Derivatives designated as cash flow hedges Interest rate swaps Included in unrealized losses on hedging instruments within other comprehensive items — (85) Amount reclassified from accumulated other comprehensive items to other income/(expense) (73) (59) Financial instruments designated as net investment hedges Foreign currency-denominated debt Included in currency translation adjustment within other comprehensive items 922 (873) Cross-currency interest rate swaps Included in currency translation adjustment within other comprehensive items 71 (79) Included in other income/(expense) 8 11 Derivatives not designated as hedging instruments Currency exchange contracts Included in cost of product revenues 12 (17) Included in other income/(expense) 162 (81) Cross-currency interest rate swaps Included in other income/(expense) — (9) Gains and losses recognized on currency exchange contracts and the interest rate swaps designated as fair value hedges are included in the accompanying statement of income together with the corresponding, offsetting losses and gains on the underlying hedged transactions. The company uses foreign currency-denominated debt and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A portion of the company’s euro-denominated senior notes and its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity. See Note 1 and Note 10 for additional information on the company's risk management objectives and strategies. Cash Flow Hedge Arrangements In 2020 and 2019, the company entered into interest rate swap arrangements to mitigate the risk of interest rates rising prior to completion of debt offerings. Based on the company's conclusion that the debt offerings were probable, the swaps hedged the cash flow risk for each of the interest payments on the planned fixed-rate debt issues. The aggregate fair value of the terminated hedges, net of tax, has been classified as a reduction to accumulated other comprehensive items and will be amortized to interest expense over the term of the related debt issuances. The company had cash outlays aggregating $85 million and $50 million in 2020 and 2019, respectively, associated with termination of the arrangements, included in other financing activities, net, in the accompanying statement of cash flows. In late 2020, the company determined that the previously anticipated debt offerings were probable of not occurring and reclassified $42 million from accumulated other comprehensive items to other income/(expense). During 2021, in connection with the extinguishment of debt (Note 10), the company reclassified $65 million from accumulated other comprehensive items to other income/(expense). Fair Value of Other Financial Instruments The carrying value and fair value of the company’s debt instruments are as follows: December 31, 2021 December 31, 2020 Carrying Fair Carrying Fair (In millions) value value value value Senior notes $ 32,072 $ 33,449 $ 21,723 $ 24,653 Commercial paper 2,522 2,522 — — Other 76 76 5 5 $ 34,670 $ 36,047 $ 21,728 $ 24,658

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	12 Months Ended
	Dec. 31, 2021
Supplemental Cash Flow Information [Abstract]
Supplemental Cash Flow Information [Text Block]	Note 15. Supplemental Cash Flow Information (In millions) 2021 2020 2019 Cash paid for: Interest $ 555 $ 471 $ 790 Income taxes 2,182 1,324 896 Non-cash investing and financing activities Acquired but unpaid property, plant and equipment 379 347 150 Fair value of equity awards exchanged 43 — — Fair value of acquisition contingent consideration 183 — — Finance lease ROU assets obtained in exchange for new finance lease liabilities 15 5 1 Declared but unpaid dividends 104 89 77 Issuance of stock upon vesting of restricted stock units 265 217 182 Cash, cash equivalents and restricted cash is included in the consolidated balance sheet as follows: December 31, December 31, (In millions) 2021 2020 Cash and cash equivalents $ 4,477 $ 10,325 Restricted cash included in other current assets 13 10 Restricted cash included in other assets 1 1 Cash, cash equivalents and restricted cash $ 4,491 $ 10,336

Restructuring and Other Costs,

Restructuring and Other Costs, Net	12 Months Ended
	Dec. 31, 2021
Restructuring and Related Activities [Abstract]
Restructuring and Other Costs, Net [Text Block]	Note 16. Restructuring and Other Costs (Income) Restructuring and other costs in 2021 primarily included charges for impairments of an acquired technology asset and a tradename asset, and, to a lesser extent, compensation due to employees at acquired businesses on the date of acquisition. In 2021, severance actions associated with facility consolidations and cost reduction measures affected less than 1% of the company’s workforce. Restructuring and other costs in 2020 primarily included continuing charges for headcount reductions and facility consolidations in an effort to streamline operations, including the closure and consolidation of operations within several facilities in the U.S. and Europe, and charges for the write-off of acquired technology. In 2020, severance actions associated with facility consolidations and cost reduction measures affected approximately 1% of the company’s workforce. Restructuring and other costs (income) in 2019 primarily included the gain on the sale of the company’s Anatomical Pathology business, and, to a lesser extent, continuing charges for headcount reductions and facility consolidations in an effort to streamline operations, including the closure and consolidation of operations within several facilities in the U.S. and Europe. In 2019, severance actions associated with facility consolidations and cost reduction measures affected approximately 1% of the company’s workforce. As of February 24, 2022, the company has identified restructuring actions that will result in additional charges of approximately $20 million, primarily in 2022, and expects to identify additional actions in future periods which will be recorded when specified criteria are met, such as communication of benefit arrangements or when the costs have been incurred. Restructuring and other costs (income) by segment are as follows: (In millions) 2021 2020 2019 Life Sciences Solutions $ 129 $ 34 $ 24 Analytical Instruments 6 26 14 Specialty Diagnostics 18 9 (471) Laboratory Products and Biopharma Services 35 23 17 Corporate 9 7 3 $ 197 $ 99 $ (413) The following table summarizes the changes in the company’s accrued restructuring balance. Other amounts reported as restructuring and other costs in the accompanying statement of income have been summarized in the notes to the table. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet. (In millions) Total (a) Balance at December 31, 2018 $ 80 Cumulative effect of accounting change (b) (28) Net restructuring charges incurred in 2019 (c) 52 Payments (69) Currency translation (1) Balance at December 31, 2019 34 Net restructuring charges incurred in 2020 (d) 51 Payments (57) Currency translation (7) Balance at December 31, 2020 21 Net restructuring charges incurred in 2021 (e) 37 Payments (40) Currency translation (1) Balance at December 31, 2021 $ 17 (a) The movements in the restructuring liability principally consist of severance and other costs such as relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment. (b) Impact of adopting new lease accounting guidance on January 1, 2019. (c) Excludes $465 million of net charges, principally $482 million of net gain on the sale of businesses (d) Excludes $48 million of charges, principally $32 million for impairment of acquired technology in the Life Sciences Solutions segment resulting from a reduction in expected cash flows and, to a lesser extent, charges across the company’s segments for fixed asset writedowns and costs associated with environmental remediation at abandoned/previously owned facilities. (e) Excludes $160 million of charges, principally $122 million for impairments of an acquired technology asset and a tradename asset in the Life Sciences Solutions and Laboratory Products and Biopharma Services segment, principally resulting from a reduction in expected cash flows, and $35 million of charges for compensation contractually due to employees of acquired businesses at the date of acquisition in the Life Sciences Solutions and Laboratory Products and Biopharma Services segments. The company expects to pay accrued restructuring costs primarily through 2022.

Nature of Operations and Summ_2

Nature of Operations and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Principles of Consolidation [Policy Text Block]	Principles of Consolidation The accompanying financial statements include the accounts of the company and its wholly and majority-owned subsidiaries. All material intercompany accounts and transactions have been eliminated. The company accounts for investments in businesses using the equity method when it has the ability to exercise significant influence but not control (generally between 20% and 50% ownership), is not the primary beneficiary and has not elected the fair value option. At December 31, 2021 and 2020, the company had such investments with carrying amounts of $576 million and $32 million, respectively. The company has elected the fair value option of accounting for certain of its investments with readily determinable fair values that would otherwise be accounted for under the equity method. At December 31, 2021, the fair value of such investments was $217 million. Redeemable Noncontrolling Interest The company owns 60% of its consolidated subsidiary PPD-SNBL K.K. The 40% ownership interest held by a third party is classified as a redeemable noncontrolling interest on the consolidated balance sheet due to certain put options under which the third party may require the company to purchase the remaining ownership interest at its pre-acquisition fair value.
Reclassification, Policy [Policy Text Block]	Presentation Certain reclassifications of prior year amounts have been made to conform to the current year presentation.
Revenue Recognition [Policy Text Block]	Revenue Recognition Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues (primarily clinical research, pharmaceutical, and instrument and enterprise services) are recognized over time as customers receive and consume the benefits of such services. For revenues recognized over time, the company generally uses costs accumulated relative to total estimated costs to measure progress as this method approximates satisfaction of the performance obligation. For contracts that contain multiple performance obligations, the company allocates the consideration to which it expects to be entitled (i.e., the transaction price) to each performance obligation based on relative standalone selling prices and recognizes the related revenues when or as control of each individual performance obligation is transferred to customers. The company exercises judgment in determining the timing of revenue by analyzing the point in time or the period over which the customer has the ability to direct the use of and obtain substantially all of the remaining benefits of the asset. The company immediately expenses contract costs that would otherwise be capitalized and amortized over a period of less than one year. Changes to the scope of services contracts generally also include changes in the transaction price. Typically, these contract modifications are not distinct from existing services provided under the contract, and result in cumulative adjustments to revenue on the modification date. Payments from customers for most instruments and consumables are typically due in a fixed number of days after shipment or delivery of the product. Service arrangements commonly call for payments in advance of performing the work (e.g., extended service contracts), upon completion of the service (e.g., pharmaceutical services) or a mix of both. Some arrangements include variable amounts of consideration that arise from discounts, rebates, and other programs and practices. In such arrangements, the company estimates the amount by which to reduce the stated contract amount to reflect the transaction price. The company records reimbursement for third-party pass-through and out-of-pocket costs as revenues and the related expenses as costs of revenues. Contract assets include revenues recognized in advance of billings where the company’s right to bill includes something other than the passage of time. Such amounts are recorded net of estimated losses resulting from the inability to invoice customers, which is primarily due to risk associated with the company’s performance. Contract assets are classified as current or noncurrent based on the amount of time expected to lapse until the company's right to consideration becomes unconditional. Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenues on service contracts. Contract liabilities are classified as current or noncurrent based on the periods over which remaining performance obligations are expected to be transferred to customers. Contract assets and liabilities are presented on a net basis in the consolidated balance sheet if they arise from different performance obligations in the same contract.
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Accounts receivable include unconditional rights to consideration from customers, which generally represent billings that do not bear interest. The company maintains allowances for doubtful accounts for estimates of expected losses resulting from the inability of its customers to pay amounts due. The allowance for doubtful accounts is the company’s best estimate of the amount of probable credit losses in existing accounts receivable. The company determines the allowance based on history of similarly aged receivables, the creditworthiness of the customer, reasons for delinquency, current economic conditions, expectations associated with future events and circumstances where reasonable and supportable forecasts are available and any other information that is relevant to the judgment. Receivables from academic and government customers as well as large, well-capitalized commercial customers have historically experienced less collectability risk. Account balances are charged off against the allowance when the company believes it is probable the receivable will not be recovered. The company does not have any off-balance-sheet credit exposure related to customers.
Warranty Obligations [Policy Text Block]	Warranty ObligationsThe company provides for the estimated cost of standard product warranties, primarily from historical information, in cost of product revenues at the time product revenues are recognized. The liability for warranties is included in other accrued expenses in the accompanying balance sheet. Extended warranty agreements are considered service contracts, which are discussed above. Costs of service contracts are recognized as incurred.
Leases [Policy Text Block]	Leases Operating leases that have commenced are included in other assets, other accrued expenses and other long-term liabilities in the consolidated balance sheet. Finance leases that have commenced are included in property, plant and equipment, net, current maturities of long-term obligations and long-term obligations in the consolidated balance sheet. Classification of lease liabilities as either current or noncurrent is based on the expected timing of payments due under the company’s obligations. Right-of-use (ROU) assets represent the company’s right to use an underlying asset for the lease term and lease liabilities represent the company’s obligation to make lease payments arising from the lease. Lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. The company recognizes operating lease expense on a straight-line basis over the lease term. Finance lease expense includes depreciation, which is recognized on a straight-line basis over the expected life of the leased asset, and an immaterial amount of interest expense. Because most of the company’s leases do not provide an implicit interest rate, the company estimates incremental borrowing rates based on the information available at the commencement date in determining the present value of lease payments. The company uses the implicit rate when readily determinable. Lease terms include the effect of options to extend or terminate the lease when it is reasonably certain that the company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term.
Research and Development [Policy Text Block]	Research and Development The company conducts research and development activities to increase its depth of capabilities in technologies, software and services. Research and development costs include employee compensation and benefits, consultants, facilities related costs, material costs, depreciation and travel. Research and development costs are expensed as incurred.
Restructuring [Policy Text Block]	Restructuring Costs Accounting for the timing and amount of termination benefits provided by the company to employees is determined based on whether: (a) the company has a substantive plan to provide such benefits, (b) the company has a written employment contract with the affected employees that includes a provision for such benefits, (c) the termination benefits are due to the occurrence of an event specified in an existing plan or agreement, or (d) the termination benefits are a one-time benefit. In certain circumstances, employee termination benefits may meet more than one of the characteristics listed above and therefore, may have individual elements that are subject to different accounting models.
Income Taxes [Policy Text Block]	Income Taxes The company recognizes deferred income taxes based on the expected future tax consequences of differences between the financial statement basis and the tax basis of assets and liabilities, calculated using enacted tax rates in effect for the year in which the differences are expected to be reflected in the tax return. A valuation allowance is provided for tax assets that will more likely than not go unused. The financial statements reflect expected future tax consequences of uncertain tax positions that the company has taken or expects to take on a tax return presuming the taxing authorities’ full knowledge of the positions and all relevant facts, but without discounting for the time value of money.
Earnings Per Share [Policy Text Block]	Earnings per Share Basic earnings per share has been computed by dividing net income attributable to Thermo Fisher Scientific Inc. by the weighted average number of shares outstanding during the year. Except where the result would be antidilutive to net income attributable to Thermo Fisher Scientific Inc., diluted earnings per share has been computed using the treasury stock method for outstanding stock options and restricted units.
Cash and Cash Equivalents [Policy Text Block]	Cash and Cash Equivalents Cash equivalents consists principally of money market funds, commercial paper and other marketable securities purchased with an original maturity of three months or less. These investments are carried at cost, which approximates market value.
Inventories [Policy Text Block]	InventoriesInventories are valued at the lower of cost or net realizable value, cost being determined by the first-in, first-out (FIFO) method. As discussed below, prior to the third quarter of 2021 certain of the company's businesses utilized the last-in, first-out (LIFO) method. The company periodically reviews quantities of inventories on hand and compares these amounts to the expected use of each product or product line. In addition, the company has certain inventory that is subject to fluctuating market pricing. The company records a charge to cost of sales for the amount required to reduce the carrying value of inventory to net realizable value. Costs associated with the procurement of inventories, such as inbound freight charges, purchasing and receiving costs, and internal transfer costs, are included in cost of revenues in the accompanying statement of income.
Property, Plant and Equipment [Policy Text Block]	Property, Plant and EquipmentProperty, plant and equipment are recorded at cost. The costs of additions and improvements are capitalized, while maintenance and repairs are charged to expense as incurred. The company generally provides for depreciation and amortization using the straight-line method over the estimated useful lives of the property as follows: buildings and improvements, 25 to 40 years; machinery and equipment (including software), 3 to 10 years; and leasehold improvements, the shorter of the term of the lease or the life of the asset. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and the resulting gain or loss is reflected in the accompanying statement of income.
Acquisition-related Intangible Assets [Policy Text Block]	Acquisition-related Intangible Assets Acquisition-related intangible assets include the costs of acquired customer relationships, product technology, tradenames, backlog and other specifically identifiable intangible assets, and are being amortized using the straight-line method over their estimated useful lives, which range up to 20 years. The company reviews these intangible assets for impairment when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets. When impairment indicators exist, the company determines whether the carrying value of its intangible assets exceeds the related undiscounted cash flows. In these situations, the carrying value is written down to fair value.
Investments [Policy Text Block]	Equity investments that do not have readily determinable fair values and are not eligible for the net asset value (NAV) practical expedient are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investments of the same issuer. The company performs qualitative assessments to identify impairments of these investments.
Goodwill [Policy Text Block]	Goodwill The company assesses goodwill for impairment at the reporting unit level annually and whenever events occur or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Such events or circumstances generally include the occurrence of operating losses or a significant decline in earnings associated with one or more of the company’s reporting units. The company is permitted to first assess qualitative factors to determine whether the quantitative goodwill impairment test is necessary. If the qualitative assessment results in a determination that the fair value of a reporting unit is more likely than not less than its carrying amount, the company performs a quantitative goodwill impairment test. The company may bypass the qualitative assessment for the reporting unit in any period and proceed directly to the goodwill impairment test. The company estimates the fair value of its reporting units by using forecasts of discounted future cash flows and peer market multiples. The company would record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value (limited to the amount of goodwill). The company determined that no impairments existed in 2021, 2020 or 2019.
Loss Contingencies [Policy Text Block]	Loss Contingencies Accruals are recorded for various contingencies, including legal proceedings, environmental, workers’ compensation, product, general and auto liabilities, self-insurance and other claims that arise in the normal course of business. The accruals are based on management’s judgment, historical claims experience, the probability of losses and, where applicable, the consideration of opinions of internal and/or external legal counsel and actuarial estimates. Additionally, the company records receivables from third-party insurers up to the amount of the loss when recovery has been determined to be probable. Certain liabilities acquired in acquisitions have been recorded at readily determinable fair values and, as such, were discounted to present value at the dates of acquisition.
Currency Translation [Policy Text Block]	Currency TranslationAll assets and liabilities of the company’s subsidiaries operating in non-U.S. dollar currencies are translated at period-end exchange rates. Resulting translation adjustments are reflected in the “accumulated other comprehensive items” component of shareholders’ equity. Revenues and expenses are translated at average exchange rates for the period.
Derivatives Contracts [Policy Text Block]	Derivative Contracts The company is exposed to certain risks relating to its ongoing business operations including changes to interest rates and currency exchange rates. The company uses derivative instruments primarily to manage currency exchange and interest rate risks. The company recognizes derivative instruments as either assets or liabilities and measures those instruments at fair value. If a derivative is a hedge, depending on the nature of the hedge, changes in the fair value of the derivative are either offset against the change in fair value of the hedged item through earnings or recognized in other comprehensive items until the hedged item is recognized in earnings. Derivatives that are not designated as hedges are recorded at fair value through earnings. The company uses short-term forward and option currency exchange contracts primarily to hedge certain balance sheet and operational exposures resulting from changes in currency exchange rates, predominantly intercompany loans and cash balances that are denominated in currencies other than the functional currencies of the respective operations. The currency-exchange contracts principally hedge transactions denominated in euro, Swiss franc, British pounds sterling, Canadian dollars, Czech koruna, Japanese yen and Hong Kong dollars. The company does not hold or engage in transactions involving derivative instruments for purposes other than risk management. Cash flow hedges . For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative is reported as a component of other comprehensive items and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings and is presented in the same income statement line item as the earnings effect of the hedged item. Fair value hedges. For derivative instruments that are designated and qualify as a fair value hedge, the gain or loss on the derivative, as well as the offsetting loss or gain on the hedged item attributable to the hedged risk, are recognized in earnings. Net investment hedges. The company uses foreign currency-denominated debt and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A portion of the company’s euro-denominated senior notes and its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity.
Use of Estimates [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and businesses that are used in assessing the risk of impairment. Risks and uncertainties associated with the ongoing COVID-19 global pandemic materially adversely affected certain of the company’s businesses in 2020, particularly in the Analytical Instruments segment and, to a lesser extent, some businesses within the other three segments. The negative impacts significantly lessened in 2021. The extent and duration of negative impacts in the future, which
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In November 2021, the FASB issued new guidance to require entities to disclose information about certain types of government assistance they receive, including cash grants and tax credits. Among other things, the new guidance requires expanded disclosure regarding the qualitative and quantitative characteristics of the nature, amount, timing, and significant terms and conditions of transactions with a government arising from a grant or other forms of assistance accounted for under a contribution model. The company will adopt this guidance in 2022 using a prospective method. The adoption of this guidance is not expected to have a material impact on the company’s disclosures; however, the impact will be dependent on the extent of transactions of this nature entered into by the company in periods subsequent to the date of adoption. In October 2021, the FASB amended guidance to recognize and measure contract assets and contract liabilities acquired in a business combination. Generally, this new guidance will result in the company recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. The company adopted this guidance in the fourth quarter of 2021 retrospectively to all business combinations completed in the first three quarters of 2021 and prospectively to all future business combinations. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements for acquisitions that closed in 2021; however, the impact in future periods will be dependent on the contract assets and contract liabilities acquired in future business combinations. In July 2021, the FASB amended guidance to require lessors to classify leases as operating leases if they have certain variable lease payment structures and would have selling losses if they were classified as sales-type or direct financing leases. The company adopted the guidance in the third quarter of 2021 using a prospective method. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements. In January 2020, the FASB issued new guidance to clarify the interaction of the accounting for certain equity securities, equity method investments, and certain forward contracts and purchased options. Among other things, the new guidance clarifies that an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying measurement principles for certain equity securities immediately before applying or discontinuing the equity method. The company adopted this guidance in 2020 using a prospective method. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements. In December 2019, the FASB issued new guidance to simplify the accounting for income taxes. Among other things, the new guidance requires the effects of enacted changes in tax laws or rates to be reflected in the annual effective tax rate computation in the interim period that includes the enactment date. The company adopted this guidance in 2021 using a prospective method. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements; however, the impact in future periods will be dependent on the extent of future events or conditions that would be affected such as enacted changes in tax laws or rates. In August 2018, the FASB issued new guidance to modify the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The company adopted the guidance in 2020 using a retrospective method. The adoption of this guidance did not have a material impact on the company’s disclosures. In August 2018, the FASB issued new guidance to modify the disclosure requirements on fair value measurements. The company adopted the guidance in 2020 with some items requiring a prospective method and others requiring a retrospective method. The adoption of this guidance did not have a material impact on the company’s disclosures. In June 2016, the FASB issued new guidance to require a financial asset measured at amortized cost basis, such as accounts receivable, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. During 2018 and 2019, the FASB issued additional guidance and clarification. The company adopted the guidance in 2020 using a modified retrospective method. The adoption of this guidance reduced accounts receivable and retained earnings by $1 million on January 1, 2020. In February 2016, the FASB issued new guidance which requires lessees to record most leases on their balance sheets as lease liabilities, initially measured at the present value of the future lease payments, with corresponding right-of-use assets. The new guidance also sets forth new disclosure requirements related to leases. During 2017 - 2019, the FASB issued additional guidance and clarification. The company adopted this guidance in January 2019. The company elected to adopt the guidance using a modified retrospective method, by applying the transition approach as of the beginning of the period of adoption. Comparative periods have not been restated. As permitted upon transition, the company did not reassess whether any expired or
Business Combinations Policy [Policy Text Block]	The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforce. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products. Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.
Stock-based Compensation Expense Policies [Policy Text Block]	Compensation cost is based on the grant-date fair value and is recognized ratably over the requisite vesting period or to the date based on qualifying retirement eligibility, if earlier, and is primarily included in selling, general and administrative expenses. Stock Options The company’s practice is to grant stock options at fair market value. Options vest over 3-5 years with terms of 7-10 years, assuming continued employment with certain exceptions. Vesting of the option awards is contingent upon meeting certain service conditions. The fair value of most option grants is estimated using the Black-Scholes option pricing model. For option grants that require the achievement of both service and market conditions, a lattice model is used to estimate fair value. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility was calculated based on the historical volatility of the company’s stock. Historical data on exercise patterns is the basis for estimating the expected life of an option. The risk-free interest rate is based on U.S. Treasury zero-coupon issues with a remaining term which approximates the expected life assumed at the date of grant. The expected annual dividend rate was calculated by dividing the company’s annual dividend, based on the most recent quarterly dividend rate, by the closing stock price on the grant date. The compensation expense recognized for all stock-based awards is net of estimated forfeitures. Forfeitures are estimated based on an analysis of actual option forfeitures. Restricted Share/Unit Awards Awards of restricted units convert into an equivalent number of shares of common stock. The awards generally vest over 3-4 years, assuming continued employment, with some exceptions. Vesting of the awards is contingent upon meeting certain service conditions and may also be contingent upon meeting certain performance and/or market conditions. The fair market value of the award at the time of the grant is amortized to expense over the requisite service period of the award, which is generally the vesting period. Recipients of restricted units have no voting rights but are entitled to accrue dividend equivalents. The fair value of service- and performance-based restricted unit awards is determined based on the number of units granted and the market value of the company’s shares on the grant date. For awards with market-based vesting conditions, the company uses a lattice model to estimate the grant-date fair value of the award.
Pension and Other Postretirement Benefit Plans, Policies [Policy Text Block]	Defined Benefit Pension Plans Employees of a number of the company’s non-U.S. and certain U.S. subsidiaries participate in defined benefit pension plans covering substantially all full-time employees at those subsidiaries. Some of the plans are unfunded, as permitted under the plans and applicable laws. The company also maintains postretirement healthcare programs at several acquired businesses where certain employees are eligible to participate. The liabilities and costs associated with the company’s postretirement healthcare programs are generally funded on a self-insured and insured-premium basis and are not material for any period presented. The company recognizes the funded status of defined benefit pension and other postretirement benefit plans as an asset or liability. This amount is defined as the difference between the fair value of plan assets and the benefit obligation. The company is required to recognize as a component of other comprehensive items, net of tax, the actuarial gains/losses and prior service costs/credits that arise but were not previously required to be recognized as components of net periodic benefit cost. Other comprehensive items is adjusted as these amounts are later recognized in income as components of net periodic benefit cost. When a company with a pension plan is acquired, any excess of projected benefit obligation over the plan assets is recognized as a liability and any excess of plan assets over the projected benefit obligation is recognized as an asset. The recognition of a new liability or a new asset results in the elimination of (a) previously existing unrecognized net gain or loss and (b) unrecognized prior service cost or credits. The discount rate reflects the rate the company would have to pay to purchase high-quality investments that would provide cash sufficient to settle its current pension obligations. The discount rate is determined based on a range of factors, including the rates of return on high-quality, fixed-income corporate bonds and the related expected duration of the obligations or, in certain instances, the company has used a hypothetical portfolio of high quality instruments with maturities that mirror the benefit obligation in order to accurately estimate the discount rate relevant to a particular plan. The company utilizes a full yield curve approach in the estimation of these components by applying the specific spot-rates along the yield curve used in the determination of the benefit obligation to the relevant projected cash flows. The expected long-term rate of return on plan assets reflects the average rate of earnings expected on the funds invested, or to be invested, to provide for the benefits included in the projected benefit obligations. In determining the expected long-term rate of return on plan assets, the company considers the relative weighting of plan assets, the historical performance of total plan assets and individual asset classes and economic and other indicators of future performance. In addition, the company may consult with and consider the opinions of financial and other professionals in developing appropriate return benchmarks. Asset management objectives include maintaining an adequate level of diversification to reduce interest rate and market risk and providing adequate liquidity to meet immediate and future benefit payment requirements. The expected rate of compensation increase reflects the long-term average rate of salary increases and is based on historic salary increase experience and management’s expectations of future salary increases. Domestic Pension Plan Assets The company’s overall objective is to manage the assets in a liability framework where investments are selected that are expected to have similar changes in fair value as the related liabilities will have upon changes in interest rates. The company invests in a portfolio of both return-seeking and liability-hedging assets, primarily through the use of institutional collective funds, to achieve long-term growth and to insulate the funded position from interest rate volatility. The strategic asset allocation uses a combination of risk controlled and index strategies in fixed income and global equities. The target allocations for the investments are approximately 10% to funds investing in U.S. equities, approximately 10% to funds investing in international equities and approximately 80% to funds investing in fixed income securities. The portfolio maintains enough liquidity at all times to meet the near-term benefit payments. Non-U.S. Pension Plan Assets The company maintains specific plan assets for many of the individual pension plans outside the U.S. The investment strategy of each plan has been uniquely established based on the country specific standards and characteristics of the plans. Several of the plans have contracts with insurance companies whereby the market risks of the benefit obligations are borne by the insurance companies. When assets are held directly in investments, generally the objective is to invest in a portfolio of

Acquisitions and Dispositions (

Acquisitions and Dispositions (Policies)	12 Months Ended
	Dec. 31, 2021
Business Combinations [Abstract]
Business Combinations Policy [Policy Text Block]	The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforce. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products. Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.

Stockbased Compensation Expense

Stockbased Compensation Expense (Policies)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Stock-based Compensation Expense Policies [Policy Text Block]	Compensation cost is based on the grant-date fair value and is recognized ratably over the requisite vesting period or to the date based on qualifying retirement eligibility, if earlier, and is primarily included in selling, general and administrative expenses. Stock Options The company’s practice is to grant stock options at fair market value. Options vest over 3-5 years with terms of 7-10 years, assuming continued employment with certain exceptions. Vesting of the option awards is contingent upon meeting certain service conditions. The fair value of most option grants is estimated using the Black-Scholes option pricing model. For option grants that require the achievement of both service and market conditions, a lattice model is used to estimate fair value. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility was calculated based on the historical volatility of the company’s stock. Historical data on exercise patterns is the basis for estimating the expected life of an option. The risk-free interest rate is based on U.S. Treasury zero-coupon issues with a remaining term which approximates the expected life assumed at the date of grant. The expected annual dividend rate was calculated by dividing the company’s annual dividend, based on the most recent quarterly dividend rate, by the closing stock price on the grant date. The compensation expense recognized for all stock-based awards is net of estimated forfeitures. Forfeitures are estimated based on an analysis of actual option forfeitures. Restricted Share/Unit Awards Awards of restricted units convert into an equivalent number of shares of common stock. The awards generally vest over 3-4 years, assuming continued employment, with some exceptions. Vesting of the awards is contingent upon meeting certain service conditions and may also be contingent upon meeting certain performance and/or market conditions. The fair market value of the award at the time of the grant is amortized to expense over the requisite service period of the award, which is generally the vesting period. Recipients of restricted units have no voting rights but are entitled to accrue dividend equivalents. The fair value of service- and performance-based restricted unit awards is determined based on the number of units granted and the market value of the company’s shares on the grant date. For awards with market-based vesting conditions, the company uses a lattice model to estimate the grant-date fair value of the award.

Pension and Other Postretirem_2

Pension and Other Postretirement Benefit Plans (Policies)	12 Months Ended
	Dec. 31, 2021
Retirement Benefits [Abstract]
Pension and Other Postretirement Benefit Plans, Policies [Policy Text Block]	Defined Benefit Pension Plans Employees of a number of the company’s non-U.S. and certain U.S. subsidiaries participate in defined benefit pension plans covering substantially all full-time employees at those subsidiaries. Some of the plans are unfunded, as permitted under the plans and applicable laws. The company also maintains postretirement healthcare programs at several acquired businesses where certain employees are eligible to participate. The liabilities and costs associated with the company’s postretirement healthcare programs are generally funded on a self-insured and insured-premium basis and are not material for any period presented. The company recognizes the funded status of defined benefit pension and other postretirement benefit plans as an asset or liability. This amount is defined as the difference between the fair value of plan assets and the benefit obligation. The company is required to recognize as a component of other comprehensive items, net of tax, the actuarial gains/losses and prior service costs/credits that arise but were not previously required to be recognized as components of net periodic benefit cost. Other comprehensive items is adjusted as these amounts are later recognized in income as components of net periodic benefit cost. When a company with a pension plan is acquired, any excess of projected benefit obligation over the plan assets is recognized as a liability and any excess of plan assets over the projected benefit obligation is recognized as an asset. The recognition of a new liability or a new asset results in the elimination of (a) previously existing unrecognized net gain or loss and (b) unrecognized prior service cost or credits. The discount rate reflects the rate the company would have to pay to purchase high-quality investments that would provide cash sufficient to settle its current pension obligations. The discount rate is determined based on a range of factors, including the rates of return on high-quality, fixed-income corporate bonds and the related expected duration of the obligations or, in certain instances, the company has used a hypothetical portfolio of high quality instruments with maturities that mirror the benefit obligation in order to accurately estimate the discount rate relevant to a particular plan. The company utilizes a full yield curve approach in the estimation of these components by applying the specific spot-rates along the yield curve used in the determination of the benefit obligation to the relevant projected cash flows. The expected long-term rate of return on plan assets reflects the average rate of earnings expected on the funds invested, or to be invested, to provide for the benefits included in the projected benefit obligations. In determining the expected long-term rate of return on plan assets, the company considers the relative weighting of plan assets, the historical performance of total plan assets and individual asset classes and economic and other indicators of future performance. In addition, the company may consult with and consider the opinions of financial and other professionals in developing appropriate return benchmarks. Asset management objectives include maintaining an adequate level of diversification to reduce interest rate and market risk and providing adequate liquidity to meet immediate and future benefit payment requirements. The expected rate of compensation increase reflects the long-term average rate of salary increases and is based on historic salary increase experience and management’s expectations of future salary increases. Domestic Pension Plan Assets The company’s overall objective is to manage the assets in a liability framework where investments are selected that are expected to have similar changes in fair value as the related liabilities will have upon changes in interest rates. The company invests in a portfolio of both return-seeking and liability-hedging assets, primarily through the use of institutional collective funds, to achieve long-term growth and to insulate the funded position from interest rate volatility. The strategic asset allocation uses a combination of risk controlled and index strategies in fixed income and global equities. The target allocations for the investments are approximately 10% to funds investing in U.S. equities, approximately 10% to funds investing in international equities and approximately 80% to funds investing in fixed income securities. The portfolio maintains enough liquidity at all times to meet the near-term benefit payments. Non-U.S. Pension Plan Assets The company maintains specific plan assets for many of the individual pension plans outside the U.S. The investment strategy of each plan has been uniquely established based on the country specific standards and characteristics of the plans. Several of the plans have contracts with insurance companies whereby the market risks of the benefit obligations are borne by the insurance companies. When assets are held directly in investments, generally the objective is to invest in a portfolio of

Nature of Operations and Summ_3

Nature of Operations and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Inventories [Table Text Block]	The components of inventories are as follows: December 31, December 31, (In millions) 2021 2020 Raw materials $ 1,922 $ 1,305 Work in process 676 540 Finished goods 2,453 2,184 Inventories $ 5,051 $ 4,029
Property, Plant and Equipment [Table Text Block]	Property, plant and equipment consists of the following: December 31, December 31, (In millions) 2021 2020 Land $ 431 $ 410 Buildings and improvements 2,575 2,192 Machinery, equipment and leasehold improvements 9,587 6,975 Property, plant and equipment, at cost 12,593 9,577 Less: Accumulated depreciation and amortization 4,260 3,665 Property, plant and equipment, net $ 8,333 $ 5,912
Finite-Lived Acquisition-related Intangible Assets [Table Text Block]	Acquisition-related intangible assets are as follows: Balance at December 31, 2021 Balance at December 31, 2020 (In millions) Gross Accumulated Amortization Net Gross Accumulated Amortization Net Definite lived: Customer relationships $ 22,802 $ (7,792) $ 15,010 $ 16,593 $ (7,450) $ 9,143 Product technology 6,041 (3,977) 2,064 5,523 (3,532) 1,991 Tradenames 1,722 (919) 803 1,213 (897) 316 Backlog 1,060 (59) 1,001 — — — 31,625 (12,747) 18,878 23,329 (11,879) 11,450 Indefinite lived: Tradenames 1,235 N/A 1,235 1,235 N/A 1,235 Acquisition-related intangible assets $ 32,860 $ (12,747) $ 20,113 $ 24,564 $ (11,879) $ 12,685
Indefinite-Lived Acquisition-related Intangible Assets [Table Text Block]	Acquisition-related intangible assets are as follows: Balance at December 31, 2021 Balance at December 31, 2020 (In millions) Gross Accumulated Amortization Net Gross Accumulated Amortization Net Definite lived: Customer relationships $ 22,802 $ (7,792) $ 15,010 $ 16,593 $ (7,450) $ 9,143 Product technology 6,041 (3,977) 2,064 5,523 (3,532) 1,991 Tradenames 1,722 (919) 803 1,213 (897) 316 Backlog 1,060 (59) 1,001 — — — 31,625 (12,747) 18,878 23,329 (11,879) 11,450 Indefinite lived: Tradenames 1,235 N/A 1,235 1,235 N/A 1,235 Acquisition-related intangible assets $ 32,860 $ (12,747) $ 20,113 $ 24,564 $ (11,879) $ 12,685
Finite-Lived Acquisition-related Intangible Assets, Future Amortization Expense [Table Text Block]	The estimated future amortization expense of acquisition-related intangible assets with definite lives is as follows: (In millions) 2022 $ 2,489 2023 2,358 2024 1,992 2025 1,669 2026 1,392 2027 and thereafter 8,978 Estimated future amortization expense of definite-lived intangible assets $ 18,878
Goodwill [Table Text Block]	The changes in the carrying amount of goodwill by segment are as follows: (In millions) Life Sciences Analytical Specialty Laboratory Total Balance at December 31, 2019 $ 8,544 $ 4,928 $ 3,184 $ 9,058 $ 25,714 Acquisition 35 — — — 35 Currency translation 11 151 186 (56) 292 Balance at December 31, 2020 8,590 5,079 3,370 9,002 26,041 Acquisitions 1,560 56 8 14,400 16,024 Currency translation (7) (92) (101) 59 (141) Balance at December 31, 2021 $ 10,143 $ 5,043 $ 3,277 $ 23,461 $ 41,924

Acquisitions and Dispositions_2

Acquisitions and Dispositions (Tables)	12 Months Ended
	Dec. 31, 2021
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	The components of the purchase price and net assets acquired for 2021 acquisitions are as follows: (In millions) PPD PeproTech European Viral Vector Business Mesa Biotech Lengnau biologics manufacturing facility Other Purchase price Cash paid $ 17,237 $ 1,947 $ 848 $ 421 $ 17 $ 298 Fair value of equity awards exchanged 43 — — — — — Fair value of contingent consideration — — — 65 1 117 Cash acquired (1,244) (83) (18) (14) — (13) $ 16,036 $ 1,864 $ 830 $ 472 $ 18 $ 402 Net assets acquired Current assets $ 2,510 $ 63 $ 39 $ 54 $ — $ 12 Property, plant and equipment 562 18 59 2 92 2 Definite-lived intangible assets: Customer relationships 6,264 514 302 — — 2 Product technology — 282 25 279 — 224 Tradenames 603 — — 2 — 2 Backlog 1,060 — — — — — Goodwill 13,781 1,190 600 237 18 198 Other assets 1,108 11 3 3 376 2 Contract liabilities (1,570) — (59) — — (1) Deferred tax assets (liabilities) (1,803) (193) (80) (72) — (28) Finance lease liabilities (86) — (24) — (82) — Debt assumed (4,299) — — — — — Other liabilities assumed (1,972) (21) (35) (33) (386) (11) Redeemable noncontrolling interest (122) — — — — — $ 16,036 $ 1,864 $ 830 $ 472 $ 18 $ 402 The components of the purchase price and net assets acquired for 2019 acquisitions are as follows: (In millions) Brammer Bio Other Purchase price Cash paid $ 1,710 $ 169 Cash acquired (36) — $ 1,674 $ 169 Net assets acquired Current assets $ 52 $ 58 Property, plant and equipment 147 102 Definite-lived intangible assets: Customer relationships 744 — Product technology 65 7 Tradenames 7 — Goodwill 938 9 Other assets 49 — Contract liabilities (110) — Deferred tax liabilities (110) (6) Other liabilities assumed (108) (1) $ 1,674 $ 169
Business Acquisition, Pro Forma Information [Table Text Block]	The following unaudited pro forma information provides the effect of the company's 2021 acquisition of PPD as if the acquisition had occurred on January 1, 2020: Year Ended December 31, December 31, (In millions) 2021 2020 Revenues $ 44,886 $ 36,887 Net income attributable to Thermo Fisher Scientific Inc. $ 7,369 $ 5,361

Revenue and Contract-related _2

Revenue and Contract-related Balances (Tables)	12 Months Ended
	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue [Table Text Block]	Disaggregated Revenues Revenues by type are as follows: (In millions) 2021 2020 2019 Revenues Consumables $ 22,608 $ 18,527 $ 13,109 Instruments 7,753 6,779 6,387 Services 8,850 6,912 6,046 Consolidated revenues $ 39,211 $ 32,218 $ 25,542 Revenues by geographic region based on customer location are as follows: (In millions) 2021 2020 2019 Revenues North America $ 19,659 $ 17,081 $ 12,896 Europe 11,134 8,284 6,358 Asia-Pacific 7,218 5,822 5,524 Other regions 1,200 1,031 764 Consolidated revenues $ 39,211 $ 32,218 $ 25,542
Contract with Customer, Asset and Liability [Table Text Block]	Noncurrent contract assets are included within other assets in the accompanying balance sheet. Noncurrent contract liabilities are included within other long-term liabilities in the accompanying balance sheet. Contract asset and liability balances are as follows: December 31, December 31, (In millions) 2021 2020 Current contract assets, net $ 968 $ 731 Noncurrent contract assets, net 9 11 Current contract liabilities 2,655 1,271 Noncurrent contract liabilities 1,238 763

Business Segment and Geograph_2

Business Segment and Geographical Information (Tables)	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Business Segment Information (In millions) 2021 2020 2019 Revenues Life Sciences Solutions $ 15,631 $ 12,168 $ 6,856 Analytical Instruments 6,069 5,124 5,522 Specialty Diagnostics 5,659 5,343 3,718 Laboratory Products and Biopharma Services 14,862 12,245 10,599 Eliminations (3,010) (2,662) (1,153) Consolidated revenues 39,211 32,218 25,542 Segment Income Life Sciences Solutions 7,817 6,109 2,446 Analytical Instruments 1,197 808 1,273 Specialty Diagnostics 1,280 1,368 930 Laboratory Products and Biopharma Services 1,844 1,271 1,324 Subtotal reportable segments 12,138 9,556 5,973 Cost of revenues charges (8) (6) (17) Selling, general and administrative (charges) credits (144) 10 (62) Restructuring and other (costs) income (197) (99) 413 Amortization of acquisition-related intangible assets (1,761) (1,667) (1,713) Consolidated operating income 10,028 7,794 4,594 Interest income 43 65 224 Interest expense (536) (553) (676) Other income/(expense) (694) (76) (70) Income before income taxes $ 8,841 $ 7,230 $ 4,072 Depreciation Life Sciences Solutions $ 197 $ 140 $ 130 Analytical Instruments 83 76 75 Specialty Diagnostics 128 100 67 Laboratory Products and Biopharma Services 423 342 292 Consolidated depreciation $ 831 $ 658 $ 564 Cost of revenues charges included in the above table consist of charges for the sale of inventories revalued at the date of acquisition and accelerated depreciation on fixed assets to estimated disposal value in connection with the consolidation of operations. Selling, general and administrative charges/credits included in the above table consist of third-party transaction/integration costs (including reimbursement thereof) related to recent/terminated acquisitions, charges/credits for changes in estimates of contingent acquisition consideration, and charges/credits related to product liability litigation. (In millions) 2021 2020 2019 Total assets Life Sciences Solutions $ 22,751 $ 20,209 $ 18,306 Analytical Instruments 9,692 9,773 9,896 Specialty Diagnostics 6,010 6,534 5,867 Laboratory Products and Biopharma Services 52,639 22,711 21,761 Corporate/other (a) 4,031 9,825 2,551 Consolidated total assets $ 95,123 $ 69,052 $ 58,381 Capital expenditures Life Sciences Solutions $ 810 $ 392 $ 151 Analytical Instruments 79 74 64 Specialty Diagnostics 167 175 83 Laboratory Products and Biopharma Services 1,327 772 554 Corporate/other 140 61 74 Consolidated capital expenditures $ 2,523 $ 1,474 $ 926 (a) Corporate assets consist primarily of cash and cash equivalents and property and equipment at the company's corporate offices.
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	Business Segment Information (In millions) 2021 2020 2019 Revenues Life Sciences Solutions $ 15,631 $ 12,168 $ 6,856 Analytical Instruments 6,069 5,124 5,522 Specialty Diagnostics 5,659 5,343 3,718 Laboratory Products and Biopharma Services 14,862 12,245 10,599 Eliminations (3,010) (2,662) (1,153) Consolidated revenues 39,211 32,218 25,542 Segment Income Life Sciences Solutions 7,817 6,109 2,446 Analytical Instruments 1,197 808 1,273 Specialty Diagnostics 1,280 1,368 930 Laboratory Products and Biopharma Services 1,844 1,271 1,324 Subtotal reportable segments 12,138 9,556 5,973 Cost of revenues charges (8) (6) (17) Selling, general and administrative (charges) credits (144) 10 (62) Restructuring and other (costs) income (197) (99) 413 Amortization of acquisition-related intangible assets (1,761) (1,667) (1,713) Consolidated operating income 10,028 7,794 4,594 Interest income 43 65 224 Interest expense (536) (553) (676) Other income/(expense) (694) (76) (70) Income before income taxes $ 8,841 $ 7,230 $ 4,072 Depreciation Life Sciences Solutions $ 197 $ 140 $ 130 Analytical Instruments 83 76 75 Specialty Diagnostics 128 100 67 Laboratory Products and Biopharma Services 423 342 292 Consolidated depreciation $ 831 $ 658 $ 564
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	Geographical Information (In millions) 2021 2020 2019 Revenues (b) United States $ 18,907 $ 16,435 $ 12,366 China 3,444 2,797 2,752 Other 16,860 12,986 10,424 Consolidated revenues $ 39,211 $ 32,218 $ 25,542 Long-lived Assets (c) United States $ 5,578 $ 3,686 $ 3,099 Other 4,286 3,001 2,349 Consolidated long-lived assets $ 9,864 $ 6,687 $ 5,448 (b) Revenues are attributed to countries based on customer location. (c) Includes property, plant and equipment, net, and operating lease ROU assets.

Stockbased Compensation Expen_2

Stockbased Compensation Expense (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The weighted average assumptions used in the Black-Scholes option pricing model are as follows: 2021 2020 2019 Expected stock price volatility 26 % 22 % 21 % Risk free interest rate 0.8 % 1.1 % 2.4 % Expected life of options (years) 4.3 4.3 4.3 Expected annual dividend 0.2 % 0.3 % 0.3 %
Share-based Payment Arrangement, Option, Activity [Table Text Block]	A summary of the company’s option activity for the year ended December 31, 2021 is presented below: Shares Weighted average exercise price Weighted average remaining contractual term Aggregate intrinsic Outstanding at December 31, 2020 5.9 $ 221.22 Granted 1.5 552.26 Issued in connection with an acquisition 0.2 492.35 Exercised (1.4) 183.63 Canceled/expired (0.2) 341.83 Outstanding at December 31, 2021 6.0 $ 319.95 4.5 $ 2,094 Vested and unvested expected to vest at December 31, 2021 5.7 $ 306.64 4.3 $ 2,035 Exercisable at December 31, 2021 2.8 $ 193.39 2.9 $ 1,307
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]	A summary of the company’s option activity for the year ended December 31, 2021 is presented below: Shares Weighted average exercise price Weighted average remaining contractual term Aggregate intrinsic Outstanding at December 31, 2020 5.9 $ 221.22 Granted 1.5 552.26 Issued in connection with an acquisition 0.2 492.35 Exercised (1.4) 183.63 Canceled/expired (0.2) 341.83 Outstanding at December 31, 2021 6.0 $ 319.95 4.5 $ 2,094 Vested and unvested expected to vest at December 31, 2021 5.7 $ 306.64 4.3 $ 2,035 Exercisable at December 31, 2021 2.8 $ 193.39 2.9 $ 1,307
Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]	A summary of the company’s restricted unit activity for the year ended December 31, 2021 is presented below: Units Weighted Unvested at December 31, 2020 0.8 $ 276.74 Granted 0.4 444.61 Issued in connection with an acquisition 0.2 628.71 Vested (0.5) 295.70 Forfeited (0.1) 326.90 Unvested at December 31, 2021 0.8 $ 425.39

Pension and Other Postretirem_3

Pension and Other Postretirement Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2021
Retirement Benefits [Abstract]
Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]	The following table provides a reconciliation of benefit obligations and plan assets of the company’s domestic and non-U.S. pension plans: Domestic pension Non-U.S. pension (In millions) 2021 2020 2021 2020 Change in projected benefit obligations Benefit obligation at beginning of year $ 1,302 $ 1,302 $ 1,486 $ 1,303 Acquisitions — — 170 — Service costs — — 27 24 Interest costs 23 35 11 18 Settlements — — (7) (38) Plan participants' contributions — — 6 5 Actuarial (gains) losses 20 44 (57) 119 Benefits paid (85) (79) (30) (26) Currency translation and other — — (54) 81 Benefit obligation at end of year $ 1,260 $ 1,302 $ 1,552 $ 1,486 Change in fair value of plan assets Fair value of plan assets at beginning of year $ 1,267 $ 1,201 $ 1,160 $ 986 Acquisitions — — 158 — Actual return on plan assets 37 138 14 92 Employer contribution 7 7 27 87 Settlements — — (7) (38) Plan participants' contributions — — 6 5 Benefits paid (85) (79) (30) (26) Currency translation and other — — (26) 54 Fair value of plan assets at end of year $ 1,226 $ 1,267 $ 1,302 $ 1,160 Funded status $ (34) $ (35) $ (250) $ (326) Accumulated benefit obligation $ 1,260 $ 1,302 $ 1,475 $ 1,417 Amounts recognized in balance sheet Noncurrent assets $ 32 $ 38 $ 205 $ 157 Current liability (7) (8) (10) (9) Noncurrent liabilities (59) (65) (445) (474) Net amount recognized $ (34) $ (35) $ (250) $ (326) Amounts recognized in accumulated other comprehensive items Net actuarial loss $ 157 $ 142 $ 167 $ 242 Prior service credits — — (3) (2) Net amount recognized $ 157 $ 142 $ 164 $ 240
Defined Benefit Plan, Assumptions [Table Text Block]	The actuarial assumptions used to compute the funded status for the plans are based upon information available as of December 31, 2021 and 2020 and are as follows: Domestic pension Non-U.S. pension 2021 2020 2021 2020 Weighted average assumptions used to determine projected benefit obligations Discount rate for determining benefit obligation 2.70 % 2.33 % 1.45 % 0.95 % Interest crediting rate for cash balance plans 2.58 % 2.16 % 1.25 % 1.25 % Average rate of increase in employee compensation N/A N/A 2.73 % 2.30 % The actuarial assumptions used to compute the net periodic pension benefit cost (income) are based upon information available as of the beginning of the year, as presented in the following table: Domestic pension benefits Non-U.S. pension benefits 2021 2020 2019 2021 2020 2019 Weighted average assumptions used to determine net benefit cost (income) Discount rate - service cost N/A N/A N/A 0.65 % 1.21 % 1.97 % Discount rate - interest cost 2.33 % 3.13 % 4.22 % 0.80 % 1.44 % 2.06 % Average rate of increase in employee compensation N/A N/A N/A 2.30 % 2.27 % 2.47 % Expected long-term rate of return on assets 4.25 % 5.00 % 5.76 % 2.02 % 2.33 % 3.25 %
Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]	The projected benefit obligation and fair value of plan assets for the company’s qualified and non-qualified pension plans with projected benefit obligations in excess of plan assets are as follows: Pension plans (In millions) 2021 2020 Pension plans with projected benefit obligations in excess of plan assets Projected benefit obligation $ 2,010 $ 2,047 Fair value of plan assets 1,521 1,529
Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block]	The accumulated benefit obligation and fair value of plan assets for the company's qualified and non-qualified pension plans with accumulated benefit obligations in excess of plan assets are as follows: Pension plans (In millions) 2021 2020 Pension plans with accumulated benefit obligations in excess of plan assets Accumulated benefit obligation $ 1,937 $ 1,976 Fair value of plan assets 1,521 1,526
Schedule of Net Benefit Costs [Table Text Block]	The net periodic pension benefit cost (income) includes the following components: Domestic pension benefits Non-U.S. pension benefits (In millions) 2021 2020 2019 2021 2020 2019 Components of net benefit cost (income) Service cost $ — $ — $ — $ 27 $ 24 $ 23 Interest cost on benefit obligation 23 35 45 11 18 24 Expected return on plan assets (40) (47) (55) (19) (19) (30) Amortization of actuarial net loss 7 6 2 12 10 6 Amortization of prior service benefit — — — — (1) (1) Settlement/curtailment loss — — — — 8 4 Net periodic benefit cost (income) $ (10) $ (6) $ (8) $ 31 $ 40 $ 26
Schedule of Expected Benefit Payments [Table Text Block]	Estimated future benefit payments during the next five years and in the aggregate for the five fiscal years thereafter, are as follows: (In millions) Domestic Non-U.S. Expected benefit payments 2022 $ 93 $ 45 2023 89 45 2024 88 49 2025 86 52 2026 84 56 2027-2031 368 307
Schedule of Allocation of Plan Assets [Table Text Block]	The fair values of the company’s plan assets at December 31, 2021 and 2020, by asset category are as follows: December 31, Quoted Significant Significant Not subject to leveling (a) (In millions) 2021 (Level 1) (Level 2) (Level 3) Domestic pension plan assets U.S. equity funds $ 124 $ — $ — $ — $ 124 International equity funds 117 — — — 117 Fixed income funds 966 — — — 966 Money market funds 19 — — — 19 Total domestic pension plans $ 1,226 $ — $ — $ — $ 1,226 Non-U.S. pension plan assets Equity funds $ 17 $ — $ — $ — $ 17 Fixed income funds 651 — — — 651 Hedge funds 3 — — — 3 Multi-asset funds 73 — — — 73 Derivative funds 253 — — — 253 Alternative investments 1 — — — 1 Insurance contracts 295 — 295 — — Cash / money market funds 9 5 — — 4 Total non-U.S. pension plans $ 1,302 $ 5 $ 295 $ — $ 1,002 (a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. December 31, Quoted Significant Significant Not subject to leveling (a) (In millions) 2020 (Level 1) (Level 2) (Level 3) Domestic pension plan assets U.S. equity funds $ 125 $ — $ — $ — $ 125 International equity funds 126 — — — 126 Fixed income funds 1,001 — — — 1,001 Money market funds 15 — — — 15 Total domestic pension plans $ 1,267 $ — $ — $ — $ 1,267 Non-U.S. pension plan assets Equity funds $ 74 $ — $ — $ — $ 74 Fixed income funds 510 — — — 510 Hedge funds 59 — — — 59 Multi-asset funds 45 — — — 45 Derivative funds 149 — — — 149 Alternative investments 6 — — — 6 Insurance contracts 262 — 262 — — Cash / money market funds 55 7 — — 48 Total non-U.S. pension plans $ 1,160 $ 7 $ 262 $ — $ 891 (a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	The components of income before provision for income taxes are as follows: (In millions) 2021 2020 2019 U.S. $ 3,340 $ 4,762 $ 2,280 Non-U.S. 5,501 2,468 1,792 Income before income taxes $ 8,841 $ 7,230 $ 4,072
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	The components of the provision for income taxes are as follows: (In millions) 2021 2020 2019 Current income tax provision Federal $ 446 $ 521 $ 267 Non-U.S. 1,148 423 544 State 160 175 62 1,754 1,119 873 Deferred income tax provision (benefit) Federal $ (227) $ (237) $ (222) Non-U.S. (399) (18) (252) State (19) (14) (25) (645) (269) (499) Provision for income taxes $ 1,109 $ 850 $ 374
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before income taxes due to the following: (In millions) 2021 2020 2019 Statutory federal income tax rate 21 % 21 % 21 % Provision for income taxes at statutory rate $ 1,857 $ 1,518 $ 855 Increases (decreases) resulting from: Foreign rate differential (255) (223) (204) Income tax credits (315) (335) (213) Global intangible low-taxed income 76 86 92 Foreign-derived intangible income (119) (156) (111) Excess tax benefits from stock options and restricted stock units (124) (114) (80) Provision for (reversal of) tax reserves, net (17) (26) 62 Intra-entity transfers (284) — (79) Foreign exchange loss on inter-company debt refinancing — (47) (62) Domestication transaction — (263) — Valuation allowance 36 379 (4) Withholding taxes 164 115 38 Basis difference on disposal of business — — 73 Tax return reassessments and settlements 1 (196) (6) State income taxes, net of federal tax 82 147 22 Other, net 7 (35) (9) Provision for income taxes $ 1,109 $ 850 $ 374
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Net deferred tax asset (liability) in the accompanying balance sheet consists of the following: (In millions) 2021 2020 Deferred tax asset (liability) Depreciation and amortization $ (4,687) $ (2,962) Net operating loss and credit carryforwards 1,652 1,668 Reserves and accruals 162 164 Accrued compensation 318 253 Inventory basis difference 181 112 Deferred interest 295 227 Unrealized (gains) losses on hedging instruments (33) 242 Other, net 251 124 Deferred tax liabilities, net before valuation allowance (1,861) (172) Less: Valuation allowance 968 933 Deferred tax liabilities, net $ (2,829) $ (1,105) The company estimates the degree to which tax assets and loss and credit carryforwards will result in a benefit based on expected profitability by tax jurisdiction and provides a valuation allowance for tax assets and loss and credit carryforwards that it believes will more likely than not expire unutilized. At December 31, 2021, all of the company’s valuation allowance relates to deferred tax assets, primarily net operating losses and disallowed interest expense carryforward, for which any subsequently recognized tax benefits will reduce income tax expense. The changes in the valuation allowance are as follows: Year Ended December 31, (In millions) 2021 2020 2019 Beginning balance $ 933 $ 408 $ 471 Additions (reductions) charged to income tax provision, net 24 514 (27) Additions due to acquisitions 30 — — Reduction due to a divestiture — — (33) Currency translation and other (19) 11 (3) Ending balance $ 968 $ 933 $ 408
Summary of Income Tax Contingencies [Table Text Block]	A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows: (In millions) 2021 2020 2019 Beginning balance $ 1,091 $ 1,552 $ 1,442 Additions due to acquisitions 26 — — Additions for tax positions of current year 32 8 53 Additions for tax positions of prior years 60 — 69 Reductions for tax positions of prior years (5) (296) (7) Closure of tax years (27) — — Settlements (53) (173) (5) Ending balance $ 1,124 $ 1,091 $ 1,552

Earnings per Share (Tables)

Earnings per Share (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	(In millions except per share amounts) 2021 2020 2019 Net income attributable to Thermo Fisher Scientific Inc. $ 7,725 $ 6,375 $ 3,696 Basic weighted average shares 394 396 400 Plus effect of: stock options and restricted stock units 3 3 3 Diluted weighted average shares 397 399 403 Basic earnings per share $ 19.62 $ 16.09 $ 9.24 Diluted earnings per share $ 19.46 $ 15.96 $ 9.17 Antidilutive stock options excluded from diluted weighted average shares 1 1 1

Debt and Other Financing Arra_2

Debt and Other Financing Arrangements (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	Effective interest rate at December 31, December 31, December 31, (Dollars in millions) 2021 2021 2020 Commercial Paper 0.01 % $ 2,522 $ — 2.15% 7-Year Senior Notes, Due 7/21/2022 (euro-denominated) — 611 3.00% 7-Year Senior Notes, Due 4/15/2023 — 1,000 Floating Rate (SOFR + 0.35%) 1.5-Year Senior Notes, Due 4/18/2023 1,000 — Floating Rate (SOFR + 0.39%) 2-Year Senior Notes, Due 10/18/2023 500 — 0.797% 2-Year Senior Notes, Due 10/18/2023 1.03 % 1,350 — Floating Rate (EURIBOR + 0.20%) 2-Year Senior Notes Due 11/18/2023 (euro-denominated) 0.00 % 1,933 — 0.000% 2-Year Senior Notes Due 11/18/2023 (euro-denominated) 0.06 % 625 — 4.15% 10-Year Senior Notes, Due 2/1/2024 — 1,000 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) 0.94 % 1,137 1,222 1.215% 3-Year Senior Notes, Due 10/18/2024 1.42 % 2,500 — Floating Rate (SOFR + 0.53%) 3-Year Senior Notes, Due 10/18/2024 500 — 0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated) 0.41 % 910 977 4.133% 5-Year Senior Notes, Due 3/25/2025 — 1,100 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) 2.10 % 728 782 0.000% 4-Year Senior Notes Due 11/18/2025 (euro-denominated) 0.16 % 625 — 3.65% 10-Year Senior Notes, Due 12/15/2025 3.77 % 350 350 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) 1.53 % 796 855 2.95% 10-Year Senior Notes, Due 9/19/2026 — 1,200 Effective interest rate at December 31, December 31, December 31, (Dollars in millions) 2021 2021 2020 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) 1.66 % 568 611 1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated) 1.97 % 682 733 3.20% 10-Year Senior Notes, Due 8/15/2027 — 750 0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated) 0.77 % 910 977 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) 1.46 % 682 733 1.750% 7-Year Senior Notes, Due 10/15/2028 1.89 % 700 — 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) 2.08 % 796 855 2.60% 10-Year Senior Notes, Due 10/1/2029 2.74 % 900 900 4.497% 10-Year Senior Notes, Due 3/25/2030 — 1,100 0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated) 0.89 % 1,990 — 0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated) 1.13 % 1,023 1,099 2.00% 10-Year Senior Notes, Due 10/15/2031 2.23 % 1,200 — 2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated) 2.55 % 682 733 1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated) 1.21 % 1,706 — 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) 2.94 % 796 855 1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated) 1.73 % 1,023 1,099 2.80% 20-Year Senior Notes, Due 10/15/2041 2.90 % 1,200 — 1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated) 1.78 % 1,421 — 5.30% 30-Year Senior Notes, Due 2/1/2044 5.37 % 400 400 4.10% 30-Year Senior Notes, Due 8/15/2047 4.23 % 750 750 1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated) 1.98 % 1,137 1,222 2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated) 2.07 % 853 — Other 76 5 Total borrowings at par value 34,971 21,919 Fair value hedge accounting adjustments — 25 Unamortized discount (117) (102) Unamortized debt issuance costs (184) (114) Total borrowings at carrying value 34,670 21,728 Finance lease liabilities 200 7 Less: Short-term obligations and current maturities 2,537 2,628 Long-term obligations $ 32,333 $ 19,107 SOFR - Secured Overnight Financing Rate EURIBOR - Euro Interbank Offered Rate
Schedule of Maturities of Long-term Debt [Table Text Block]	As of December 31, 2021, the annual repayment requirements for debt obligations are as follows: (In millions) Borrowings Finance Lease Liabilities 2022 $ 2,522 $ 15 2023 5,396 12 2024 4,138 12 2025 2,610 12 2026 797 12 2027 and thereafter 19,508 137 $ 34,971 $ 200

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Lease, Cost [Table Text Block]	As a lessee, the consolidated financial statements include the following relating to operating leases: (In millions) 2021 2020 2019 Balance sheet ROU assets $ 1,531 $ 775 Operating lease liabilities - current 266 184 Operating lease liabilities - noncurrent 1,203 626 Statement of income Operating lease costs $ 254 $ 224 $ 208 Variable lease costs 66 49 41 Statement of cash flows Cash used in operating activities for payments of amounts included in the measurement of operating lease liabilities $ 288 $ 222 $ 208 Operating lease ROU assets obtained in exchange for new operating lease liabilities 293 202 205 Weighted average at end of year Remaining operating lease term 9.9 years 6.3 years 6.2 years Discount rate 2.6 % 3.4 % 4.0 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	As of December 31, 2021, future payments of operating lease liabilities are as follows: (In millions) 2022 $ 303 2023 248 2024 193 2025 144 2026 120 2027 and thereafter 650 Total lease payments 1,658 Less: imputed interest 189 Total operating lease liability $ 1,469

Comprehensive Income and Shar_2

Comprehensive Income and Shareholders Equity (Tables)	12 Months Ended
	Dec. 31, 2021
Stockholders' Equity Note [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Changes in each component of accumulated other comprehensive items, net of tax are as follows: (In millions) Currency Unrealized Pension and Total Balance at December 31, 2020 $ (2,438) $ (91) $ (278) $ (2,807) Other comprehensive items before reclassifications 373 — 36 409 Amounts reclassified from accumulated other comprehensive items — 56 13 69 Net other comprehensive items 373 56 49 478 Balance at December 31, 2021 $ (2,065) $ (35) $ (229) $ (2,329)

Fair Value Measurements and F_2

Fair Value Measurements and Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2021 and December 31, 2020: December 31, Quoted Significant Significant (In millions) 2021 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 2,210 $ 2,210 $ — $ — Investments 298 298 — — Warrants 15 — 15 — Insurance contracts 181 — 181 — Derivative contracts 36 — 36 — Total assets $ 2,740 $ 2,508 $ 232 $ — Liabilities Derivative contracts $ 1 $ — $ 1 $ — Contingent consideration 317 — — 317 Total liabilities $ 318 $ — $ 1 $ 317 December 31, Quoted Significant Significant (In millions) 2020 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 8,971 $ 8,971 $ — $ — Investments 21 21 — — Warrants 7 — 7 — Insurance contracts 157 — 157 — Derivative contracts 28 — 28 — Total assets $ 9,184 $ 8,992 $ 192 $ — Liabilities Derivative contracts $ 132 $ — $ 132 $ — Contingent consideration 70 — — 70 Total liabilities $ 202 $ — $ 132 $ 70
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones, as well as changes in the fair values of the investments underlying a recapitalization investment portfolio), of the contingent consideration. (In millions) 2021 2020 Contingent consideration Beginning balance $ 70 $ 55 Acquisitions (including assumed balances) 403 28 Payments (109) (4) Changes in fair value included in earnings (47) (9) Ending balance $ 317 $ 70
Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]	The following table provides the aggregate notional value of outstanding derivative contracts. December 31, December 31, (In millions) 2021 2020 Notional amount Interest rate swaps - fair value hedges $ — $ 1,000 Cross-currency interest rate swaps - designated as net investment hedges 900 900 Currency exchange contracts 2,149 5,206
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	Fair value – assets Fair value – liabilities December 31, December 31, December 31, December 31, (In millions) 2021 2020 2021 2020 Derivatives designated as hedging instruments Interest rate swaps (a) $ — $ 25 $ — $ — Cross-currency interest rate swaps (a) 25 — — 46 Derivatives not designated as hedging instruments Currency exchange contracts (b) 11 3 1 86 Total derivatives $ 36 $ 28 $ 1 $ 132 (a) The fair values of the interest rate swaps and cross-currency interest rate swaps are included in the accompanying balance sheet under the caption other assets or other long-term liabilities. (b) The fair value of the currency exchange contracts is included in the accompanying balance sheet under the captions other current assets or other accrued expenses. The following amounts related to cumulative basis adjustments for fair value hedges were included in the accompanying balance sheet under the caption long-term obligations: Carrying amount of the hedged liability Cumulative amount of fair value hedging adjustment - increase (decrease) included in carrying amount of liability December 31, December 31, December 31, December 31, (In millions) 2021 2020 2021 2020 Long-term obligations $ — $ 1,020 $ — $ 25
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance [Table Text Block]	Gain (loss) recognized (In millions) 2021 2020 Fair value hedging relationships Interest rate swaps Hedged long-term obligations - included in other income/(expense) $ 25 $ (38) Derivatives designated as hedging instruments - included in other income/(expense) (3) 38 Derivatives designated as cash flow hedges Interest rate swaps Included in unrealized losses on hedging instruments within other comprehensive items — (85) Amount reclassified from accumulated other comprehensive items to other income/(expense) (73) (59) Financial instruments designated as net investment hedges Foreign currency-denominated debt Included in currency translation adjustment within other comprehensive items 922 (873) Cross-currency interest rate swaps Included in currency translation adjustment within other comprehensive items 71 (79) Included in other income/(expense) 8 11 Derivatives not designated as hedging instruments Currency exchange contracts Included in cost of product revenues 12 (17) Included in other income/(expense) 162 (81) Cross-currency interest rate swaps Included in other income/(expense) — (9)
Fair Value, by Balance Sheet Grouping [Table Text Block]	The carrying value and fair value of the company’s debt instruments are as follows: December 31, 2021 December 31, 2020 Carrying Fair Carrying Fair (In millions) value value value value Senior notes $ 32,072 $ 33,449 $ 21,723 $ 24,653 Commercial paper 2,522 2,522 — — Other 76 76 5 5 $ 34,670 $ 36,047 $ 21,728 $ 24,658
Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]	The carrying value and fair value of the company’s debt instruments are as follows: December 31, 2021 December 31, 2020 Carrying Fair Carrying Fair (In millions) value value value value Senior notes $ 32,072 $ 33,449 $ 21,723 $ 24,653 Commercial paper 2,522 2,522 — — Other 76 76 5 5 $ 34,670 $ 36,047 $ 21,728 $ 24,658

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	12 Months Ended
	Dec. 31, 2021
Supplemental Cash Flow Information [Abstract]
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	(In millions) 2021 2020 2019 Cash paid for: Interest $ 555 $ 471 $ 790 Income taxes 2,182 1,324 896 Non-cash investing and financing activities Acquired but unpaid property, plant and equipment 379 347 150 Fair value of equity awards exchanged 43 — — Fair value of acquisition contingent consideration 183 — — Finance lease ROU assets obtained in exchange for new finance lease liabilities 15 5 1 Declared but unpaid dividends 104 89 77 Issuance of stock upon vesting of restricted stock units 265 217 182
Restrictions on Cash and Cash Equivalents [Table Text Block]	Cash, cash equivalents and restricted cash is included in the consolidated balance sheet as follows: December 31, December 31, (In millions) 2021 2020 Cash and cash equivalents $ 4,477 $ 10,325 Restricted cash included in other current assets 13 10 Restricted cash included in other assets 1 1 Cash, cash equivalents and restricted cash $ 4,491 $ 10,336

Restructuring and Other Costs_2

Restructuring and Other Costs, Net (Tables)	12 Months Ended
	Dec. 31, 2021
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Costs [Table Text Block]	Restructuring and other costs (income) by segment are as follows: (In millions) 2021 2020 2019 Life Sciences Solutions $ 129 $ 34 $ 24 Analytical Instruments 6 26 14 Specialty Diagnostics 18 9 (471) Laboratory Products and Biopharma Services 35 23 17 Corporate 9 7 3 $ 197 $ 99 $ (413)
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	The following table summarizes the changes in the company’s accrued restructuring balance. Other amounts reported as restructuring and other costs in the accompanying statement of income have been summarized in the notes to the table. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet. (In millions) Total (a) Balance at December 31, 2018 $ 80 Cumulative effect of accounting change (b) (28) Net restructuring charges incurred in 2019 (c) 52 Payments (69) Currency translation (1) Balance at December 31, 2019 34 Net restructuring charges incurred in 2020 (d) 51 Payments (57) Currency translation (7) Balance at December 31, 2020 21 Net restructuring charges incurred in 2021 (e) 37 Payments (40) Currency translation (1) Balance at December 31, 2021 $ 17 (a) The movements in the restructuring liability principally consist of severance and other costs such as relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment. (b) Impact of adopting new lease accounting guidance on January 1, 2019. (c) Excludes $465 million of net charges, principally $482 million of net gain on the sale of businesses (d) Excludes $48 million of charges, principally $32 million for impairment of acquired technology in the Life Sciences Solutions segment resulting from a reduction in expected cash flows and, to a lesser extent, charges across the company’s segments for fixed asset writedowns and costs associated with environmental remediation at abandoned/previously owned facilities. (e) Excludes $160 million of charges, principally $122 million for impairments of an acquired technology asset and a tradename asset in the Life Sciences Solutions and Laboratory Products and Biopharma Services segment, principally resulting from a reduction in expected cash flows, and $35 million of charges for compensation contractually due to employees of acquired businesses at the date of acquisition in the Life Sciences Solutions and Laboratory Products and Biopharma Services segments.

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Oct. 02, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials		$ 1,922	$ 1,305
Work in process		676	540
Finished goods		2,453	2,184
Inventories		5,051	4,029
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Inventories		5,051	4,029
Value of inventories maintained using the LIFO method			274
Excess of estimated replacement cost over stated LIFO value			49
Product [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cost of Goods and Services Sold		$ (13,594)	$ (11,407)	$ (10,037)
Change in Accounting Principle, Other
Inventory Disclosure [Abstract]
Inventories	$ 33
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of LIFO Inventory	5.00%
Inventories	$ 33
Change in Accounting Principle, Other | Product [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cost of Goods and Services Sold	33
Change in Accounting Principle, Other | Laboratory Products and Biopharma Services [Member]
Inventory Disclosure [Abstract]
Inventories	20
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Inventories	20
Change in Accounting Principle, Other | Laboratory Products and Biopharma Services [Member] | Product [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cost of Goods and Services Sold	20
Change in Accounting Principle, Other | Specialty Diagnostics [Member]
Inventory Disclosure [Abstract]
Inventories	13
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Inventories	13
Change in Accounting Principle, Other | Specialty Diagnostics [Member] | Product [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cost of Goods and Services Sold	$ 13

Property, Plant and Equipment (

Property, Plant and Equipment (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	$ 12,593	$ 9,577
Less: Accumulated depreciation and amortization	4,260	3,665
Property, plant and equipment, net	8,333	5,912
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	431	410
Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	$ 2,575	2,192
Buildings and Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	25 years
Buildings and Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	40 years
Machinery, Equipment and Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	$ 9,587	$ 6,975
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years

Acquisition-related Intangible

Acquisition-related Intangible Assets (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Intangible Assets [Line Items]
Definite-Lived Intangible Assets, Gross	$ 31,625	$ 23,329
Accumulated Amortization	(12,747)	(11,879)
Definite-Lived Intangible Assets, Net	18,878	11,450
Acquisition-related Intangible Assets, Gross	32,860	24,564
Acquisition-related Intangible Assets, net of Accumulated Amortization	20,113	12,685
Finite-Lived Intangible Assets, Net, Future Amortization Expense [Abstract]
2022	2,489
2023	2,358
2024	1,992
2025	1,669
2026	1,392
2027 and thereafter	8,978
Definite-Lived Intangible Assets, Net	18,878	11,450
Other Intangible Assets, Net	$ 33	43
Maximum [Member]
Intangible Assets [Line Items]
Estimated Useful Life (in years)	20 years
Tradenames [Member]
Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets	$ 1,235	1,235
Customer Relationships [Member]
Intangible Assets [Line Items]
Definite-Lived Intangible Assets, Gross	22,802	16,593
Accumulated Amortization	(7,792)	(7,450)
Definite-Lived Intangible Assets, Net	15,010	9,143
Finite-Lived Intangible Assets, Net, Future Amortization Expense [Abstract]
Definite-Lived Intangible Assets, Net	15,010	9,143
Product Technology [Member]
Intangible Assets [Line Items]
Definite-Lived Intangible Assets, Gross	6,041	5,523
Accumulated Amortization	(3,977)	(3,532)
Definite-Lived Intangible Assets, Net	2,064	1,991
Finite-Lived Intangible Assets, Net, Future Amortization Expense [Abstract]
Definite-Lived Intangible Assets, Net	2,064	1,991
Tradenames [Member]
Intangible Assets [Line Items]
Definite-Lived Intangible Assets, Gross	1,722	1,213
Accumulated Amortization	(919)	(897)
Definite-Lived Intangible Assets, Net	803	316
Finite-Lived Intangible Assets, Net, Future Amortization Expense [Abstract]
Definite-Lived Intangible Assets, Net	803	$ 316
Backlog [Member]
Intangible Assets [Line Items]
Definite-Lived Intangible Assets, Gross	1,060
Accumulated Amortization	(59)
Definite-Lived Intangible Assets, Net	1,001
Finite-Lived Intangible Assets, Net, Future Amortization Expense [Abstract]
Definite-Lived Intangible Assets, Net	$ 1,001

Goodwill (Details)

Goodwill (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Goodwill [Roll Forward]
Beginning balance	$ 26,041	$ 25,714
Acquisitions	16,024	35
Currency translation	(141)	292
Ending balance	41,924	26,041
Life Sciences Solutions [Member]
Goodwill [Roll Forward]
Beginning balance	8,590	8,544
Acquisitions	1,560	35
Currency translation	(7)	11
Ending balance	10,143	8,590
Analytical Instruments [Member]
Goodwill [Roll Forward]
Beginning balance	5,079	4,928
Acquisitions	56
Currency translation	(92)	151
Ending balance	5,043	5,079
Specialty Diagnostics [Member]
Goodwill [Roll Forward]
Beginning balance	3,370	3,184
Acquisitions	8
Currency translation	(101)	186
Ending balance	3,277	3,370
Laboratory Products and Biopharma Services [Member]
Goodwill [Roll Forward]
Beginning balance	9,002	9,058
Acquisitions	14,400
Currency translation	59	(56)
Ending balance	$ 23,461	$ 9,002

Additional Accounting Policy an

Additional Accounting Policy and Balance Sheet Disclosures (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Equity Method Investments	$ 576	$ 32
Equity Securities, FV-NI, Noncurrent	217
Cost Method Investments	22	28
Alternative Investment	16	0
Foreign Currency Transaction Gain (Loss), before Tax	$ 25	$ 24	$ 52
PPD-SNBL K.K.
Noncontrolling Interest [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent	60.00%
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	40.00%

Recent Accounting Pronouncement

Recent Accounting Pronouncements (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020	Jan. 01, 2020	Jan. 01, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accounts Receivable, less Allowances	$ 7,977	$ 5,741
Retained earnings	$ 35,431	$ 28,116
Accounting Standards Update 2016-02 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Retained earnings				$ 4
Cumulative Effect, Period of Adoption, Adjustment [Member] | Accounting Standards Update 2016-13 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accounts Receivable, less Allowances			$ (1)
Retained earnings			$ (1)

Acquisitions Purchase Price (De

Acquisitions Purchase Price (Details) - USD ($) $ in Millions	Dec. 30, 2021	Dec. 08, 2021	Sep. 30, 2021	Feb. 25, 2021	Jan. 15, 2021	Apr. 30, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Purchase Price
Fair value of equity awards exchanged							$ 43
Fair value of contingent consideration							$ 183
Net Assets Acquired [Abstract]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (in years)							14 years		14 years
Payments to Acquire Businesses, Net of Cash Acquired							$ 19,395	$ 38	$ 1,843
Customer Relationships [Member]
Net Assets Acquired [Abstract]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (in years)							17 years		14 years
Product Technology [Member]
Net Assets Acquired [Abstract]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (in years)							11 years		13 years
Tradenames [Member]
Net Assets Acquired [Abstract]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (in years)							7 years		2 years
Backlog [Member]
Net Assets Acquired [Abstract]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (in years)							3 years
PPD, Inc. [Member]
Purchase Price
Cash paid		$ 17,237
Fair value of equity awards exchanged		43
Cash acquired		(1,244)
Total purchase price		16,036
Net Assets Acquired [Abstract]
Current assets		2,510
Property, plant and equipment		562
Goodwill		13,781
Other assets		1,108
Contract liabilities		(1,570)
Deferred tax liabilities		(1,803)
Finance lease liabilities		(86)
Debt assumed		(4,299)
Other liabilities assumed		(1,972)
Redeemable noncontrolling interest		(122)
Total net assets acquired		16,036
Payments to Acquire Businesses, Net of Cash Acquired		15,990
PPD, Inc. [Member] | Customer Relationships [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets		6,264
PPD, Inc. [Member] | Tradenames [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets		603
PPD, Inc. [Member] | Backlog [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets		$ 1,060
PeproTech, Inc. [Member]
Purchase Price
Cash paid	$ 1,947
Cash acquired	(83)
Total purchase price	1,864
Net Assets Acquired [Abstract]
Current assets	63
Property, plant and equipment	18
Goodwill	1,190
Other assets	11
Deferred tax liabilities	(193)
Other liabilities assumed	(21)
Total net assets acquired	1,864
Payments to Acquire Businesses, Net of Cash Acquired	1,860
PeproTech, Inc. [Member] | Customer Relationships [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets	514
PeproTech, Inc. [Member] | Product Technology [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets	$ 282
European Viral Vector Manufacturing Business [Member]
Purchase Price
Cash paid					$ 848
Cash acquired					(18)
Total purchase price					830
Net Assets Acquired [Abstract]
Current assets					39
Property, plant and equipment					59
Goodwill					600
Other assets					3
Contract liabilities					(59)
Deferred tax liabilities					(80)
Finance lease liabilities					(24)
Other liabilities assumed					(35)
Total net assets acquired					830
Payments to Acquire Businesses, Net of Cash Acquired					830
European Viral Vector Manufacturing Business [Member] | Customer Relationships [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets					302
European Viral Vector Manufacturing Business [Member] | Product Technology [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets					$ 25
Mesa Biotech [Member]
Purchase Price
Cash paid				$ 421
Fair value of contingent consideration				65
Cash acquired				(14)
Total purchase price				472
Net Assets Acquired [Abstract]
Current assets				54
Property, plant and equipment				2
Goodwill				237
Other assets				3
Deferred tax liabilities				(72)
Other liabilities assumed				(33)
Total net assets acquired				472
Payments to Acquire Businesses, Net of Cash Acquired				407
Mesa Biotech [Member] | Product Technology [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets				279
Mesa Biotech [Member] | Tradenames [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets				$ 2
Lengnau biologics manufacturing facility [Member]
Purchase Price
Cash paid			$ 17
Fair value of contingent consideration			1
Total purchase price			18
Net Assets Acquired [Abstract]
Property, plant and equipment			92
Goodwill			18
Other assets			376
Finance lease liabilities			(82)
Other liabilities assumed			(386)
Total net assets acquired			18
Lessee, Lease Liability Payments Due			$ 555
Brammer Bio [Member]
Purchase Price
Cash paid						$ 1,710
Cash acquired						(36)
Total purchase price						1,674
Net Assets Acquired [Abstract]
Current assets						52
Property, plant and equipment						147
Goodwill						938
Other assets						49
Contract liabilities						(110)
Deferred tax liabilities						(110)
Other liabilities assumed						(108)
Total net assets acquired						1,674
Goodwill, Expected Tax Deductible Amount						405
Brammer Bio [Member] | Customer Relationships [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets						744
Brammer Bio [Member] | Product Technology [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets						65
Brammer Bio [Member] | Tradenames [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets						$ 7
Other [Member]
Purchase Price
Cash paid							$ 298		$ 169
Fair value of contingent consideration							117
Cash acquired							(13)
Total purchase price							402	$ 63	169
Net Assets Acquired [Abstract]
Current assets							12		58
Property, plant and equipment							2		102
Goodwill							198		9
Other assets							2
Contract liabilities							(1)
Deferred tax liabilities							(28)		(6)
Other liabilities assumed							(11)		(1)
Total net assets acquired							402		169
Other [Member] | Customer Relationships [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets							2
Other [Member] | Product Technology [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets							224		$ 7
Other [Member] | Tradenames [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets							$ 2

Acquisition Pro Forma Results (

Acquisition Pro Forma Results (Details) - PPD, Inc. [Member] - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition, Pro Forma Information [Abstract]
Revenues		$ 44,886	$ 36,887
Net income attributable to Thermo Fisher Scientific Inc.		7,369	5,361
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual	$ 378
Business Combination, Pro Forma Information, Operating Income (Loss) of Acquiree since Acquisition Date, Actual	$ (60)
Non-recurring Pro Forma Adjustments, Transaction Costs [Member]
Business Acquisition, Pro Forma Information [Abstract]
Net income attributable to Thermo Fisher Scientific Inc.		$ 312	$ (197)

Disposition (Details)

Disposition (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Jun. 28, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal		$ 0	$ 0	$ 482
Revenues		$ 39,211	$ 32,218	25,542
Anatomical Pathology business [Member] | Disposal Group, Held-for-sale, Not Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Consideration	$ 1,130
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal				$ 478
Revenues	$ 115

Revenue (Details)

Revenue (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Revenues	$ 39,211	$ 32,218	$ 25,542
North America [Member]
Disaggregation of Revenue [Line Items]
Revenues	19,659	17,081	12,896
Europe [Member]
Disaggregation of Revenue [Line Items]
Revenues	11,134	8,284	6,358
Asia Pacific [Member]
Disaggregation of Revenue [Line Items]
Revenues	7,218	5,822	5,524
Other Regions [Member]
Disaggregation of Revenue [Line Items]
Revenues	1,200	1,031	764
Consumables [Member]
Disaggregation of Revenue [Line Items]
Revenues	22,608	18,527	13,109
Instruments [Member]
Disaggregation of Revenue [Line Items]
Revenues	7,753	6,779	6,387
Service [Member]
Disaggregation of Revenue [Line Items]
Revenues	$ 8,850	$ 6,912	$ 6,046

Revenue Performance Obligations

Revenue Performance Obligations (Details) $ in Millions	Dec. 31, 2021USD ($)
Revenue from Contract with Customer [Abstract]
Revenue, Remaining Performance Obligation, Amount	$ 28,300
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-12-31
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, Remaining Performance Obligation, Percentage	59.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	12 months

Contract Assets and Liabilities

Contract Assets and Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Abstract]
Contract assets, net	$ 968	$ 731
Noncurrent contract assets, net	9	11
Contract liabilities	2,655	1,271
Noncurrent contract liabilities	$ 1,238	$ 763

Business Segment Information (D

Business Segment Information (Details) $ in Millions		12 Months Ended
		Dec. 31, 2021USD ($)Segment	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Segment Reporting Information [Line Items]
Number of Reportable Segments | Segment		4
Revenues		$ 39,211	$ 32,218	$ 25,542
Restructuring and other (costs) income		(197)	(99)	413
Amortization of acquisition-related intangible assets		(1,761)	(1,667)	(1,713)
Operating Income		10,028	7,794	4,594
Interest income		43	65	224
Interest expense		(536)	(553)	(676)
Other income/(expense)		(694)	(76)	(70)
Income before income taxes		8,841	7,230	4,072
Depreciation of property, plant and equipment		831	658	564
Total Assets		95,123	69,052	58,381
Capital Expenditures		2,523	1,474	926
Life Sciences Solutions [Member]
Segment Reporting Information [Line Items]
Restructuring and other (costs) income		(129)	(34)	(24)
Total Assets		22,751	20,209	18,306
Capital Expenditures		810	392	151
Analytical Instruments [Member]
Segment Reporting Information [Line Items]
Restructuring and other (costs) income		(6)	(26)	(14)
Total Assets		9,692	9,773	9,896
Capital Expenditures		79	74	64
Specialty Diagnostics [Member]
Segment Reporting Information [Line Items]
Restructuring and other (costs) income		(18)	(9)	471
Total Assets		6,010	6,534	5,867
Capital Expenditures		167	175	83
Laboratory Products and Biopharma Services [Member]
Segment Reporting Information [Line Items]
Restructuring and other (costs) income		(35)	(23)	(17)
Total Assets		52,639	22,711	21,761
Capital Expenditures		1,327	772	554
Corporate and Other [Member]
Segment Reporting Information [Line Items]
Total Assets	[1]	4,031	9,825	2,551
Capital Expenditures		140	61	74
Total Reportable Segments [Member]
Segment Reporting Information [Line Items]
Operating Income		12,138	9,556	5,973
Total Reportable Segments [Member] | Life Sciences Solutions [Member]
Segment Reporting Information [Line Items]
Revenues		15,631	12,168	6,856
Operating Income		7,817	6,109	2,446
Depreciation of property, plant and equipment		197	140	130
Total Reportable Segments [Member] | Analytical Instruments [Member]
Segment Reporting Information [Line Items]
Revenues		6,069	5,124	5,522
Operating Income		1,197	808	1,273
Depreciation of property, plant and equipment		83	76	75
Total Reportable Segments [Member] | Specialty Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenues		5,659	5,343	3,718
Operating Income		1,280	1,368	930
Depreciation of property, plant and equipment		128	100	67
Total Reportable Segments [Member] | Laboratory Products and Biopharma Services [Member]
Segment Reporting Information [Line Items]
Revenues		14,862	12,245	10,599
Operating Income		1,844	1,271	1,324
Depreciation of property, plant and equipment		423	342	292
Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
Revenues		(3,010)	(2,662)	(1,153)
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Cost of revenues charges		(8)	(6)	(17)
Selling, general and administrative (charges) credits		(144)	10	(62)
Restructuring and other (costs) income		(197)	(99)	413
Amortization of acquisition-related intangible assets		$ (1,761)	$ (1,667)	$ (1,713)
[1]	Corporate assets consist primarily of cash and cash equivalents and property and equipment at the company's corporate offices.

Geographical Information (Detai

Geographical Information (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		$ 39,211	$ 32,218	$ 25,542
Long-lived Assets	[1]	9,864	6,687	5,448
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[2]	18,907	16,435	12,366
Long-lived Assets	[1]	5,578	3,686	3,099
China
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[2]	3,444	2,797	2,752
All Other Countries
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[2]	16,860	12,986	10,424
Long-lived Assets	[1]	$ 4,286	$ 3,001	$ 2,349
[1]	Includes property, plant and equipment, net, and operating lease ROU assets.
[2]	Revenues are attributed to countries based on customer location.

Other Expense, Net (Details)

Other Expense, Net (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of Equity Method Investments [Line Items]
Loss on early extinguishment of debt	$ (767)	$ 0	$ (184)
Fees Associated with Short-term Financing Commitments	36	81
Gain (Loss) on Sale of Investments	66	10	44
Payments of Financing Costs	36	51
Interest Rate Swaps [Member] | Cash Flow Hedging [Member] | Other Expense [Member]
Schedule of Equity Method Investments [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax	$ 65	$ 42
Corporate Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Gain (Loss) on Sale of Investments			28
Proceeds from Sale of Equity Method Investments			$ 42

Stockbased Compensation, Stock

Stockbased Compensation, Stock Option Disclosures (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected Stock Price Volatility	26.00%	22.00%	21.00%
Risk Free Interest Rate	0.80%	1.10%	2.40%
Expected Life of Options (years)	4 years 3 months 18 days	4 years 3 months 18 days	4 years 3 months 18 days
Expected Annual Dividend	0.20%	0.30%	0.30%
Weighted Average Grant Date Fair Value of Options Granted in Period (in dollars per share)	$ 123.97	$ 61.19	$ 53.37
Total Intrinsic Value of Options Exercised in Period	$ 501	$ 457	$ 320
Options Outstanding [Roll Forward]
Options Outstanding, Beginning Balance	5.9
Granted	1.5
Issued in connection with an acquisition	0.2
Exercised	(1.4)
Canceled / Expired	(0.2)
Options Outstanding, Ending Balance	6	5.9
Options, Additional Disclosures [Abstract]
Options Outstanding, Weighted Average Exercise Price, Beginning of Period (in dollars per share)	$ 221.22
Grants in Period, Weighted Average Exercise Price (in dollars per share)	552.26
Issued in Connection with an Acquisition in Period, Weighted Average Exercise Price (in dollars per share)	492.35
Exercises in Period, Weighted Average Exercise Price (in dollars per share)	183.63
Canceled / Expired in Period, Weighted Average Exercise Price (in dollars per share)	341.83
Options Outstanding, Weighted Average Exercise Price, End of Period (in dollars per share)	$ 319.95	$ 221.22
Options Outstanding, Weighted Average Remaining Contractual Term	4 years 6 months
Options Outstanding, Aggregate Intrinsic Value	$ 2,094
Options Vested and Unvested Expected to Vest	5.7
Options Vested and Unvested Expected to Vest, Weighted Average Exercise Price (in dollars per share)	$ 306.64
Options Vested and Unvested Expected to Vest, Weighted Average Remaining Contractual Term	4 years 3 months 18 days
Options Vested and Unvested Expected to Vest, Aggregate Intrinsic Value	$ 2,035
Options Exercisable	2.8
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 193.39
Options Exercisable, Weighted Average Remaining Contractual Term	2 years 10 months 24 days
Options Exercisable, Intrinsic Value	$ 1,307
Share-based Payment Arrangement, Option [Member]
Options, Additional Disclosures [Abstract]
Unrecognized Compensation Costs On Nonvested Awards	$ 243
Unrecognized Compensation Costs On Nonvested Awards, Weighted Average Period Of Recognition	2 years 10 months 24 days
Minimum [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award Requisite Service Period	3 years
Option Term	7 years
Maximum [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award Requisite Service Period	5 years
Option Term	10 years

Stockbased Compensation, Restri

Stockbased Compensation, Restricted Units Disclosures (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Unvested Restricted Units [Roll Forward]
Unvested Restricted Units, Beginning Balance	0.8
Granted	0.4
Issued in connection with an acquisition	0.2
Vested	(0.5)
Forfeited	(0.1)
Unvested Restricted Units, Ending Balance	0.8	0.8
Restricted Units, Additional Disclosures [Abstract]
Unvested Restricted Units, Weighted Average Grant Date Fair Value, Beginning Balance (in dollars per share)	$ 276.74
Granted, Weighted Average Grant Date Fair Value (in dollars per share)	444.61
Issued in Connection with an Acquisition, Weighted Average Grant Date Fair Value (in dollars per share)	628.71
Vested, Weighted Average Grant Date Fair Value (in dollars per share)	295.70
Forfeited, Weighted Average Grant Date Fair Value (in dollars per share)	326.90
Unvested Restricted Units, Weighted Average Grant Date Fair Value, Ending Balance (in dollars per share)	$ 425.39	$ 276.74
Fair Value of Units Vested	$ 151	$ 126	$ 118
Restricted Stock Units (RSUs) [Member]
Restricted Units, Additional Disclosures [Abstract]
Unrecognized Compensation Costs On Nonvested Awards	$ 250
Unrecognized Compensation Costs On Nonvested Awards, Weighted Average Period Of Recognition	2 years 1 month 6 days
Restricted Stock Units (RSUs) [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award Requisite Service Period	3 years
Restricted Stock Units (RSUs) [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award Requisite Service Period	4 years

Employee Stock Purchase Plans (

Employee Stock Purchase Plans (Details) - shares shares in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Purchase Price (% of Market Price on Purchase Date)	95.00%
Maximum Employee Subscription Rate (% of Gross Wages)	10.00%
Stock Issued During Period, Employee Stock Purchase Plans (in shares)	0.1	0.1	0.2

Pensions DC Plans (Details)

Pensions DC Plans (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Retirement Benefits [Abstract]
Defined Contribution Plan, Cost	$ 299	$ 254	$ 232

Pensions Funded Status (Details

Pensions Funded Status (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Defined Benefit Plan Disclosure [Line Items]
Cash contributions to retirement plans	$ 34	$ 96	$ 50
Minimum [Member]
Defined Benefit Plan Disclosure [Line Items]
Estimated Employer Contributions in Next Fiscal Year	40
Maximum [Member]
Defined Benefit Plan Disclosure [Line Items]
Estimated Employer Contributions in Next Fiscal Year	60
Pension Plans, Defined Benefit [Member] | United States
Change in Projected Benefit Obligation [Roll Forward]
Benefit obligation at beginning of year	1,302	1,302
Interest costs	23	35	45
Actuarial (gains) losses	20	44
Benefits paid	(85)	(79)
Benefit obligation at end of year	1,260	1,302	1,302
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	1,267	1,201
Actual return on plan assets	37	138
Employer contribution	7	7
Benefits paid	(85)	(79)
Fair value of plan assets at end of year	1,226	1,267	1,201
Funded status	(34)	(35)
Accumulated benefit obligation	1,260	1,302
Amounts Recognized in Balance Sheet [Abstract]
Noncurrent assets	32	38
Current liability	(7)	(8)
Noncurrent liabilities	(59)	(65)
Net amount recognized	(34)	(35)
Amounts Recognized in Accumulated Other Comprehensive Loss [Abstract]
Net actuarial loss	157	142
Net amount recognized	$ 157	$ 142
Weighted Average Assumptions Used to Determine Benefit Obligation [Abstract]
Discount rate for determining benefit obligation	2.70%	2.33%
Interest crediting rate for cash balance plans	2.58%	2.16%
Pension Plans, Defined Benefit [Member] | Foreign Plan [Member]
Change in Projected Benefit Obligation [Roll Forward]
Benefit obligation at beginning of year	$ 1,486	$ 1,303
Business Combination	170
Service costs	27	24	23
Interest costs	11	18	24
Settlements	(7)	(38)
Plan participants' contributions	6	5
Actuarial (gains) losses	(57)	119
Benefits paid	(30)	(26)
Currency translation and other	(54)	81
Benefit obligation at end of year	1,552	1,486	1,303
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	1,160	986
Business Combination	158
Actual return on plan assets	14	92
Employer contribution	27	87
Settlements	(7)	(38)
Plan participants' contributions	6	5
Benefits paid	(30)	(26)
Currency translation and other	(26)	54
Fair value of plan assets at end of year	1,302	1,160	$ 986
Funded status	(250)	(326)
Accumulated benefit obligation	1,475	1,417
Amounts Recognized in Balance Sheet [Abstract]
Noncurrent assets	205	157
Current liability	(10)	(9)
Noncurrent liabilities	(445)	(474)
Net amount recognized	(250)	(326)
Amounts Recognized in Accumulated Other Comprehensive Loss [Abstract]
Net actuarial loss	167	242
Prior service credits	(3)	(2)
Net amount recognized	$ 164	$ 240
Weighted Average Assumptions Used to Determine Benefit Obligation [Abstract]
Discount rate for determining benefit obligation	1.45%	0.95%
Interest crediting rate for cash balance plans	1.25%	1.25%
Average rate of increase in employee compensation	2.73%	2.30%

Pensions Net Benefit Cost (Deta

Pensions Net Benefit Cost (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Components of Net Periodic Benefit Cost (Income) [Abstract]
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible List]	Other income/(expense)
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Expected Return (Loss), Statement of Income or Comprehensive Income [Extensible List]	Other income/(expense)
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Amortization of Gain (Loss), Statement of Income or Comprehensive Income [Extensible List]	Other income/(expense)
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Amortization of Prior Service Cost (Credit), Statement of Income or Comprehensive Income [Extensible List]	Other income/(expense)
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Settlement and Curtailment Gain (Loss), Statement of Income or Comprehensive Income [Extensible List]	Other income/(expense)
Pension Plans, Defined Benefit [Member] | United States
Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost (Income) [Abstract]
Discount rate - interest cost	2.33%	3.13%	4.22%
Expected long-term rate of return on assets	4.25%	5.00%	5.76%
Components of Net Periodic Benefit Cost (Income) [Abstract]
Interest cost on benefit obligation	$ 23	$ 35	$ 45
Expected return on plan assets	(40)	(47)	(55)
Amortization of actuarial net loss	7	6	2
Net periodic benefit cost (income)	$ (10)	$ (6)	$ (8)
Pension Plans, Defined Benefit [Member] | Foreign Plan [Member]
Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost (Income) [Abstract]
Discount rate - service cost	0.65%	1.21%	1.97%
Discount rate - interest cost	0.80%	1.44%	2.06%
Average rate of increase in employee compensation	2.30%	2.27%	2.47%
Expected long-term rate of return on assets	2.02%	2.33%	3.25%
Components of Net Periodic Benefit Cost (Income) [Abstract]
Service cost	$ 27	$ 24	$ 23
Interest cost on benefit obligation	11	18	24
Expected return on plan assets	(19)	(19)	(30)
Amortization of actuarial net loss	12	10	6
Amortization of prior service benefit		(1)	(1)
Settlement/curtailment loss		8	4
Net periodic benefit cost (income)	$ 31	$ 40	$ 26

Pensions Benefit Obligation in

Pensions Benefit Obligation in Excess of Assets (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]
Projected benefit obligation	$ 2,010	$ 2,047
Fair value of plan assets	1,521	1,529
Pension Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Accumulated benefit obligation	1,937	1,976
Fair value of plan assets	$ 1,521	$ 1,526

Pension Expected Benefit Paymen

Pension Expected Benefit Payments (Details) - Pension Plans, Defined Benefit [Member] $ in Millions	Dec. 31, 2021USD ($)
United States
Defined Benefit Plan, Expected Future Benefit Payments [Abstract]
2022	$ 93
2023	89
2024	88
2025	86
2026	84
2027-2031	368
Foreign Plan [Member]
Defined Benefit Plan, Expected Future Benefit Payments [Abstract]
2022	45
2023	45
2024	49
2025	52
2026	56
2027-2031	$ 307

Pensions FV Assets (Details)

Pensions FV Assets (Details) - Pension Plans, Defined Benefit [Member] - USD ($) $ in Millions		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
United States
Defined Benefit Plan Disclosure [Line Items]
Fair Value of Plan Assets		$ 1,226	$ 1,267	$ 1,201
United States | Fair Value Measured at Net Asset Value Per Share [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair Value of Plan Assets	[1]	$ 1,226	1,267
United States | U.S. Equity Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets, Approximate Target Allocation, Percentage		10.00%
Fair Value of Plan Assets		$ 124	125
United States | U.S. Equity Funds [Member] | Fair Value Measured at Net Asset Value Per Share [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair Value of Plan Assets	[1]	$ 124	125
United States | International Equity Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets, Approximate Target Allocation, Percentage		10.00%
Fair Value of Plan Assets		$ 117	126
United States | International Equity Funds [Member] | Fair Value Measured at Net Asset Value Per Share [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair Value of Plan Assets	[1]	$ 117	126
United States | Fixed Income Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets, Approximate Target Allocation, Percentage		80.00%
Fair Value of Plan Assets		$ 966	1,001
United States | Fixed Income Funds [Member] | Fair Value Measured at Net Asset Value Per Share [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair Value of Plan Assets	[1]	966	1,001
United States | Money Market Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair Value of Plan Assets		19	15
United States | Money Market Funds [Member] | Fair Value Measured at Net Asset Value Per Share [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair Value of Plan Assets	[1]	19	15
Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair Value of Plan Assets		1,302	1,160	$ 986
Foreign Plan [Member] | Quoted Prices in Active Markets (Level I) [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair Value of Plan Assets		5	7
Foreign Plan [Member] | Significant Other Observable Inputs (Level 2) [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair Value of Plan Assets		295	262
Foreign Plan [Member] | Fair Value Measured at Net Asset Value Per Share [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair Value of Plan Assets	[1]	1,002	891
Foreign Plan [Member] | Fixed Income Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair Value of Plan Assets		651	510
Foreign Plan [Member] | Fixed Income Funds [Member] | Fair Value Measured at Net Asset Value Per Share [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair Value of Plan Assets	[1]	651	510
Foreign Plan [Member] | Equity Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair Value of Plan Assets		17	74
Foreign Plan [Member] | Equity Funds [Member] | Fair Value Measured at Net Asset Value Per Share [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair Value of Plan Assets	[1]	17	74
Foreign Plan [Member] | Hedge Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair Value of Plan Assets		3	59
Foreign Plan [Member] | Hedge Funds [Member] | Fair Value Measured at Net Asset Value Per Share [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair Value of Plan Assets	[1]	3	59
Foreign Plan [Member] | Multi-asset Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair Value of Plan Assets		73	45
Foreign Plan [Member] | Multi-asset Funds [Member] | Fair Value Measured at Net Asset Value Per Share [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair Value of Plan Assets	[1]	73	45
Foreign Plan [Member] | Derivative Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair Value of Plan Assets		253	149
Foreign Plan [Member] | Derivative Funds [Member] | Fair Value Measured at Net Asset Value Per Share [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair Value of Plan Assets	[1]	253	149
Foreign Plan [Member] | Alternative Investments [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair Value of Plan Assets		1	6
Foreign Plan [Member] | Alternative Investments [Member] | Fair Value Measured at Net Asset Value Per Share [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair Value of Plan Assets	[1]	1	6
Foreign Plan [Member] | Insurance Contracts [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair Value of Plan Assets		295	262
Foreign Plan [Member] | Insurance Contracts [Member] | Significant Other Observable Inputs (Level 2) [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair Value of Plan Assets		295	262
Foreign Plan [Member] | Cash / Money Market Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair Value of Plan Assets		9	55
Foreign Plan [Member] | Cash / Money Market Funds [Member] | Quoted Prices in Active Markets (Level I) [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair Value of Plan Assets		5	7
Foreign Plan [Member] | Cash / Money Market Funds [Member] | Fair Value Measured at Net Asset Value Per Share [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair Value of Plan Assets	[1]	$ 4	$ 48
Foreign Plan [Member] | Minimum [Member] | Fixed Income Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets, Approximate Target Allocation, Percentage		40.00%
Foreign Plan [Member] | Minimum [Member] | Equity Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets, Approximate Target Allocation, Percentage		0.00%
Foreign Plan [Member] | Minimum [Member] | Multi-asset Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets, Approximate Target Allocation, Percentage		0.00%
Foreign Plan [Member] | Minimum [Member] | Derivative Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets, Approximate Target Allocation, Percentage		0.00%
Foreign Plan [Member] | Maximum [Member] | Fixed Income Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets, Approximate Target Allocation, Percentage		90.00%
Foreign Plan [Member] | Maximum [Member] | Equity Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets, Approximate Target Allocation, Percentage		25.00%
Foreign Plan [Member] | Maximum [Member] | Multi-asset Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets, Approximate Target Allocation, Percentage		35.00%
Foreign Plan [Member] | Maximum [Member] | Derivative Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets, Approximate Target Allocation, Percentage		30.00%
[1]	Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.

Income Taxes Components (Detail

Income Taxes Components (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Components of Income From Continuing Operations Before Income Taxes [Abstract]
U.S.	$ 3,340	$ 4,762	$ 2,280
Non-U.S.	5,501	2,468	1,792
Income before income taxes	8,841	7,230	4,072
Current Income Tax Provision [Abstract]
Federal	446	521	267
Non-U.S.	1,148	423	544
State	160	175	62
Total Current Income Tax Provision	1,754	1,119	873
Deferred Income Tax Provision (Benefit) [Abstract]
Federal	(227)	(237)	(222)
Non-U.S.	(399)	(18)	(252)
State	(19)	(14)	(25)
Total Deferred Income Tax Provision (Benefit)	(645)	(269)	(499)
Provision for income taxes	$ 1,109	$ 850	$ 374

Income Taxes Rate Reconciliatio

Income Taxes Rate Reconciliation (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Statutory federal income tax rate	21.00%	21.00%	21.00%
Provision for income taxes at statutory rate	$ 1,857	$ 1,518	$ 855
Foreign rate differential	(255)	(223)	(204)
Income tax credits	(315)	(335)	(213)
Global intangible low-taxed income	76	86	92
Foreign-derived intangible income	(119)	(156)	(111)
Excess tax benefits from stock options and restricted stock units	(124)	(114)	(80)
Provision for (reversal of) tax reserves, net	(17)	(26)	62
Intra-entity transfers	(284)		(79)
Foreign exchange loss on inter-company debt refinancing		(47)	(62)
Domestication transaction		(263)
Valuation allowance	36	379	(4)
Withholding taxes	164	115	38
Basis difference on disposal of business		0	73
Tax return reassessments and settlements	1	(196)	(6)
State income taxes, net of federal tax	82	147	22
Other, net	7	(35)	(9)
Provision for income taxes	1,109	850	374
US foreign tax credits generated by repatriation of foreign earnings		96	75
Deferred Tax Implications
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Intra-entity transfers	188
Capital Loss
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Intra-entity transfers	$ 96
Deferred Tax Asset, Interest Carryforward [Member]
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Valuation allowance		212
United States
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Provision for (reversal of) tax reserves, net		(378)
Valuation allowance		156
Tax return reassessments and settlements		(25)
Unrecognized tax benefits reclassed to accrued income taxes in connection with IRS settlement		144
Charge for Expired Tax Credits due to Audit Settlement		$ 53
Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | Anatomical Pathology business [Member]
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Income Tax Provision Related to Gain of Sale of Business			$ 191

Income Taxes Deferred Taxes (De

Income Taxes Deferred Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Deferred Tax Assets (Liabilities) [Abstract]
Depreciation and amortization	$ (4,687)	$ (2,962)
Net operating loss and credit carryforwards	1,652	1,668
Reserves and accruals	162	164
Accrued compensation	318	253
Inventory basis difference	181	112
Deferred interest	295	227
Unrealized (gains) losses on hedging instruments	(33)	242
Other, net	251	124
Deferred tax liabilities, net before valuation allowance	(1,861)	(172)
Valuation Allowance	968	933	$ 408
Deferred tax liabilities, net	(2,829)	(1,105)
Valuation Allowance [Roll Forward]
Beginning Balance	933	408	471
Additions (reductions) charged to income tax provision, net	24	514	(27)
Additions due to acquisitions	30
Reduction due to a divestiture			(33)
Currency translation and other	(19)	11	(3)
Ending Balance	$ 968	$ 933	$ 408

Income Taxes Loss Carryforwards

Income Taxes Loss Carryforwards (Details) $ in Millions	Dec. 31, 2021USD ($)
Tax Credit Carryforward [Line Items]
Undistributed Earnings of Foreign Subsidiaries	$ 24,000
Foreign Tax Credit Carryforwards [Member]
Tax Credit Carryforward [Line Items]
Tax Credit Carryforward, Amount	610
Deferred Interest Carryforward [Member]
Tax Credit Carryforward [Line Items]
Tax Credit Carryforward, Amount	295
Federal [Member]
Operating Loss Carryforwards [Line Items]
Net Operating Loss Carryforwards	72
State [Member]
Operating Loss Carryforwards [Line Items]
Net Operating Loss Carryforwards	88
Non- U.S. [Member]
Operating Loss Carryforwards [Line Items]
Net Operating Loss Carryforwards	1,180
Portion of Non- U.S. with expiration dates [Member]
Operating Loss Carryforwards [Line Items]
Net Operating Loss Carryforwards	$ 419

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Reconciliation of Unrecognized Tax Benefits [Roll Forward]
Balance at beginning of year	$ 1,091	$ 1,552	$ 1,442
Additions due to acquisitions	26
Additions for tax positions of current year	32	8	53
Additions for tax positions of prior years	60		69
Reductions for tax positions of prior years	(5)	(296)	(7)
Closure of tax years	(27)
Settlements	(53)	(173)	(5)
Balance at end of year	1,124	1,091	1,552
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued	59	78
Federal and State [Member]
Reconciliation of Unrecognized Tax Benefits [Roll Forward]
Unrecognized Tax Benefits, Period Increase (Decrease)	(75)	(410)	45
Foreign [Member]
Reconciliation of Unrecognized Tax Benefits [Roll Forward]
Unrecognized Tax Benefits, Period Increase (Decrease)	$ 80	$ (51)	$ 70

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Earnings Per Share [Abstract]
Net income	$ 7,725	$ 6,375	$ 3,696
Basic Weighted Average Shares	394	396	400
Effect of Stock Options and Restricted Stock Units	3	3	3
Diluted Weighted Average Shares	397	399	403
Basic Earnings Per Share (in dollars per share)	$ 19.62	$ 16.09	$ 9.24
Diluted Earnings Per Share (in dollars per share)	$ 19.46	$ 15.96	$ 9.17
Antidilutive stock options excluded from diluted weighted average shares	1	1	1

Debt Outstanding Debt (Details)

Debt Outstanding Debt (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Total borrowings at par value	$ 34,971	$ 21,919
Fair value hedge accounting adjustments		25
Unamortized discount	(117)	(102)
Unamortized debt issuance costs	(184)	(114)
Total borrowings at carrying value	34,670	21,728
Finance lease liabilities	200	7
Less: Short-term obligations and current maturities	2,537	2,628
Long-term obligations	32,333	19,107
Maturities of Long-term Debt [Abstract]
2022	2,522
2023	5,396
2024	4,138
2025	2,610
2026	797
2027 and thereafter	19,508
Total Repayments of Principal	34,971	21,919
2022	15
2023	12
2024	12
2025	12
2026	12
2027 and thereafter	137
Total Repayments of Finance Lease Liabilities	$ 200	$ 7
Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]	Long-term obligations	Long-term obligations
Commercial Paper Programs [Member]
Debt Instrument [Line Items]
Effective Interest Rate	0.01%
Total borrowings at par value	$ 2,522
Total borrowings at carrying value	2,522
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	2,522
Senior Notes [Member]
Debt Instrument [Line Items]
Total borrowings at carrying value	$ 32,072	$ 21,723
Debt Instrument, Call Feature	Each of the fixed rate senior notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium and accrued interest. Except for the euro-denominated floating rate senior notes, which may not be redeemed early, the floating rate senior notes may be redeemed in whole or in part on or after their applicable call dates at a redemption price of 100% of the principal amount plus accrued interest.
Senior Notes [Member] | 2.15% 7-Year Senior Notes, Due 7/21/2022 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	2.15%
Debt Instrument, Term	7 years
Debt Instrument, Maturity Date	Jul. 21, 2022
Total borrowings at par value		611
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal		611
Senior Notes [Member] | 3.00% 7-Year Senior Notes, Due 4/15/2023 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	3.00%
Debt Instrument, Term	7 years
Debt Instrument, Maturity Date	Apr. 15, 2023
Total borrowings at par value		1,000
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal		1,000
Senior Notes [Member] | Floating Rate (SOFR +0.35%) 1.5 Year Senior Notes, Due 4/18/2023 [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	0.35%
Debt Instrument, Term	1 year 6 months
Debt Instrument, Maturity Date	Apr. 18, 2023
Total borrowings at par value	$ 1,000
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 1,000
Senior Notes [Member] | Floating Rate (SOFR +0.39%) 2-Year Senior Notes, Due 10/18/2023 [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	0.39%
Debt Instrument, Term	2 years
Debt Instrument, Maturity Date	Oct. 18, 2023
Total borrowings at par value	$ 500
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 500
Senior Notes [Member] | 0.797% 2-Year Senior Notes, Due 10/18/2023 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	0.797%
Debt Instrument, Term	2 years
Debt Instrument, Maturity Date	Oct. 18, 2023
Effective Interest Rate	1.03%
Total borrowings at par value	$ 1,350
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 1,350
Senior Notes [Member] | Floating Rate (EURIBOR +0.20%) 2 Year Senior Notes, Due 11/18/2023 (euro-denominated) [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	0.20%
Debt Instrument, Term	2 years
Debt Instrument, Maturity Date	Nov. 18, 2023
Effective Interest Rate	0.00%
Total borrowings at par value	$ 1,933
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 1,933
Senior Notes [Member] | 0.000% 2-Year Senior Notes, Due 11/18/2023 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	0.00%
Debt Instrument, Term	2 years
Debt Instrument, Maturity Date	Nov. 18, 2023
Effective Interest Rate	0.06%
Total borrowings at par value	$ 625
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 625
Senior Notes [Member] | 4.15% 10-Year Senior Notes, Due 2/1/2024 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	4.15%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Feb. 1, 2024
Total borrowings at par value		1,000
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal		1,000
Senior Notes [Member] | 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	0.75%
Debt Instrument, Term	8 years
Debt Instrument, Maturity Date	Sep. 12, 2024
Effective Interest Rate	0.94%
Total borrowings at par value	$ 1,137	1,222
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 1,137	1,222
Senior Notes [Member] | 1.215% 3-Year Senior Notes, Due 10/18/2024 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	1.215%
Debt Instrument, Term	3 years
Debt Instrument, Maturity Date	Oct. 18, 2024
Effective Interest Rate	1.42%
Total borrowings at par value	$ 2,500
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 2,500
Senior Notes [Member] | Floating Rate (SOFR +0.53%) 3-Year Senior Notes, Due 10/18/2024 [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	0.53%
Debt Instrument, Term	3 years
Debt Instrument, Maturity Date	Oct. 18, 2024
Total borrowings at par value	$ 500
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 500
Senior Notes [Member] | 0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	0.125%
Debt Instrument, Term	5 years 6 months
Debt Instrument, Maturity Date	Mar. 1, 2025
Effective Interest Rate	0.41%
Total borrowings at par value	$ 910	977
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 910	977
Senior Notes [Member] | 4.133% 5-Year Senior Notes, Due 3/25/2025 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	4.133%
Debt Instrument, Term	5 years
Debt Instrument, Maturity Date	Mar. 25, 2025
Total borrowings at par value		1,100
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal		1,100
Senior Notes [Member] | 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	2.00%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Apr. 15, 2025
Effective Interest Rate	2.10%
Total borrowings at par value	$ 728	782
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 728	782
Senior Notes [Member] | 0.000% 4-Year Senior Notes, Due 11/18/2025 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	0.00%
Debt Instrument, Term	4 years
Debt Instrument, Maturity Date	Nov. 18, 2025
Effective Interest Rate	0.16%
Total borrowings at par value	$ 625
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 625
Senior Notes [Member] | 3.65% 10-Year Senior Notes, Due 12/15/2025 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	3.65%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Dec. 15, 2025
Effective Interest Rate	3.77%
Total borrowings at par value	$ 350	350
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 350	350
Senior Notes [Member] | 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	1.40%
Debt Instrument, Term	8 years 6 months
Debt Instrument, Maturity Date	Jan. 23, 2026
Effective Interest Rate	1.53%
Total borrowings at par value	$ 796	855
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 796	855
Senior Notes [Member] | 2.95% 10-Year Senior Notes, Due 9/19/2026 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	2.95%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Sep. 19, 2026
Total borrowings at par value		1,200
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal		1,200
Senior Notes [Member] | 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	1.45%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Mar. 16, 2027
Effective Interest Rate	1.66%
Total borrowings at par value	$ 568	611
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 568	611
Senior Notes [Member] | 1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	1.75%
Debt Instrument, Term	7 years
Debt Instrument, Maturity Date	Apr. 15, 2027
Effective Interest Rate	1.97%
Total borrowings at par value	$ 682	733
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 682	733
Senior Notes [Member] | 3.20% 10-Year Senior Notes, Due 8/15/2027 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	3.20%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Aug. 15, 2027
Total borrowings at par value		750
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal		750
Senior Notes [Member] | 0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	0.50%
Debt Instrument, Term	8 years 6 months
Debt Instrument, Maturity Date	Mar. 1, 2028
Effective Interest Rate	0.77%
Total borrowings at par value	$ 910	977
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 910	977
Senior Notes [Member] | 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	1.375%
Debt Instrument, Term	12 years
Debt Instrument, Maturity Date	Sep. 12, 2028
Effective Interest Rate	1.46%
Total borrowings at par value	$ 682	733
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 682	733
Senior Notes [Member] | 1.750% 7-Year Senior Notes, Due 10/15/2028 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	1.75%
Debt Instrument, Term	7 years
Debt Instrument, Maturity Date	Oct. 15, 2028
Effective Interest Rate	1.89%
Total borrowings at par value	$ 700
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 700
Senior Notes [Member] | 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	1.95%
Debt Instrument, Term	12 years
Debt Instrument, Maturity Date	Jul. 24, 2029
Effective Interest Rate	2.08%
Total borrowings at par value	$ 796	855
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 796	855
Senior Notes [Member] | 2.60% 10-Year Senior Notes, Due 10/1/2029 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	2.60%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Oct. 1, 2029
Effective Interest Rate	2.74%
Total borrowings at par value	$ 900	900
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 900	900
Senior Notes [Member] | 4.497% 10-Year Senior Notes, Due 3/25/2030 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	4.497%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Mar. 25, 2030
Total borrowings at par value		1,100
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal		1,100
Senior Notes [Member] | 0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	0.80%
Debt Instrument, Term	9 years
Debt Instrument, Maturity Date	Oct. 18, 2030
Effective Interest Rate	0.89%
Total borrowings at par value	$ 1,990
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 1,990
Senior Notes [Member] | 0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	0.875%
Debt Instrument, Term	12 years
Debt Instrument, Maturity Date	Oct. 1, 2031
Effective Interest Rate	1.13%
Total borrowings at par value	$ 1,023	1,099
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 1,023	1,099
Senior Notes [Member] | 2.00% 10-Year Senior Notes, Due 10/15/2031 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	2.00%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Oct. 15, 2031
Effective Interest Rate	2.23%
Total borrowings at par value	$ 1,200
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 1,200
Senior Notes [Member] | 2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	2.375%
Debt Instrument, Term	12 years
Debt Instrument, Maturity Date	Apr. 15, 2032
Effective Interest Rate	2.55%
Total borrowings at par value	$ 682	733
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 682	733
Senior Notes [Member] | 1.125% 12-Year Senior Notes Due 10/18/2033 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	1.125%
Debt Instrument, Term	12 years
Debt Instrument, Maturity Date	Oct. 18, 2033
Effective Interest Rate	1.21%
Total borrowings at par value	$ 1,706
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 1,706
Senior Notes [Member] | 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	2.875%
Debt Instrument, Term	20 years
Debt Instrument, Maturity Date	Jul. 24, 2037
Effective Interest Rate	2.94%
Total borrowings at par value	$ 796	855
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 796	855
Senior Notes [Member] | 1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	1.50%
Debt Instrument, Term	20 years
Debt Instrument, Maturity Date	Oct. 1, 2039
Effective Interest Rate	1.73%
Total borrowings at par value	$ 1,023	1,099
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 1,023	1,099
Senior Notes [Member] | 2.80% 20-Year Senior Notes, Due 10/15/2041 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	2.80%
Debt Instrument, Term	20 years
Debt Instrument, Maturity Date	Oct. 15, 2041
Effective Interest Rate	2.90%
Total borrowings at par value	$ 1,200
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 1,200
Senior Notes [Member] | 1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	1.625%
Debt Instrument, Term	20 years
Debt Instrument, Maturity Date	Oct. 18, 2041
Effective Interest Rate	1.78%
Total borrowings at par value	$ 1,421
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 1,421
Senior Notes [Member] | 5.30% 30-Year Senior Notes, Due 2/1/2044 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	5.30%
Debt Instrument, Term	30 years
Debt Instrument, Maturity Date	Feb. 1, 2044
Effective Interest Rate	5.37%
Total borrowings at par value	$ 400	400
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 400	400
Senior Notes [Member] | 4.10% 30-Year Senior Notes, Due 8/15/2047 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	4.10%
Debt Instrument, Term	30 years
Debt Instrument, Maturity Date	Aug. 15, 2047
Effective Interest Rate	4.23%
Total borrowings at par value	$ 750	750
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 750	750
Senior Notes [Member] | 1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	1.875%
Debt Instrument, Term	30 years
Debt Instrument, Maturity Date	Oct. 1, 2049
Effective Interest Rate	1.98%
Total borrowings at par value	$ 1,137	1,222
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 1,137	1,222
Senior Notes [Member] | 2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	2.00%
Debt Instrument, Term	30 years
Debt Instrument, Maturity Date	Oct. 18, 2051
Effective Interest Rate	2.07%
Total borrowings at par value	$ 853
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	853
Other Debt [Member]
Debt Instrument [Line Items]
Total borrowings at par value	76	5
Total borrowings at carrying value	76	5
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$ 76	$ 5

Debt Short-term Financing (Deta

Debt Short-term Financing (Details)	12 Months Ended
	Dec. 31, 2021USD ($)	Jan. 07, 2022USD ($)
Short-term Financing [Line Items]
Line of Credit Facility, Remaining Borrowing Capacity	$ 78,000,000
Revolving Credit Facility [Member]
Short-term Financing [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 3,000,000,000
Debt, Covenant, Minimum Consolidated Interest Coverage Ratio	3.5
Line of Credit Facility, Amount Outstanding	$ 0
Letters of Credit Outstanding, Amount	4,000,000
Revolving Credit Facility [Member] | Subsequent Event [Member]
Short-term Financing [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		$ 5,000,000,000
Commercial Paper Programs [Member]
Short-term Financing [Line Items]
Short-term Borrowings	$ 2,520,000,000
Commercial Paper Programs [Member] | U.S. Commercial Paper Program [Member]
Short-term Financing [Line Items]
Maximum Period to Maturity Allowed Under Program	397 days
Commercial Paper Programs [Member] | Euro Commercial Paper Program [Member]
Short-term Financing [Line Items]
Maximum Period to Maturity Allowed Under Program	183 days

Debt Redemption (Details)

Debt Redemption (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Feb. 24, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Extinguishment of Debt [Line Items]
Gain (Loss) on Extinguishment of Debt		$ (767)	$ 0	$ (184)
Subsequent Event [Member]
Extinguishment of Debt [Line Items]
Gain (Loss) on Extinguishment of Debt	$ (26)
Cross Currency Interest Rate Contract [Member]
Extinguishment of Debt [Line Items]
Proceeds from Hedge, Investing Activities				44
Interest Rate Swaps [Member]
Extinguishment of Debt [Line Items]
Proceeds from Hedge, Financing Activities		$ 22
Payments for Hedge, Financing Activities				$ 17

Leases (Details)

Leases (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Lessee, Lease, Description [Line Items]
ROU assets	$ 1,531	$ 775
Operating lease liabilities - current	266	184
Operating lease liabilities - noncurrent	1,203	626
Operating lease costs	254	224	$ 208
Variable lease costs	66	49	41
Cash used in operating activities for payments of amounts included in the measurement of operating lease liabilities	288	222	208
Operating lease ROU assets obtained in exchange for new operating lease liabilities	$ 293	$ 202	$ 205
Weighted Average Remaining Lease Term	9 years 10 months 24 days	6 years 3 months 18 days	6 years 2 months 12 days
Weighted Average Discount Rate	2.60%	3.40%	4.00%
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Other assets	Other assets
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Other accrued expenses	Other accrued expenses
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Other long-term liabilities	Other long-term liabilities
2022	$ 303
2023	248
2024	193
2025	144
2026	120
2027 and thereafter	650
Total lease payments	1,658
Imputed Interest	189
Total operating lease liability	1,469
Lease Residual Value Guarantee [Member]
Lessee, Lease, Description [Line Items]
Guarantor Obligations, Maximum Exposure, Undiscounted	$ 147
Minimum [Member]
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Remaining Lease Term	1 month
Lessee, Operating Lease, Renewal Term	1 year
Maximum [Member]
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Remaining Lease Term	30 years
Lessee, Operating Lease, Renewal Term	10 years
Lessee, Operating Lease, Option to Terminate, Term	1 year

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Unrecorded Unconditional Purchase Obligation [Line Items]
Unrecorded Unconditional Purchase Obligation	$ 2,510
Accrual for Environmental Loss Contingencies Disclosure [Abstract]
Accrual for Environmental Loss Contingencies, Net	65
Letters of Credit / Bank Guarantees [Member]
Guarantor Obligations [Line Items]
Guarantor Obligations, Maximum Exposure, Undiscounted	$ 266
Guarantor Obligations, Term	Substantially all of these letters of credit and guarantees expire before 2039.
Surety Bonds and Other Guarantees [Member]
Guarantor Obligations [Line Items]
Guarantor Obligations, Maximum Exposure, Undiscounted	$ 95
Guarantor Obligations, Term	The expiration of these bonds and guarantees ranges through 2023.
Inventories [Member] | Analytical Instruments [Member] | Cost of Sales [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Inventory, Firm Purchase Commitment, Loss		$ 108
Businesses Sold [Member] | Pension Obligation Guarantee [Member]
Guarantor Obligations [Line Items]
Guarantor Obligations, Maximum Exposure, Undiscounted	$ 36
Product Liability, Workers Compensation and Other Personal Injury Matters [Member]
Loss Contingency [Abstract]
Loss Contingency Accrued	216
Loss Contingency, Accrual, Gross	223
Estimated Amount Due from Insurers, Net	100
Estimated Amount Due from Insurers, Undiscounted	106
Loss Contingency Accrual, Product Liability, Gross, Divested Business	11
Product Liability, Workers Compensation and Other Personal Injury Matters [Member] | Minimum [Member]
Loss Contingency [Abstract]
Loss Contingency, Estimate of Possible Loss	216
Product Liability, Workers Compensation and Other Personal Injury Matters [Member] | Maximum [Member]
Loss Contingency [Abstract]
Loss Contingency, Estimate of Possible Loss	$ 375

Comprehensive Income and Shar_3

Comprehensive Income and Shareholders' Equity (Details) - USD ($) shares in Millions, $ in Millions	1 Months Ended	12 Months Ended
	Jan. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 40,855	$ 34,517	$ 29,684	$ 27,594
Other comprehensive items before reclassifications		409
Amounts reclassified from accumulated other comprehensive items		69
Total other comprehensive items		478	(128)	(180)
Balance		40,855	34,517	29,684
Payments for Repurchase of Common Stock		$ 2,000	1,500	1,500
Class of Stock Disclosures [Abstract]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)		23
Subsequent Event [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Payments for Repurchase of Common Stock	$ 2,000
Purchases of company common stock (in shares)	3.3
Currency Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ (2,065)	$ (2,438)
Other comprehensive items before reclassifications		373
Total other comprehensive items		373
Balance		(2,065)	(2,438)
Unrealized Losses on Hedging Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(35)	(91)
Amounts reclassified from accumulated other comprehensive items		56
Total other comprehensive items		56
Balance		(35)	(91)
Pension and Other Postretirement Benefit Liability Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(229)	(278)
Other comprehensive items before reclassifications		36
Amounts reclassified from accumulated other comprehensive items		13
Total other comprehensive items		49
Balance		(229)	(278)
Accumulated Other Comprehensive Items [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ (2,329)	(2,807)	(2,679)	(2,498)
Total other comprehensive items		478	(128)	(181)
Balance		$ (2,329)	$ (2,807)	$ (2,679)

Fair Value Measurements, Assets

Fair Value Measurements, Assets and Liabilities (Details) - Fair Value, Recurring [Member] - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Assets [Abstract]
Cash equivalents	$ 2,210	$ 8,971
Investments	298	21
Warrants	15	7
Insurance contracts	181	157
Derivative contracts	36	28
Total assets	2,740	9,184
Liabilities [Abstract]
Derivative contracts	1	132
Contingent consideration	317	70
Total liabilities	318	202
Quoted Prices in Active Markets (Level I) [Member]
Assets [Abstract]
Cash equivalents	2,210	8,971
Investments	298	21
Total assets	2,508	8,992
Significant Other Observable Inputs (Level 2) [Member]
Assets [Abstract]
Warrants	15	7
Insurance contracts	181	157
Derivative contracts	36	28
Total assets	232	192
Liabilities [Abstract]
Derivative contracts	1	132
Total liabilities	1	132
Significant Unobservable Inputs (Level 3) [Member]
Liabilities [Abstract]
Contingent consideration	317	70
Total liabilities	$ 317	$ 70

Fair Value Measurements and F_3

Fair Value Measurements and Fair Value of Financial Instruments Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) - Contingent Consideration [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 70	$ 55
Acquisitions (including assumed balances)	403	28
Payments	(109)	(4)
Changes in fair value included in earnings	(47)	(9)
Ending balance	$ 317	$ 70
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Selling, general and administrative expenses	Selling, general and administrative expenses

Fair Value Measurements, Deriva

Fair Value Measurements, Derivative Assets & Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Derivatives, Fair Value [Line Items]
Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability		$ 25
Long-term Obligations [Member]
Derivatives, Fair Value [Line Items]
Hedged Liability, Fair Value Hedge		1,020
Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability		25
Interest Rate Swaps [Member] | Derivatives Designated as Hedging Instrument [Member] | Other Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets		25
Interest Rate Swaps [Member] | Fair Value Hedging [Member]
Derivatives, Fair Value [Line Items]
Notional Amount Of Derivatives		1,000
Cross Currency Interest Rate Contract [Member] | Derivatives Designated as Hedging Instrument [Member] | Other Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets	$ 25
Cross Currency Interest Rate Contract [Member] | Derivatives Designated as Hedging Instrument [Member] | Other Long-term Liabilities [Member]
Derivatives, Fair Value [Line Items]
Derivative Liabilities		46
Cross Currency Interest Rate Contract [Member] | Net Investment Hedging [Member]
Derivatives, Fair Value [Line Items]
Notional Amount Of Derivatives	900	900
Currency Exchange Contracts [Member]
Derivatives, Fair Value [Line Items]
Notional Amount Of Derivatives	2,149	5,206
Currency Exchange Contracts [Member] | Derivatives Not Designated as Hedging Instrument [Member] | Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets	11	3
Currency Exchange Contracts [Member] | Derivatives Not Designated as Hedging Instrument [Member] | Other Accrued Expenses [Member]
Derivatives, Fair Value [Line Items]
Derivative Liabilities	1	86
Fair Value, Recurring [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets	36	28
Derivative Liabilities	$ 1	$ 132

Fair Value Measurements, Deri_2

Fair Value Measurements, Derivative Instruments, Gains & Losses (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Interest Rate Swaps [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Payments for Hedge, Financing Activities			$ 17
Cross Currency Interest Rate Contract [Member] | Other Expense [Member] | Derivatives Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative, Net		$ (9)
Currency Exchange Contracts [Member] | Other Expense [Member] | Derivatives Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative, Net	$ 162	(81)
Currency Exchange Contracts [Member] | Cost of Sales [Member] | Derivatives Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative, Net	12	(17)
Fair Value Hedging [Member] | Interest Rate Swaps [Member] | Other Expense [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Hedged Debt in Fair Value Hedge	25	(38)
Gain (Loss) on Derivative, Net	(3)	38
Cash Flow Hedging [Member] | Interest Rate Swaps [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax		(85)
Payments for Hedge, Financing Activities		85	$ 50
Cash Flow Hedging [Member] | Interest Rate Swaps [Member] | Other Expense [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax	65	42
Cash Flow Hedging [Member] | Interest Rate Swaps [Member] | Other Expense [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax	(73)	(59)
Net Investment Hedging [Member] | Foreign currency-denominated debt [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) in Currency Translation Adjustment on Net Investment Hedge	922	(873)
Net Investment Hedging [Member] | Cross Currency Interest Rate Contract [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) in Currency Translation Adjustment on Net Investment Hedge	71	(79)
Net Investment Hedging [Member] | Cross Currency Interest Rate Contract [Member] | Other Expense [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative, Net	$ 8	$ 11

Fair Value of Other Instruments

Fair Value of Other Instruments (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Obligations - Carrying Value	$ 34,670	$ 21,728
Debt Instrument, Fair Value Disclosure	36,047	24,658
Senior Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Obligations - Carrying Value	32,072	21,723
Debt Instrument, Fair Value Disclosure	33,449	24,653
Commercial Paper Programs [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Obligations - Carrying Value	2,522
Debt Instrument, Fair Value Disclosure	2,522
Other Debt [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Obligations - Carrying Value	76	5
Debt Instrument, Fair Value Disclosure	$ 76	$ 5

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Supplemental Cash Flow Information [Abstract]
Cash Paid For Interest	$ 555	$ 471	$ 790
Cash Paid For Income Taxes	2,182	1,324	896
Non-cash Investing and Financing Activities [Abstract]
Acquired but unpaid property, plant and equipment	379	347	150
Fair value of equity awards exchanged	43
Fair value of contingent consideration	183
Finance lease ROU assets obtained in exchange for new finance lease liabilities	15	5	1
Declared but unpaid dividends	104	89	77
Issuance of stock upon vesting of restricted stock units	265	217	182
Cash and cash equivalents	4,477	10,325
Restricted cash included in other current assets	13	10
Restricted cash included in other assets	1	1
Cash, cash equivalents and restricted cash	$ 4,491	$ 10,336	$ 2,422	$ 2,117
Restricted Cash and Cash Equivalents, Current, Asset, Statement of Financial Position [Extensible List]	Other current assets
Restricted Cash and Cash Equivalents, Noncurrent, Asset, Statement of Financial Position [Extensible List]	Other assets

Restructuring and Other Costs_3

Restructuring and Other Costs, Net (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Feb. 24, 2022
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Percentage of Total Workforce Eliminated, Less Than	1.00%	1.00%	1.00%
Restructuring and other costs (income)	$ 197	$ 99	$ (413)
Life Sciences Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs (income)	129	34	24
Analytical Instruments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs (income)	6	26	14
Specialty Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs (income)	18	9	(471)
Laboratory Products and Biopharma Services [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs (income)	35	23	17
Corporate [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs (income)	$ 9	$ 7	$ 3
Forecast [Member]
Restructuring Cost and Reserve [Line Items]
Identified Future Restructuring Costs				$ 20

Restructuring Reserves (Details

Restructuring Reserves (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Restructuring Reserve [Roll Forward]
Beginning balance	$ 21	$ 34	$ 80
Net restructuring charges incurred	37	51	52
Payments	(40)	(57)	(69)
Currency translation	(1)	(7)	(1)
Ending balance	17	21	34
Restructuring and Related Costs, Other Costs (Income), Net	160	48	465
Loss (Gain) on Divestiture of Businesses	0	0	$ (482)
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income [Extensible List]			Restructuring and other costs (income)
Impairment of Intangible Assets (Excluding Goodwill)	122	$ 32
Charges For Cash Compensation Due To Employees Of Acquired Businesses	$ 35
Other restructuring charges			$ 17
Restructuring Reserve, Expected Final Year of Payments	2022
Specialty Diagnostics [Member]
Restructuring Reserve [Roll Forward]
Loss (Gain) on Divestiture of Businesses			(482)
Cumulative Effect, Period of Adoption, Adjustment [Member]
Restructuring Reserve [Roll Forward]
Beginning balance			$ (28)